

**THE ROLE OF PHYSICAL ACTIVITY ON CARDIOVASCULAR DISEASE RISK
FACTORS IN POSTMENOPAUSAL WOMEN**

by

Kelley Kathryn Pettee

BS, Athletic Training/Exercise Science, Ithaca College, 1996

MS, Clinical Exercise Physiology, Northeastern University, 1999

Submitted to the Graduate Faculty of
Graduate School of Public Health in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy

University of Pittsburgh

2006

UNIVERSITY OF PITTSBURGH
GRADUATE SCHOOL OF PUBLIC HEALTH

This dissertation was presented

by

Kelley Kathryn Pettee

It was defended on

July 10, 2006

and approved by

Dissertation Advisor:

Andrea M. Kriska

Associate Professor, Department of Epidemiology
Graduate School of Public Health, University of Pittsburgh

Bret H. Goodpaster

Assistant Professor, Department of Medicine
School of Medicine, University of Pittsburgh

B. Delia Johnson

Research Associate, Department of Epidemiology
Graduate School of Public Health, University of Pittsburgh

Lewis H. Kuller

Professor, Department of Epidemiology
Graduate School of Public Health, University of Pittsburgh

Trevor J. Orchard

Professor, Department of Epidemiology
Graduate School of Public Health, University of Pittsburgh

Copyright © by Kelley Kathryn Pettee

2006

**THE ROLE OF PHYSICAL ACTIVITY ON CARDIOVASCULAR DISEASE RISK
FACTORS IN POSTMENOPAUSAL WOMEN**

Kelley Kathryn Pettee, PhD

University of Pittsburgh, 2006

Cardiovascular disease (CVD) is the leading cause of death among women in the US. CVD is still thought to be a “man’s disease” and remains underappreciated by the public and under treated by health-care providers. Yet, unlike men, a large proportion of deaths attributable to CVD occur in asymptomatic women, making early detection and diagnosis difficult. Therefore, both the development of primary CVD prevention strategies to decrease the risk of CVD and screening tools that will aid in the early detection of women who are at increased risk for CVD has major public health implications.

Hormone therapy (HT) has been shown to beneficially affect adverse changes to CVD risk factors that occur during menopause; however, HT is no longer indicated for general CVD prevention. Increased physical activity (PA) levels, either separately or as part of a lifestyle intervention, may decrease CVD risk in women; however, previous reports have not adequately accounted for concurrent changes in HT status.

Strategies for primary CVD prevention and early detection in postmenopausal women were examined using 508 women from the Woman on the Move through Activity and Nutrition (WOMAN) study. At baseline, PA was found to be related to more favorable lipid and lipoprotein subclass levels; however, some of these associations were influenced by current HT use. Results at 18 months suggested that a lifestyle intervention was effective for general CVD risk factor reduction regardless of HT continuation or discontinuation. Additionally, lifestyle

appeared to attenuate increases in lipid levels that resulted from discontinuing HT. Finally, a simple walking endurance test may provide supplemental information when ascertaining CVD risk in women.

In the post-WHI era, concern and confusion about the risks associated with HT has left women and health-care providers searching for alternative means to decrease risk of CVD. Findings from the current report suggest that a non-pharmacological approach for CVD risk factor reduction is both safe and effective for primary CVD prevention in postmenopausal women. In light of the current controversies surrounding the use of HT, the promotion of healthy lifestyle behaviors for CVD risk factor reduction has important public health implications.

TABLE OF CONTENTS

PREFACE.....	XV
1 INTRODUCTION	1
1.1 MENOPAUSE AND CARDIOVASCULAR DISEASE RISK.....	1
1.2 HORMONE THERAPY AND CARDIOVASCULAR DISEASE	2
1.3 PHYSICAL ACTIVITY LEVELS IN POSTMENOPAUSAL WOMEN	3
1.4 STUDY GOAL	7
2 REVIEW OF LITERATURE	11
2.1 MENOPAUSE AND CARDIOVASCULAR DISEASE RISK.....	11
2.2 HORMONE THERAPY AND CARDIOVASCULAR DISEASE	14
2.3 PHYSICAL ACTIVITY ASSESSMENT IN EPIDEMIOLOGICAL STUDIES	22
2.3.1 Subjective Measures: Physical Activity Questionnaires	24
2.3.1.1 Complexity.....	24
2.3.1.2 Time Frame	25
2.3.1.3 Activity Type	25
2.3.2 Objective Measures: Pedometer	26
2.3.3 Physical Activity Assessment Issues in Women	27
2.4 POSTMENOPAUSAL WOMEN AND PHYSICAL ACTIVITY LEVELS	27

2.4.1	Relationship between Physical Activity Levels and CVD	27
2.4.1.1	Accuracy of Physical Activity Assessment	29
2.4.1.2	Methodological Concerns.....	29
2.4.2	Relationship between Physical Activity Levels and Lipids.....	31
2.4.2.1	Accuracy of Physical Activity Assessment	33
2.4.2.2	Methodological Concerns.....	34
2.4.3	Relationship between Lifestyle Intervention and CVD Risk Factor Reduction	35
2.4.4	Relationship between Physical Activity, Walking Performance and Subclinical CVD Measures.....	37
2.5	CONCLUSION	40
2.5.1	Objectives of the Project	41
3	METHODS.....	43
3.1	BRIEF OVERVIEW OF THE WOMAN CLINICAL TRIAL	43
3.2	MEASURES.....	45
3.2.1	Physical Activity Measures	45
3.2.1.1	Past Year Modifiable Activity Questionnaire (MAQ).....	45
3.2.1.2	Past Week Modifiable Activity Questionnaire (MAQ)	46
3.2.1.3	Pedometer	46
3.1.2	Completed Clinic Visit.....	47
3.1.3	Lipoprotein Subclasses	47
3.1.4	Long Distance Corridor Walk	48
3.1.5	Measures of Subclinical Disease	49

3.1.5.1	Electron Beam Computed Tomography (EBCT)	49
3.1.5.2	Carotid Ultrasound.....	50
3.3.	STATISTICAL ANALYSIS.....	51
3.4.	CONCLUSION	54
4	THE RELATIONSHIP BETWEEN PHYSICAL ACTIVITY AND LIPOPROTEIN SUB-CLASS LEVELS IN POST-MENOPAUSAL WOMEN: THE INFLUENCE OF HORMONE THERAPY	56
4.1	ABSTRACT.....	57
4.2	INTRODUCTION	58
4.3	METHODS.....	59
4.3.1	Study Population.....	60
4.3.2	Physical Activity.....	60
4.3.3	Hormone Therapy Status.....	61
4.3.4	Lipid and Lipoprotein Subclass Measures	61
4.3.5	Other Measures.....	62
4.3.6	Analytic Procedures.....	62
4.4	RESULTS	63
4.5	DISCUSSION.....	65
4.6	REFERENCES	70
5	CAN A LIFESTYLE INTERVENTION ATTENUATE THE EFFECT OF DISCONTINUING HORMONE THERAPY ON CARDIOVASCULAR RISK FACTORS?	77
5.1	ABSTRACT.....	78

5.2	INTRODUCTION	79
5.3	METHODS.....	80
5.3.1	Study Population.....	80
5.3.2	Group Randomization: Intervention Design.....	81
5.3.3	Physical Activity.....	82
5.3.4	Hormone Therapy Groups.....	83
5.3.5	Clinical Measures.....	83
5.3.6	Other Measures.....	84
5.3.7	Statistical Methods.....	84
5.4	RESULTS	85
5.5	DISCUSSION.....	87
5.6	REFERENCES	92
6	ASSOCIATIONS BETWEEN WALKING PERFORMANCE DETERMINED BY THE LONG DISTANCE CORRIDOR WALK, PHYSICAL ACTIVITY LEVELS, AND SUBCLINICAL MEASURES OF CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN	99
6.1	ABSTRACT.....	100
6.2	INTRODUCTION	101
6.3	METHODS.....	103
6.3.1	Study Population.....	103
6.3.2	Demographic and Clinical Measures	104
6.3.3	Long Distance Corridor Walk.....	104
6.3.4	Physical Activity Measures	105

6.3.5	Subclinical CVD Measures	106
6.3.6	Statistical Methods.....	107
6.4	RESULTS.....	108
6.5	DISCUSSION.....	110
6.6	REFERENCES	114
7	DISCUSSION.....	119
7.1	SUMMARY OF FINDINGS.....	119
7.1.1	Paper 1	120
7.1.2	Paper 2	120
7.1.3	Paper 3	121
7.2	PUBLIC HEALTH SIGNIFICANCE AND CLINICAL IMPLICATIONS.....	122
7.2.1	Paper 1	122
7.2.2	Paper 2	123
7.2.3	Paper 3	124
7.3	LIMITATIONS.....	124
7.3.1	Paper 1	126
7.3.2	Paper 2	126
7.3.3	Paper 3	127
7.4	FUTURE RESEARCH.....	128
7.5	CONCLUSION	128
	APPENDIX A : WOMAN STUDY PARTICIPANT INFORMATION FORM.....	130
	APPENDIX B : WOMAN STUDY PHLEBOTOMY FORM	139

APPENDIX C : WOMAN STUDY PHYSICAL ACTIVITY MEASURES	141
APPENDIX D : WOMAN STUDY DIETARY MEASURES.....	147
BIBLIOGRAPHY.....	159

LIST OF TABLES

Table 2-1: Evidence for the relationship between hormone therapy and cardiovascular disease prevention	15
Table 2-2: Recent evidence for the relationship between physical activity levels and cardiovascular disease development in postmenopausal women.	28
Table 2-3: Evidence for the relationship between physical activity levels and lipids in postmenopausal women.	33
Table 3-1: Time Line for WOMAN Study Measurements through the 18 Month Follow-Up	44
Table 4-1: Participant Characteristics Stratifying by Current Hormone Therapy Use in the WOMAN Study	73
Table 4-2: Final Multivariate Linear Regression Model for Leisure Physical Activity and Lipoprotein Subclasses for the Entire Cohort (n=482).....	74
Table 4-3: Multivariate Linear Regression Model for Leisure Physical Activity and Lipoprotein Subclasses for Hormone Therapy Users and Non-Hormone Therapy Users	75
Table 5-1: Baseline Cardiovascular Disease Risk Factor Levels between HT Continuers and HT Discontinuers	95
Table 5-2: 18 Month Change in Cardiovascular Risk Factors by Hormone Therapy Group and Randomized Group Assignment (n=231).....	96

Table 5-3: 18 Month Change in Cardiovascular Risk Factors after Adjustment (MLR Models) (n=231).....	97
Table 6-1: Baseline Characteristics of the WOMAN Study Cohort (n=492).....	116
Table 6-2: Spearman Rank Order Correlations Between Walk Time from the Long Distance Corridor Walk (LDCW) and Related Factors.....	117
Table 6-3: Characteristics of Study Participants by Quartiles of Walk Time (n=492).....	118

LIST OF FIGURES

Figure 2-1: Physical Activity Spectrum (Adapted from Kriska, 2000) ¹⁴³	24
Figure 4-1: Mean Lipoprotein Subclass Levels by Leisure Physical Activity, stratified by Current Homone Therapy Use.	76
Figure 5-1: 18 Month Change in Total Cholesterol and LDL-C by Randomized Group Assignment and HT group	98

PREFACE

“God grant me the serenity to accept the things I cannot change; courage to change the things I can; and wisdom to know the difference.” ~Reinhold Niebuhr.

This degree is the accomplishment of many important people in my life. I would like to thank my advisor, Dr. Andrea Kriska, for teaching me and providing me with opportunities that few students are lucky enough to get and Dr. Lewis Kuller for the opportunity to work as a graduate student researcher on the WOMAN Study. My committee members, Drs. Bret Goodpaster, Delia Johnson, and Trevor Orchard, have my sincere appreciation for their time, input, and dedication to this project. I am also very grateful for the support of the WOMAN study staff and other key staff members in the department. Finally, I would like to thank my many mentors, particularly Dr. Marilyn Cairns, who was instrumental to the achievement of this degree.

I would like to thank my family and close friends for all of their love and support. Mom and Dad, my successes in life are yours as well, I would not be where I am today without you. Thank you Mike, Sara, Amy and Julie for your humor and encouraging words that helped me keep going. Thank you Nana and Gramps (Pettee) and Gramma and Grampa (Gault) for pulling strings for me in heaven. Darcy, I am so very grateful to have you as my best friend, thanks for putting up with me! Thank you Kristi, I couldn't have shared an office with anyone else. Mark, thank you for the good times and support through the difficult times. Thank you Jen, Molly, Rachel, Beth, and others for your encouragement and support over the past 4 years.

1 INTRODUCTION

1.1 MENOPAUSE AND CARDIOVASCULAR DISEASE RISK

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among women in westernized countries. In the United States (U.S.) alone, more than half a million women die each year as a result of CVD and CVD mortality rates continue to rise⁴. In addition, a large proportion of deaths attributable to CVD occur in women with no previous symptoms, making early detection and diagnosis difficult^{1,2}.

The escalating rates of CVD observed in older, postmenopausal women may be related to the substantial adverse cardiovascular changes that occur as a woman transitions from pre- to post-menopausal status. In many women, CVD risk factors, including dyslipidemia, hypertension, abdominal adiposity, and insulin resistance develop during the menopausal transition^{5,6}. The alterations in lipid metabolism caused by estrogen deficiency are thought to be a substantial component of CVD development in postmenopausal women. In addition to the adverse changes in CVD risk factors, detrimental lifestyle changes, such as an increase in sedentary behaviors, that are common as one ages have been suggested to play a critical role in CVD development^{3,7-10}.

1.2 HORMONE THERAPY AND CARDIOVASCULAR DISEASE

Results of past observational epidemiological studies suggested that postmenopausal women taking hormone therapy had a 40-50% reduction of CVD when compared to non-hormone therapy users¹¹. However, recent evidence from randomized clinical trials has failed to validate the proposed cardio-protective benefits of hormone therapy. The Heart and Estrogen/progestin Replacement Study (HERS), found that among postmenopausal women with documented CVD, there was an increased risk of future CVD events within the first year of study randomization among hormone therapy users¹². Similar findings were observed in the Women's Health Initiative (WHI). The WHI consisted of three separate study arms: 1) low-fat dietary pattern, calcium and vitamin D supplementation, 2) combined estrogen and progestin, and 3) estrogen only. In 2002, the combined estrogen and progestin arm was terminated early due to growing evidence that women without previous CVD who were randomized to receive the combined hormone therapy had an increased risk of CVD, stroke, pulmonary embolism, and breast cancer¹³. In 2004, the estrogen alone arm was discontinued as well because results suggested that estrogen therapy increased the risk of stroke and did not appear to reduce the risk of CVD¹⁴. Findings from these studies have culminated in changed recommendations for prescription and distribution of hormone therapy in postmenopausal women^{15, 16}. Current guidelines recommend against the routine use of combined estrogen and progestin or unopposed estrogen for the prevention of cardiovascular disease in postmenopausal women¹⁷.

Beyond CVD incidence, hormone therapy has also been shown to impact a number of CVD risk factors. In general, hormone therapy has been suggested to alter the lipid profile in postmenopausal women. When compared to non-hormone therapy users, women taking hormone therapy consistently had decreased LDL and increased HDL and triglyceride levels as

measured by traditional measures^{3, 7, 9, 18, 19}. All can be considered beneficial changes with the exception of elevated triglycerides. Additionally, results from the combined estrogen and progestin arm of the WHI study suggested that women randomized to hormone therapy had greater reductions in both insulin and glucose levels. However, systolic blood pressure among the group receiving combination therapy was 1 mmHg higher at the first year follow-up visit and remained 1 to 2 mmHg higher at subsequent follow-up visits. Diastolic blood pressure did not differ between groups²⁰. This recent evidence from randomized clinical trials has failed to validate the cardio-protective benefit of hormone therapy. Therefore, other strategies need to be pursued in order to decrease CVD risk in women.

1.3 PHYSICAL ACTIVITY LEVELS IN POSTMENOPAUSAL WOMEN

One possible strategy for CVD prevention among older women may be to increase physical activity levels. Participation in regular amounts of physical activity has been demonstrated to play a vital role in the health and well-being of individuals of all ages²¹. Regular physical activity levels may help prevent or control many chronic diseases such as cardiovascular disease²²⁻²⁴, diabetes²⁵⁻²⁸, cancer^{29, 30}, depression^{31, 32}, and functional decline^{33, 34}.

Despite the well established benefits, only 38.6% of adults reported being physically inactive during their leisure time, defined as never engaging in any light, moderate, or vigorous leisure time physical activity. Additionally, over 68% of Americans did not meet the current minimum physical activity guidelines³⁵, defined as 30 minutes of moderate intensity activity, such as that of a brisk walk, on most if not all days of the week²¹.

Specific subgroups of the population, such as women, minorities, and the elderly are less likely to participate in regular amounts of physical activity³⁵. Older, postmenopausal women are among the least active subgroups in America³⁵. Higher rates of physical inactivity are particularly alarming due to the demonstrated beneficial link between physical activity and a number of conditions that affect older women.

Previous reports suggest that individuals with regular physical activity levels have a reduced risk of developing CVD^{21-24, 36}. Inactive individuals are considered twice as likely to develop CVD as their active counterparts³⁶. The inverse association between physical activity and CVD development may be due in part to the beneficial role of physical activity on the underlying etiology of cardiovascular risk factors^{6, 37}. As a result, physical inactivity has been identified as a major modifiable risk factor for CVD development due in part to numerous associated physiological benefits³⁸.

In general, physical activity has been shown to improve myocardial contraction, decrease resting heart rate, and increase stroke volume^{39, 40}. Additionally, there is improvement in endothelial function and flow-mediated dilation, increase in coronary artery formation and a decrease in clotting as a result of physical activity⁴⁰⁻⁴². Most of the past studies suggesting an inverse relationship between physical activity and CVD risk, many earlier studies were performed in men. The assumed benefit of physical activity on CVD development in women was extrapolated from such data⁴³. Only recent investigations on the relationship between physical activity and CVD development have specifically targeted older women. Current evidence suggests that there is, in fact, a beneficial relationship between physical activity and CVD development among older, postmenopausal women⁴⁴⁻⁵⁰.

The inverse relationship between physical activity and CVD may be explained by the reduction of cardiovascular risk factors (ie. hypertension, diabetes) in women who are physically active. However, the relationship between physical activity and lipids in postmenopausal women has been inconclusive⁵¹. Some studies have demonstrated a beneficial relationship between physical activity and lipids, while others suggest no association. To complicate matters, the association with physical activity may differ depending upon the specific lipoprotein in question. For example, some studies may suggest a positive association between physical activity and HDL levels; however, in the same investigation find no relationship between physical activity and other lipids.

The inconsistent findings on the relationship between physical activity and lipids in postmenopausal women may be due to a number of factors. For one, there were differences in the assessment of physical activity. For example, some studies on physical activity and lipids assessed fitness levels using maximum VO_2 testing^{7, 8, 19, 52-55}, rather than physical activity levels. Secondly, the study population differed in their hormone therapy use. Some studies included women taking hormone therapy^{52, 54, 55}, while others specifically excluded hormone therapy users⁵⁶⁻⁵⁸. In addition, when controlling for hormone therapy during statistical analyses, some studies adjusted for current use of hormones^{52, 54, 55}, while others adjusted for past hormone therapy use⁷.

The relationship between physical activity and lipids in postmenopausal women may be better clarified using specific lipoprotein subclasses and not traditional cholesterol measures. Specific lipoprotein subclasses, such as LDL size, total and small LDL particle number may relate better to cardiovascular disease development than traditional measures⁵⁹. Nuclear magnetic spectroscopy (NMR) is a relatively new technique that directly measures lipoprotein

subclasses. Little is known about the relationship between physical activity levels and lipoprotein subclasses and this relationship has yet to be explored in postmenopausal women on and off HT.

Despite the inconclusive relationship between physical activity and lipid levels, physical activity has been suggested to be beneficially related to other CVD risk factors. Regular activity improves the sensitivity of liver, skeletal muscle, and adipose tissue to insulin³⁷⁻³⁹. Furthermore, physical activity decreases both overall body weight and visceral fat accumulation^{21, 60-63}. It is also well established that physical activity decreases blood pressure^{21, 60, 64} and favorably alters markers of the inflammatory process⁶⁵⁻⁶⁹.

In addition to examining the independent associations between physical activity and CVD risk factors, more recent randomized clinical trials have explored the combined effect of physical activity, diet, and weight loss (lifestyle based approach) on CVD risk factor reduction and/or chronic disease prevention. Results from randomized clinical trials have demonstrated success in populations at risk for diabetes²⁵⁻²⁸ and heart disease⁷⁰; however, few studies incorporating lifestyle changes have targeted women at or after menopause. The Women's Healthy Lifestyle Project (WHLP), a randomized clinical trial, examined the effects of a lifestyle intervention on CVD risk factor change from pre- to post-menopause^{71, 72}. Results from WHLP demonstrated that a lifestyle based approach was successful at preventing weight gain⁷³ and rise in LDL-C levels⁷⁴ among women in peri- to post-menopause. However, these previous reports did not account for concurrent changes in HT status, an issue which has become particularly relevant in the post-WHI era.

The identification of women who are at an increased risk of incident CVD is as important to primary CVD prevention efforts. As stated above, a large proportion of CVD related deaths occur in women with no previous symptoms^{1,2}. The identification of asymptomatic women who are at increased risk for CVD also has important public health implications. Past epidemiological studies have suggested that exercise capacity and/or cardiovascular fitness is an independent predictor of cardiovascular events and death among asymptomatic women^{2, 75}. However, the gold standard technique used to evaluate cardiovascular fitness levels [maximal oxygen uptake (VO₂ max)] may not be financially practical in large epidemiological studies due to time constraints, staff burden, high equipment costs, and safety concerns⁷⁶. Tests of walking endurance, such as the long distance corridor walk (LDCW) have been substituted for this gold standard measure in older populations with promising results. However, few data are available regarding the applicability of this test in middle-aged, postmenopausal women.

1.4 STUDY GOAL

The identification of safe and effective primary CVD prevention strategies and screening tools that will aid in the early detection of asymptomatic women who are at increased risk for incident CVD has major public health implications. Therefore, the specific aims of the current investigation are to: 1). examine the cross-sectional relationship between physical activity, lipids, and lipoprotein subclass levels by current HT use, 2). determine the effect of lifestyle intervention on adverse CVD risk factor changes that may result from HT discontinuation, and 3). investigate the utility of a walking performance protocol among a cohort of overweight, middle-aged postmenopausal women. To accomplish these goals, we utilized a cohort of 508

postmenopausal women, aged 52 to 62, enrolled in the Women On the Move through Activity and Nutrition (WOMAN) Study. The WOMAN study is a randomized clinical trial of primary cardiovascular disease prevention in Pittsburgh, Pennsylvania (PA). Eligibility criteria for enrollment into the study included waist circumference ≥ 80 centimeters (cm), body mass index between 25-39.9 kilograms per meters squared (kg/m^2), not currently taking lipid lowering drugs, having a low density lipoprotein (LDL-c) level between 100-160 milligrams per deciliter (mg/dL), no physical limitation that would preclude walking, no known diabetes, and no diagnosed psychotic disorder and depression.

The recruitment of eligible WOMAN study participants was directly impacted by publication of the results from the combined estrogen progestin arm of the WHI and resulted in a natural experiment. Initial entry criteria for the WOMAN study required potential participants to be current HT users with at least two years of prior use. Approximately midway through the recruitment process, results were publicized from the estrogen/progestin (E+P) arm of the WHI trial indicating adverse effects among HT users¹³. In response to the WHI findings, the eligibility criteria in the WOMAN study were modified to include women with a recent history of HT use as it was deemed unethical to require potential participants to use HT. As a result, 204 (40.2%) of the WOMAN study participants were not current HT users at baseline. The changes in these eligibility criteria have provided the unique and timely opportunity to investigate the separate and combined role of physical activity as part of a lifestyle intervention for CVD risk factor reduction by current HT use and during HT discontinuation.

Using the WOMAN study cohort, we have the opportunity to clarify the cross-sectional associations between leisure physical activity and lipids using specific lipoprotein subclass measures and investigate how these relationships may be influenced by current HT use. In

addition to examining the independent contribution of physical activity for primary CVD prevention, we will also be able to investigate the effectiveness of a lifestyle intervention that includes physical activity in attenuating adverse changes to CVD risk factors that may develop as a result of discontinuing HT. Finally, tests of walking endurance have been used with promising results for estimating fitness levels, functional ability, and general health status in older adults. However, little is known regarding the applicability of these tests in younger populations. Data from the WOMAN study will allow us the opportunity to investigate the usefulness of the long distance corridor walk (LDCW) in middle-aged, postmenopausal women.

Specifically, the study meets the following objectives:

Paper 1: Examine the cross-sectional relationship between physical activity levels and lipoprotein subclasses by hormone therapy status at baseline.

- a. It is hypothesized that leisure physical activity will be beneficially related to some of the lipoprotein sub-classes in postmenopausal women; however, there will be a few lipoprotein subclasses in which physical activity is only significantly related in women not taking hormone therapy.

Paper 2: To determine if a lifestyle intervention promoting weight and waist circumference reduction through beneficial physical activity and dietary practices can attenuate unfavorable CVD risk factor changes that are likely to occur as postmenopausal women discontinue hormone therapy (HT) use.

- a. It is hypothesized that discontinuation of hormone therapy has negative consequences on many CVD risk factors.
- b. A lifestyle intervention will attenuate these negative consequences of discontinuing hormone therapy with regards to many CVD risk factors.

Paper 3: To determine the utility of the LDCW as a measure of health status in middle-aged, postmenopausal women.

- a. Walking performance, more specifically walk time, will be significantly related to demographic factors, anthropometric measures, subjective and objective measures of physical activity, and CVD risk factors in postmenopausal women.

2 REVIEW OF LITERATURE

In this literature review, the results of studies that have examined the relationship between physical activity (separately and as part of a lifestyle intervention), cardiovascular disease risk factors, and hormone therapy in postmenopausal women are presented. In addition, the results of investigations that have utilized tests of walking endurance to determine associations with mortality and incident CVD are briefly outlined. The strengths and weaknesses of the existing literature that lead to the development of the current project will also be discussed.

2.1 MENOPAUSE AND CARDIOVASCULAR DISEASE RISK

Currently, cardiovascular disease (CVD) is the leading cause of morbidity and mortality among older women and mortality rates continue to rise. Coronary heart disease (CHD) accounts for the majority of CVD deaths in women and disproportionately affects racial and ethnic minorities⁴. In the past, the number of CVD related deaths was strikingly higher in men when compared to women. Since 1984, the gap between male and females deaths attributed to CVD has narrowed dramatically⁴. The reasons for this gender discrepancy are not well understood; however, studies have suggested that the clinical presentation of CVD in women differs from that of men. A large proportion of deaths attributable to CVD occur in women with no previous symptoms^{1,2}, making

early detection in women particularly challenging. Risk factors suggested to be specific to development of CVD in women include dyslipidemia, inflammation, and insulin resistance⁷⁷.

Menopause is defined as the permanent cessation of menses. The menopausal transition defines the period of time in a woman's life between her pre- and post-menopausal years. During this time, levels of endogenous sex hormones such as estrogen decrease. The lack of estrogen is thought to be related to unfavorable changes in cardiovascular risk factors. In many women, CVD risk factors, including dyslipidemia, hypertension, abdominal adiposity, and insulin resistance begin to develop during the menopausal transition^{5, 6}. These changes have been suggested to explain the increase in development of CVD in older, postmenopausal women.

One consequence of estrogen loss at menopause is an increase in centralized, or intra-abdominal fat⁷⁸. Higher intra-abdominal fat has been identified as an important CVD risk factor, independent of overall obesity⁷⁹, due in part to its role in the development of dyslipidemia, inflammation, and insulin resistance⁶. Furthermore, centralized adiposity is associated with a greater risk for type 2 diabetes, higher triglyceride levels, and greater number of atherogenic, small, dense LDL particles⁸⁰.

Alterations in lipid metabolism caused by the excess in intra-abdominal fat are thought to contribute to the increase in CVD development in postmenopausal women. The proposed mechanism by which centralized fat stores increase risk of dyslipidemia is outlined briefly. It has been suggested that excess intra-abdominal fat is associated with an increase in insulin resistance, free fatty acid (FFA) levels, and decreased adiponectin (an adipocyte-derived peptide). These factors contribute to the increased secretion of apolipoprotein B (apo B) containing particles, which subsequently lead to high triglyceride levels, as well as an increase in hepatic lipase activity (liver enzyme). The increase in hepatic lipase activity results in a

preponderance of small, dense LDL particles, which are thought to be atherogenic, and a reduction in larger, anti-atherogenic HDL particles⁶.

The increase in intra-abdominal fat is also associated with increased levels of inflammatory markers, including C-reactive protein (CRP). Increased CRP levels have been shown to be a strong predictor of future cardiovascular events⁸¹. Centralized adiposity is also directly related to insulin resistance and compensatory hyperinsulinemia, independent of total body fat⁸².

The adverse changes to cardiovascular risk factors among postmenopausal women, such as the development of dyslipidemia, are demonstrated in results published from the Healthy Women Study (HWS). HWS was designed to investigate the changes in biological characteristics of a woman as she transitions through menopause. At study entry, all participants were between the ages of 42 and 50 years and pre-menopausal. Following the baseline assessment, women were asked to report their menstrual status on a monthly basis. A woman was considered postmenopausal when she stopped menstruating and/or had taken hormone therapy for 12 consecutive months. Study participants were re-evaluated at that time and 2, 5, and 8 years after menopause. Changes in cardiovascular risk factors were then compared during the perimenopause (defined as premenopause to 1 year after cessation of menses) and early postmenopause (defined as 1 to 5 years after the menopause). Results suggested that perimenopause was associated with increases in LDL cholesterol, triglycerides, and body mass index, while postmenopause was associated with increases in systolic blood pressure, pulse pressure, and fasting glucose⁸³.

2.2 HORMONE THERAPY AND CARDIOVASCULAR DISEASE

As mentioned previously, the lack of estrogen that accompanies menopause is related to a number of CVD risk factors, including dyslipidemia, inflammation, and insulin resistance. As a result, the use of exogenous hormone therapy was thought to be a cardio-protective strategy in postmenopausal women. Earlier observational studies supported the beneficial relationship between hormone therapy use and prevention of CVD⁸⁴⁻⁸⁹. A meta-analysis of epidemiological studies suggested that overall hormone therapy users had a 40-50% reduction of CVD risk when compared to non-hormone therapy users¹¹. However, recent evidence from randomized clinical trials has failed to validate the proposed cardio-protective benefits of hormone therapy.

The evidence for the relationship between hormone therapy and cardiovascular disease in postmenopausal women is presented in table 2.1 by type of study design. Of the five hospital based case/control studies, one demonstrated a positive association⁹⁰, two a negative association^{91, 92}, and two investigations suggested no association between hormone therapy and cardiovascular disease development^{93, 94}. Population-based case/control studies found more promising results. Of the eleven studies presented, nine found a negative association⁹⁵⁻¹⁰³ and only two found no association between hormone therapy and cardiovascular disease development^{104, 105}.

Table 2-1: Evidence for the relationship between hormone therapy and cardiovascular disease prevention

Study Design	Association	Studies	
Case-Control (Hospital Based)	0/+/-/0/-	Rosenberg ⁹³ ; Jick ⁹⁰ ; Jick ⁹¹ ; Rosenberg ⁹⁴ ; Szklo ⁹²	
Case-Control (Population Based)	-/-/-/-/-/0/-/-/0	Talbott ⁹⁵ ; Pfeiffer ⁹⁶ ; Ross ⁹⁷ ; Bain ⁹⁸ ; Adam ⁹⁹ ; Beard ¹⁰⁰ ; Thompson ¹⁰⁴ ; Psaty ¹⁰¹ ; Newton ¹⁰² ; O'Keefe ¹⁰³ ; Sidney ¹⁰⁵	
Cross-Sectional	-/-/-	Sullivan ¹⁰⁶ ; Gruchow ¹⁰⁷ ; McFarland ¹⁰⁸	
Prospective	Includes Non-HT Users	-/-/+/-/-/-/-/-/-/- /-/-/-/-/- + new use; 0 prior-current use/ + new use; - prior-current use/ + new use; - prior-current use	Hammond ¹⁰⁹ ; Lafferty ¹¹⁰ ; Stampfer ¹¹¹ ; Wilson ⁸⁹ ; Bush ¹¹² ; Petitti ¹¹³ ; Criqui ¹¹⁴ ; Henderson ¹¹⁵ ; Croft ¹¹⁶ ; Hernandez ¹¹⁷ ; Sullivan ¹¹⁸ ; Henderson ¹¹⁹ ; Stampfer ¹²⁰ ; Wolf ¹²¹ ; Sullivan ¹²² ; Grodstein ¹²³ ; Alexander ¹²⁴ ; Heckbert ¹²⁵ ; Grodstein ⁸⁴
	No Non-HT Users	-/-	Burch ¹²⁶ ; Hunt ¹²⁷
Randomized Clinical Trial	-/0/0/+/+/+/0	Nachtigall ¹²⁸ ; Hulley ¹² ; Herrington ¹²⁹ ; Waters ¹³⁰ ; Clarke ¹³¹ ; Rossouw ¹³ ; Anderson ¹⁴	

+ indicates positive association (hormone therapy users had an increased CVD risk); - indicates negative association (hormone therapy users had a decreased CVD risk); 0 indicates no association

The limitations of the case-control study design itself may partially explain the inconsistent findings that are presented in table 2.1. Case-control studies have a number of limitations, including the possibility of recall bias. For example, it may be difficult for a woman to accurately recall the correct type, dosage and/or number of years that she had taken hormone therapy. In addition, case-control studies often rely on existing medical records and proper selection and enrollment of an appropriate control group. This is especially true in hospital based case-control studies where the distribution of a particular exposure, in this case hormone therapy, may not reflect the distribution of the hormone therapy in the general population¹³².

As presented in table 2.1, all three of the cross-sectional studies demonstrated a negative relationship between hormone therapy and CVD. The results from these studies suggest that

current hormone therapy users had a decreased risk of cardiovascular disease when compared to non-hormone therapy users¹⁰⁶⁻¹⁰⁸.

The cross-sectional study design eliminates some of the restrictions of other study designs including case-control and prospective studies. As compared to case-control studies, cross-sectional study participants no longer have to recall hormone use and are typically defined as current hormone therapy users or non-users. Also, cross-sectional studies do not require the use of an appropriate control group. These factors may partially explain the consistent findings from the cross-sectional studies. Similarly, cross-sectional studies are not subject to limitations that are encountered when using prospective study designs. In cross-sectional studies, there are no issues on misclassification of hormone therapy status, which may affect the results of prospective studies.

Although, all three cross-sectional studies presented in table 2.1 suggested a negative association between hormone therapy and CVD, they are subject to a number of limitations. Cross-sectional studies cannot establish a temporal relationship between hormone therapy use and CVD. Also, prevalent, rather than incident, cases of CVD are identified; therefore, a relationship between hormone therapy use and CVD may be associated with survival rather than risk of development of the disease¹³².

Table 2.1 also presents the prospective studies that examined the relationship between hormone therapy and cardiovascular disease in postmenopausal women. The results of these studies are broken down into prospective studies that included a group of non-hormone therapy users and those that included hormone therapy users only. Of the nineteen prospective studies that included a group of non-hormone therapy users, fifteen demonstrated a negative relationship^{109-114, 119-123} and one a positive relationship⁸⁹ between hormone therapy use and cardiovascular

disease risk. The three remaining prospective studies included a group of postmenopausal women that were non-hormone therapy users. These three studies found mixed results depending upon whether the woman was a new, current, or prior hormone therapy user. All three of these studies, suggested that new users had an increased risk of developing CVD, while prior or current hormone therapy users showed no additional benefit beyond non-hormone therapy users^{84, 124, 125}. Two studies presented in table 2.1 excluded non-hormone therapy users and demonstrated a negative association between hormone therapy and CVD^{126, 127}.

Prospective study designs avoid the issues that affect other study designs. One important benefit of prospective study designs is that a temporal relationship between hormone therapy use and CVD risk can be established when investigating this relationship. However, as mentioned previously, prospective studies in which the exposure is only measured at one time point, may have problems with misclassification of hormone therapy status and may negatively impact the study results¹³². This may be one possible explanation for those prospective studies that did not suggest a negative association between hormone therapy and CVD.

The evidence from randomized clinical trials is far more conclusive than observational studies. The randomization process done in many clinical trials ensures that the study groups will be comparable in all respects except for hormone therapy status. Therefore, hormone therapy use and risk of CVD can be more clearly studied, without the known and unknown influence of potential confounding factors¹³². An early randomized clinical trial found a negative association between hormone therapy and CVD risk¹²⁸. However, after ten years of follow-up, only 4 of the 168 total women randomized developed CVD. The negative association that was suggested by this early study may have been due to the limited sample size as well as

the low number of cardiovascular events that were observed. Therefore, results from this randomized clinical trial may be difficult to interpret.

Evidence from recent randomized clinical trials has failed to validate the results suggested by past observational studies. The Heart and Estrogen/progestin Replacement Study (HERS), a secondary CVD prevention trial, found that among postmenopausal women with documented CVD there was an increased risk of CVD within the first year of study randomization for women randomized to hormone therapy ¹². Two additional secondary prevention studies found no association between hormone therapy and progression of coronary atherosclerosis ^{129, 130}, while another found an increased risk of CVD among users of a transdermal estrogen patch ¹³¹.

Primary CVD prevention randomized clinical trials were conducted in addition to secondary prevention trials. The Women's Health Initiative (WHI) was the foremost primary CVD prevention trial conducted in postmenopausal women. The WHI focused on defining strategies that could potentially decrease CVD, breast and colorectal cancer, and fractures risk in postmenopausal women. The WHI enrolled 161,809 postmenopausal women, aged 50 to 79 years, between 1993 and 1998 across 40 clinical centers in the United States. Eligible study participants were randomized into one of three separate study arms: 1) low-fat dietary pattern, calcium and vitamin D supplementation, 2) combined estrogen and progestin hormone therapy, and 3) hormone therapy consisting of estrogen only ¹³.

The primary outcome for the estrogen plus progestin arm of the WHI was CHD. CHD was defined as acute myocardial infarct (MI) requiring overnight hospitalization, silent MI determined from serial electrocardiograms, or CHD death. The study population for this arm of the clinical trial included 16,608 women of which 8,506 received conjugated equine estrogens

(0.625 mg/d, plus 2.5 mg/d medroxyprogesterone acetate) and the remaining 8,102 were given a placebo. Formal monitoring began in 1997. In 1999 the data safety monitoring board (DSMB) observed small, early adverse effects in cardiovascular outcomes, but none of the disease specific boundaries had been crossed. Approximately three years later (2002), the DSMB observed that the adverse effects in cardiovascular diseases persisted, although these results were still within monitoring boundaries. However, at this point, the boundary for breast cancer incidence had been crossed. Based on these data, the DSMB concluded that the evidence for breast cancer harm, along with the increase in CHD and other cardiovascular disease outcomes, outweighed the benefit of reduced fractures and colorectal cancer. As a result of these findings, the combined estrogen and progestin arm was terminated early after a mean follow-up of 5.2 years (planned duration was 8.5 years) ¹³.

In 2004, the final results from the estrogen plus progestin arm of the WHI were published and provided an updated analysis of coronary endpoints (acute MI, silent MI, CHD death, angina, acute coronary syndromes, and congestive heart failure). Women randomly assigned to receive estrogen plus progestin had a 24% higher risk of CHD when compared to women in the placebo group. Furthermore, the cumulative hazard rates of CHD showed an elevated risk among women taking estrogen and progestin soon after randomization and rates did not begin to converge between groups until 6 years post randomization. Additional analysis was performed to determine whether certain subgroups of women were at a higher or lower risk for CHD with estrogen and progestin based on baseline levels of lipid, inflammatory and thrombotic biomarkers. Only women randomized to hormone therapy, with higher levels of LDL cholesterol at baseline, had evidence of a pattern of hazard ratios for CHD that were different from patterns found among other women (Manson, 2003).

Similarly, the primary outcome for the estrogen only arm of WHI was CHD development. Again, CHD was defined as acute myocardial infarct (MI) requiring overnight hospitalization, silent MI determined from serial electrocardiograms, or CHD death. The study population for this arm of the clinical trial included 10,739 postmenopausal women with prior hysterectomy. Women were randomly assigned to receive either conjugated equine estrogens [n=5310 (0.625 mg/d)] or placebo (n=5429). As with the combined hormone therapy arm, formal monitoring of disease rate comparisons began in 1997 by the DSMB. In early 2000 and again in 2001, the DSMB recommended that participants in both arms of the study be informed of the early increases in CHD, stroke, and blood clot development that was found in women taking either form of hormone therapy. After the early termination of the estrogen and progestin arm, participants in the estrogen alone arm were notified about the increase in breast cancer that was observed in the E+P arm. In 2004, after additional review, the National Institutes of Health (NIH) decided to stop the intervention phase of the trial on the basis that estrogen increased the risk of stroke and did not appear to affect CHD development ¹⁴.

Despite the benefits suggested in observational studies, the negative results generated from both the primary and secondary prevention randomized clinical trials are far more conclusive. Only randomized clinical trials can establish the efficacy and safety of hormone therapy use for prevention CVD in postmenopausal women. As a result of the negative findings, current guidelines recommend against routine hormone therapy use for chronic conditions, including CVD. Furthermore, current hormone therapy users are currently advised to taper doses and ultimately discontinue use ¹⁵.

Hormone therapy has been shown to impact a number of cardiovascular risk factors. In the estrogen and progestin arm of the WHI, women randomly assigned to hormone therapy had

greater reductions in glucose and insulin levels. Also, body weight and waist circumference were lower among women taking hormone therapy; however, waist to hip ratio did not differ between groups. Among women receiving hormones, systolic blood pressure was 1 mmHg higher at the first year follow-up visit and remained 1 to 2 mmHg higher at subsequent follow-up visits. Diastolic blood pressure did not differ between groups²⁰.

Hormone therapy use has also been suggested to improve the overall lipid profile of older, postmenopausal women. Past studies have shown that, estrogen users had lower levels of LDL cholesterol levels and higher HDL cholesterol and triglyceride levels than non-users^{3, 7, 9, 18, 19}. All can be considered beneficial changes with the exception of the rise in triglyceride levels. Triglycerides have been identified as an independent risk factor for CVD among women^{18, 133}.

Lipoproteins comprise several distinct subclasses that differ in size, density, and composition^{18, 133, 134}. Disease risk is typically based on the indirect measurement of cholesterol that is carried by these lipoproteins. However, the amount of cholesterol that the particles actually contain varies from person to person due to differences in particle core composition and diameter. It has been suggested that CVD risk may be better quantified using specific lipoprotein subclasses measurement as opposed to traditional methods^{134, 135}. Traditional methods simply quantify the cholesterol carried within the particle as a surrogate marker for the actual lipoprotein concentration¹³⁴. Nuclear Magnetic Resonance (NMR) spectroscopy allows lipoproteins and their subclasses to be rapidly and directly quantified in order to provide a more accurate assessment of risk factors relating to CVD development among postmenopausal women. Past studies have suggested that LDL particle size, total and small LDL particle number is associated with incident CVD among older women⁵⁹.

Although hormone therapy users tend to have lower LDL cholesterol levels than non-users, estrogen has been found to also decrease LDL particle size^{136, 137}. Small LDL particles have been shown to be more atherogenic than larger LDL particles and are negatively correlated with large HDL levels^{133, 138}. Moreover, small LDL particles have a low affinity to LDL receptors and are more susceptible to oxidative metabolism and binding to arterial wall proteoglycans, setting the stage for atherosclerosis¹³⁹.

2.3 PHYSICAL ACTIVITY ASSESSMENT IN EPIDEMIOLOGICAL STUDIES

Physical activity is a complex behavior and selecting the proper assessment tool(s) is challenging, particularly among free-living populations. The lack of a reasonable gold standard measure and inconsistent use of physical activity terminology has contributed to confusion in this field. Measurement is further complicated by the fact that there are several health-related dimensions of physical activity¹⁴⁰, which may require the use of different assessment tools. The qualitative difference among the various dimensions of physical activity contributes to the diversity in the mechanisms behind the relationship of physical activity and specific diseases and; therefore, alter how physical activity should be assessed. When examining the relationship between physical activity and a disease or condition, it is important to focus on the dimension(s) of physical activity that is most likely to be associated with the specific outcome of interest.

Energy expenditure is defined as the exchange of energy required to perform biological work. Components of total energy expenditure include basal metabolic rate, which typically encompasses 50-70% of total energy, the thermic effect of food, which accounts for another 7-10% and physical activity¹⁴¹. Physical activity is the most variable component of total energy

expenditure and includes structured (sports, leisure, and occupational activity) and non-structured activities (housework, childcare, and activities of daily living).

Although similar, the terms physical activity and exercise have different meanings. Physical activity is defined as any bodily movement produced by skeletal muscles that result in increased energy expenditure¹⁴². Therefore, things such as housework, gardening, occupational, and leisure activity may all be considered types of physical activity. On the other hand, exercise is defined as planned, structured, and repetitive bodily movements done to improve or maintain one or more components of physical fitness and is usually associated with sport or conditioning activities¹⁴². When differentiating between the two, exercise is a type of physical activity, but not all physical activity is considered exercise. The term physical fitness is also confused with physical activity and/or exercise and can be defined as a set of attributes, such as cardiorespiratory fitness or muscle strength, that individuals have or can achieve that relate to the ability to participate in exercise and/or physical activity¹⁴².

Physical activity may be comprised of several different domains, including transportation, sports/leisure, school/occupation, and housework/child or elderly care and may span across an entire continuum of intensity levels. In order to accurately assess physical activity levels, it is essential that the entire spectrum of activity be captured (Figure 2.1)¹⁴³. It also becomes imperative that the assessment tool elicits information on the types of physical activities that encompass the greatest proportion of energy expenditure in the study population of interest. As illustrated in figure 2.1, the lower end of the physical activity intensity spectrum is comprised of general activities of daily living such as bathing, feeding, and grooming. The remainder of the intensity spectrum is comprised of activities that range in intensity from low to moderate and moderate to high levels. The relative contribution of each of these types of activity

to total energy expenditure in a specific population will vary depending upon the population of interest.




Figure 2-1: Physical Activity Spectrum (Adapted from Kriska, 2000) ¹⁴³

2.3.1 Subjective Measures: Physical Activity Questionnaires

Self-report questionnaires are the most frequently used method of assessing physical activity levels among community-based individuals. Questionnaires vary in their complexity, time frame, and type of activity that is assessed. Each of these considerations will be outlined in more detail in the following section.

2.3.1.1 Complexity

Physical activity questionnaires vary in their complexity, from single item questionnaires to more complex quantitative history questionnaires estimating physical activity over a lifetime. More complex questionnaires, such as recall questionnaires, attempt to survey a wide range of

popular activities over a defined time frame. Recall questionnaires detail the frequency, duration, and types of activities performed during a defined recall period (e.g., past day, week, month, or year)¹⁴⁴.

2.3.1.2 Time Frame

Subjective questionnaires can either ask about usual activity or inquire about activity performed within the past day, week, month, year, or even over a lifetime. Participants may be asked to use diaries and logs to record activities over 1 day, 3 days, or the past week. Questionnaires focusing on a long time frame, such as 1 year, are more likely to reflect usual activity patterns and have been used extensively in epidemiologic studies. Questionnaires with short time frames have two advantages over those with longer time frames: the estimates are less vulnerable to recall bias and more practical to validate with objective tools. However, assessment over a short time period is less likely to reflect “usual” behavior, as activity levels may vary with seasons or as a result of illness or time constraints¹⁴⁴. To obtain the best estimate of physical activity levels, some questionnaires include assessment over both a short and long time period.

2.3.1.3 Activity Type

As mentioned previously, physical activity may be comprised of several different domains. Early studies in physical activity epidemiology estimated physical activity performed at work¹⁴⁵,¹⁴⁶. However, since physical activity levels at work have continued to decline in most industrialized countries³⁶, assessment of leisure-time physical activity is often assumed to be the best representation of physical activity in a population. For this reason, most contemporary physical activity surveys only assess leisure-time activities that require energy expenditure above that of daily living. Some questionnaires include both leisure and occupational activity

components to be used in situations where the contribution of these components are either unknown or cannot be assumed^{147, 148}.

2.3.2 Objective Measures: Pedometer

Pedometers have gained widespread popularity in research and practice settings to quantify ambulation in terms of accumulated steps in free-living settings. Pedometers are small, inexpensive, battery operated devices worn at the waist that have the ability to measure ambulatory activity in terms of steps taken (and distance walked if stride length is available)¹⁴⁹. The vertical forces of foot-strike cause movement of a spring-suspended lever arm to open and close an electrical circuit, which registers a “step”. In theory, step registration should reflect only the vertical forces of foot-strike and hence ambulatory activity. However, any vertical force through the hip area (e.g., sitting down hard onto a chair, riding on a bike or in a car over rough terrain) can also trigger the device.

Pedometers have demonstrated reasonable precision for use in research and clinical settings where walking is the primary type of activity. Moreover, their ease of administration makes them a practical assessment tool for individuals encompassing nearly all age groups¹⁵⁰. However, pedometers do not provide information relating to activity type, duration, or intensity. Therefore, accurate quantification of activity-related energy expenditure, time spent in type- or intensity-specific activities, and patterns of activity (e.g., short versus continuous bouts) cannot be assessed using the pedometer. Similar to other movement monitors, pedometers are unable to quantify upper body movements or to assess activity levels in individuals at slower gait speeds

¹⁴⁹.

2.3.3 Physical Activity Assessment Issues in Women

It is well established that certain subgroups of the population (older adults and women) acquire most of their physical activity in lower intensity activities of which subjective measures tend to do a poor job assessing^{144, 151}. Therefore, the supplemental use of objective measures may be required for a more accurate assessment of physical activity in these populations. This is particularly important when lower intensity activities comprise the bulk of energy expenditure¹⁴³.

2.4 POSTMENOPAUSAL WOMEN AND PHYSICAL ACTIVITY LEVELS

2.4.1 Relationship between Physical Activity Levels and CVD

With the mounting evidence against any cardio-protective benefits of hormone therapy, it is essential that other strategies be developed in order to prevent CVD among postmenopausal women. As mentioned previously, non-pharmacological strategies such as maintaining regular physical activity levels are particularly appealing. Unfortunately, older, postmenopausal women are among the least active subgroups in the U.S., with more than 41% of women in this age group reporting being physically inactive during their leisure time³⁵.

Over the past few decades, evidence has accumulated on the role of physical activity in the prevention and treatment of CVD. The evidence clearly suggests that individuals who participate in regular physical activity have a reduced risk of developing CVD^{21, 22}. As a result,

physical inactivity has been identified as one of the major modifiable risk factors for CVD development due in part to the numerous physiological benefits.

In terms of cardiovascular benefits, physical activity improves myocardial contraction, decreases resting heart rate, and increases stroke volume both at rest and during exercise^{38, 40, 42}. Regular physical activity has been shown to improve endothelial function and flow-mediated dilation and increase coronary collateral artery formation^{38, 40, 42}. Physical activity also reduces platelet aggregation, which decreases the risk for clotting^{38, 40, 42}. Other adaptations that occur as a result of physical activity include the stimulation of lipid oxidation during activity and recovery and increases in lipoprotein lipase activity increases which in turn increases triglyceride clearance at rest and during activity^{38, 39}. Regular physical activity levels also improves the sensitivity of liver, skeletal muscle, and adipose tissue to insulin^{38, 39}. Physical activity is also indirectly protective against CVD development because it decreases blood pressure and obesity³⁸.

Prior studies demonstrating an inverse relationship between physical activity and CVD risk were mainly performed in men. The relationship between physical activity and CVD risk in women was inconclusive, with an assumed benefit extrapolated from what was found in men⁴³. The recent evidence for the relationship between physical activity levels and cardiovascular disease in postmenopausal women is presented in table 2.2 by study design.

Table 2-2: Recent evidence for the relationship between physical activity levels and cardiovascular disease development in postmenopausal women.

Study Design	Association	Studies
Case-Control	-/0	Lemaitre ¹⁵² ; O'Conner ¹⁵³
Prospective	-/0/-/-/0/-/-/-/-	LaCroix ⁴⁴ ; Lissner ¹⁵⁴ ; Folsom ⁴⁵ ; Kushi ⁴⁶ ; Sesso ⁴³ ; Manson ⁴⁸ ; Lee ⁴⁹ ; Manson ⁴⁷ ; Owens ⁵⁰

+ indicates positive association; - indicates negative association; 0 indicates no association

Of the two case/control studies presented in table 2.2, one found a beneficial relationship between physical activity and cardiovascular outcome¹⁵² while another showed no relationship¹⁵³. Seven of the nine prospective studies presented in Table 2.2 found a beneficial relationship between physical activity and cardiovascular disease⁴⁴⁻⁵⁰. The large number of studies suggesting an inverse relationship between physical activity levels and cardiovascular disease in postmenopausal women may be due to a number of factors, including the physical activity assessment tool that was used. The accuracy of the physical activity measure as other methodological factors will be described in detail in the following sections.

2.4.1.1 Accuracy of Physical Activity Assessment

All nine of the prospective studies presented in table 2.2 assessed leisure physical activity levels by subjective questionnaires^{43-50, 131, 153, 154} and did not rely on fitness measures that often reflect more vigorous types of activities. Three of the nine longitudinal studies examined if the protective effect of physical activity on CVD risk applies for moderate intensity activities that are common in women, such as walking. Data from these investigations indicate that moderate intensity activities are, in fact, associated with lower CVD rates in women^{48, 49, 155}, and that the benefits are similar for both moderate and vigorous activities^{48, 155}. There are no studies to date examining the relationship between CVD and lower intensity activities using objective monitoring.

2.4.1.2 Methodological Concerns

Although many studies presented in table 2.2 suggest an inverse relationship between physical activity and CVD, it should be noted that research in this area may have been affected by the possible misclassification of physical activity. Non-differential misclassification, a problem

intrinsic to the data collection methods, results from the degree of inaccuracy that characterizes how information was obtained in a particular study¹³². For example, misclassification could occur in prospective studies if physical activity is measured only during study entry while current, not prior, activity levels would have been more protective against incident CVD that was assessed at the end of the study. Six of the nine prospective studies presented in table 2.2 assessed physical activity only at baseline^{43-46, 49, 155} and all had follow-up periods of 4 years or longer. Therefore, a major limitation to the findings of these six prospective studies is the possible misclassification of physical activity. Despite this potential limitation, only one of these six studies did not find an inverse association between physical activity and CVD⁴³.

Another consideration in prospective study designs is the possibility that the study cohort will not have enough incident cases of CVD during the study duration. A low CVD incidence affects the power to detect a statistically significant association. Five studies presented in table 2.2 had less than a 2% incident rate for CVD [Folsom (1.2%); Kushi (1.8%); Manson (0.8%); Lee (0.6%); Manson (0.4%)]^{45, 46, 48, 49, 155}. However, despite this low incidence rate, all five studies suggested an inverse relationship between physical activity levels and CVD development in women. This suggests that the beneficial effects of physical activity on CVD development may be mediated through positive changes to cardiovascular risk factors.

Another potentially important limitation of past studies on the role of physical activity in cardiovascular disease prevention in post-menopausal women is the treatment of hormone therapy. As mentioned in an earlier section, use of hormone therapy has been shown to affect the development of cardiovascular disease in postmenopausal women. However, five of the eleven studies presented in table 2.2 did not assess hormone therapy status and; therefore, did not adjust for this potentially confounding factor in their analyses^{44, 46, 152-154}.

Loss to follow-up presents another methodological limitation. One investigation reported a high percentage loss to follow-up. In the College Alumni Health Study, only 66% of the study cohort was followed successfully⁴³. This high loss to follow-up rate may explain why this study failed to find an association between physical activity and CVD.

A final methodological concern is that individuals who avoid physical activity may do so because of poor health or a functional limitation that is a result rather than a cause of his/her disease status. Individuals with sub-clinical disease may have limited function, which may limit physical activity. Sub-clinical disease has no recognizable clinical diagnosis and is distinct from a clinical disease with specific signs and symptoms. Therefore, low reported physical activity levels may serve as a marker of the disease process and not usual behavior. Likewise, individuals who participate in physical activity may also have other health-promoting lifestyle behaviors which may also affect CVD development.

2.4.2 Relationship between Physical Activity Levels and Lipids

Research investigating the relationship between physical activity and lipid levels in women has been inconclusive¹⁵⁶. The evidence for the relationship between lipids in postmenopausal women and physical activity is presented in table 2.3. Some prior cross-sectional studies have suggested that total cholesterol does not change with physical activity^{52, 57}, while others have shown a decrease in total cholesterol levels^{54, 55}. Prospective studies show the same inconsistencies with regards to total cholesterol levels, some have suggested no association^{8, 53}, while others demonstrated an inverse relationship with physical activity^{7, 19}. There has also been suggestion that physical activity is beneficially related to LDL levels, while others have shown no change. One cross-sectional study suggested a negative association⁵⁵, while another found no

association between physical activity levels and LDL cholesterol⁵². Similar inconsistencies are obtained in longitudinal studies. An investigation by Binder et al.⁷, suggested an inverse relationship, while others showed no association^{8, 53} between physical activity and LDL levels. With regards to triglycerides, some cross-sectional studies have suggested a decrease in triglyceride levels among postmenopausal women who participate in physical activity^{52, 54, 55}, while an investigation by Cauley et al.⁵⁷ reported no change. Longitudinal studies investigating the relationship between physical activity and triglyceride levels among postmenopausal women have also be subject to the same discrepancies. Some investigations reported no association^{7, 8, 53, 58}, while one study reported an inverse relationship between physical activity and triglyceride levels¹⁹. Many cross-sectional studies have suggested a beneficial effect of physical activity on HDL levels⁵⁴⁻⁵⁷; however, prospective studies investigating this relationship have failed to validate this response^{7, 8, 19, 53, 58}.

Because of these uncertain findings, some have suggested that participation in physical activity may not be effective in postmenopausal women⁸. However, as discussed in the following sections, the conflicting findings of prior studies may be related to the assessment tool used to measure physical activity as well as other methodological concerns, such as the selection of an appropriate study population and the possible interaction of hormone therapy in the relationship between physical activity and lipid levels.

Table 2-3: Evidence for the relationship between physical activity levels and lipids in postmenopausal women.

Lipid	Association	Studies	
Total Cholesterol	Cross-sectional	0/0/-/-	Cauley ⁵⁸ ; Stevenson ⁵² ;; Haddock ⁵⁴ ; Hagberg ⁵⁵
	Prospective	-/0/-/0	Lindheim ¹⁹ ; Ready ⁵³ ; Binder ⁷ ; Klebanoff ⁸
Low Density Lipoprotein	Cross-sectional	0/-	Stevenson ⁵² ; Hagberg ⁵⁵
	Prospective	0/-/0	Ready ⁵³ ; Binder ⁷ ; Klebanoff ⁸
High Density Lipoprotein	Cross-sectional	+ /+ /0 /+ /+	Cauley ⁵⁶ ; Cauley ⁵⁷ ; Stevenson ⁵² ; Haddock ⁵⁴ ; Hagberg ⁵⁵
	Prospective	0/0/0/+/0	Cauley ⁵⁸ ; Lindheim ¹⁹ ; Ready ⁵³ ; Binder ⁷ ; Klebanoff ⁸
Triglyceride	Cross-sectional	0/-/-/-	Cauley ⁵⁷ ; Stevenson ⁵² ; Haddock ⁵⁴ ; Hagberg ⁵⁵
	Prospective	0/-/0/0/0	Cauley ⁵⁸ ; Lindheim ¹⁹ ; Ready ⁵³ ; Binder ⁷ ; Klebanoff ⁸

+ indicates positive association; - indicates negative association; 0 indicates no association

2.4.2.1 Accuracy of Physical Activity Assessment

A number of investigations in the area of physical activity and lipids in postmenopausal women utilized measures of physical fitness as surrogates for population appropriate measurements of physical activity^{7, 8, 53-55}. As mentioned previously, women tend to participate primarily in low to moderate intensity activities¹⁵⁷. Therefore, fitness measures that reflect more vigorous activities may not be appropriate assessment tools to use in this population.

Surprisingly, the earliest three investigations included both subjective and objective measures of physical activity when examining this relationship in 229 postmenopausal women⁵⁶⁻⁵⁸. The combination of physical activity assessment measures provides information across the physical activity spectrum (Figure 2.1). In these studies, physical activity was measured subjectively using the Paffenbarger Harvard Alumni Survey and objectively using a Large-Scale Integrated (LSI) monitor. Both the cross-sectional^{56, 57} and longitudinal investigations⁵⁸ suggested that physical activity as measured by objective measures of physical activity were not related to lipid levels. However, both cross-sectional studies^{56, 57} suggested a beneficial

relationship with HDL when physical activity was assessed subjectively. Despite the utilization of objective monitoring in these investigations, more work is needed using more recent and technologically advanced objective devices in a larger cohort of postmenopausal women.

2.4.2.2 Methodological Concerns

One methodological concern in the area of physical activity and lipids is the suggestion that individuals with elevated pre-exercise cholesterol levels respond more favorably to physical activity¹⁵⁸. Therefore, it may be unlikely that physical activity will make an impact on lipid levels that appear to be within normal limits. To date studies investigating the relationship between physical activity and lipids in postmenopausal women included only those with normal lipid profiles^{7, 8, 19, 52-58}.

Also, as mentioned previously, exogenous hormone therapy use alters the lipid profile of postmenopausal women. Past studies examining the relationship between physical activity and lipids have differed in their inclusion or exclusion of postmenopausal women on hormone therapy. Four of the ten studies presented in table 2.3 excluded hormone therapy users^{53, 56-58}, while another four investigations included both hormone therapy users and non-users^{8, 52, 54, 55}. Therefore, the inconclusive results demonstrated between physical activity and lipids in postmenopausal women may be partially explained by the differing inclusion/exclusion criteria used to define the study population.

NMR spectroscopy is a diagnostic test for the rapid and direct measurement of lipoprotein particle subclasses. Due to the novelty of this technology, there is currently limited information available on the relationship between physical activity and lipoprotein subclasses. The role of physical activity on specific lipoprotein subclasses, as well as those lipoprotein

subclasses that are thought to be related to CVD among postmenopausal women, has yet to be explored.

2.4.3 Relationship between Lifestyle Intervention and CVD Risk Factor Reduction

The combined benefit of physical activity, diet, and weight loss has been examined in randomized clinical trials testing the overall effect of a lifestyle based approach on CVD risk factor reduction and/or chronic disease prevention. Results from randomized clinical trials have demonstrated success in populations at risk for both type 2 diabetes²⁵⁻²⁸ and heart disease⁷⁰; however, few studies incorporating lifestyle have been done specifically in women at or after menopause.

The Women's Healthy Lifestyle Project (WHLP) was developed in response to the previously mentioned prospective investigation known as the Healthy Women Study (HWS) (refer to section 2.1: Menopause and Cardiovascular Disease Risk). Again, the HWS was developed to examine the physiologic changes that take place during the menopausal transition. Findings from the HWS suggested that menopause is associated with weight gain and adverse CVD risk factor changes⁸³. Consequently, the WHLP was a 5-year randomized clinical trial designed to examine the effect of a behavioral based lifestyle intervention on weight gain and adverse changes to LDL-C that likely result during the menopausal transition^{71, 72}. At study entry, the WHLP population consisted of 535 healthy, pre-menopausal women who were randomly assigned to either a lifestyle intervention consisting of dietary and behavioral modification or to an assessment-only control group. Participants in the lifestyle intervention group were also given modest weight loss goals (5-15 lbs) to prevent weight gain above baseline

levels. Both groups attended follow-up clinic visits at 6, 18, 30, 42, and 54 months after randomization.

At the 54 month follow up visit, 56% of the entire study cohort were still menstruating regularly and considered pre-menopausal; 10% were peri-menopausal (having missed 3-11 consecutive periods), and 35% were post-menopausal (having missed 12 consecutive periods or having had a hysterectomy). Of those women who had become postmenopausal by 54 months, 56% of control and 61% of intervention participants reported HT use. Results from the WHLP demonstrated significant differences between randomized groups with regards to systolic and diastolic blood pressure, triglyceride, glucose, and insulin levels. In addition, the lifestyle intervention resulted in a significantly smaller increase in LDL-C levels over 54 months; this difference between randomized groups was similar among hormone users and non-users. Based on these promising findings, the investigators concluded that a lifestyle based approach can successfully attenuate the rise in LDL-C levels that results due to menopause⁷⁴.

The investigators from WHLP also explored the effectiveness of the lifestyle intervention to prevent weight gain. Again, the main weight goal of the intervention was to prevent weight gain above baseline levels. At 54 months, 55% of the participants randomized to receive the intervention were at or below baseline weight compared with only 26% of controls. More specifically, the mean weight change in the intervention group was 0.1 (5.2) kg below baseline levels compared with an average gain of 2.4 (4.9) kg that was observed in the assessment group. Not surprisingly, change in WC followed the same trend as weight change. With regards to behavioral modification, participants randomized to the intervention reported higher physical activity levels and consumed fewer calories and less fat than women in the assessment group.

Therefore, in addition to CVD risk factor reduction, the lifestyle intervention was also successful at preventing weight gain among women from peri- to post-menopause⁷³.

Unfortunately, little is known regarding the overall effectiveness of lifestyle modification for primary CVD prevention among postmenopausal women. In addition, findings from WHLP did not account for concurrent changes in HT status, an issue which has become particularly relevant in the post-WHI era. Therefore, the role of lifestyle on CVD risk factor reduction among postmenopausal women in various states of HT use has yet to be explored.

2.4.4 Relationship between Physical Activity, Walking Performance and Subclinical CVD Measures

As mentioned previously a large proportion of CVD related deaths occur in asymptomatic women. Specifically, approximately 2/3 of all sudden deaths attributable to CVD occur in women with no previous symptoms^{1,2}. Women differ from men with regards to both the clinical presentation of CVD and performance on standard diagnostic tests⁷⁵, making early detection among women a challenge. Therefore, in addition to prevention strategies, the development of tools that aid in the early detection of asymptomatic women who are at an increased risk of CVD has major public health implications.

Past epidemiological studies have shown that cardiovascular fitness, as measured by exercise capacity, is an independent predictor of cardiovascular events and death among asymptomatic women^{2, 75, 159, 160}. Results from the St. James Women Take Heart Project study suggested that for each 1 MET increase in exercise capacity, there was a 17% reduction in all cause mortality among asymptomatic women⁷⁵. The prognostic value of measuring exercise capacity in women asymptomatic for CVD was confirmed in the Lipids Research Clinics

Prevalence Study¹⁶¹. Based on these findings, the investigators concluded that the addition of a cardiorespiratory fitness measure to traditional risk factor assessment may be valuable for early detection, particularly among women with no apparent symptoms.

Maximal oxygen uptake (VO_2 max), the most accurate assessment of cardiovascular fitness, is typically estimated from a symptom limited treadmill or cycle ergometry based exercise stress test. However, VO_2 max protocols may not be practical in large epidemiological studies due to time constraints, staff burden and required medical oversight, high equipment costs, and safety concerns^{76, 162}. In instances where VO_2 max testing is not realistic, tests of walking endurance have been substituted for this gold standard measure to estimate fitness levels.

Walking endurance protocols were primarily developed to estimate exercise capacity in diseased and/or older populations¹⁶³. The walking endurance test, a 12 minute walking test, was introduced in 1968 as a submaximal, field test to estimate VO_2 max (based on achieved HR)¹⁶⁴. In 1982, Butland et al. found that decreasing the total duration of the test from 12 to 6 minutes, to make it more feasible in populations with chronic diseases, did not significantly reduce the utility of the test¹⁶⁵. As a result, the 6 minute walk test (6MWT) was used primarily in diseased populations who were not able to tolerate traditional VO_2 max protocols and/or long periods of exertion. Originally, the 6MWT was used to estimate fitness levels in individuals with chronic respiratory disorders¹⁶⁵⁻¹⁶⁷. However, in the mid-1980's, researchers reported the utility of this test to assess fitness levels in individuals with chronic heart failure^{168, 169}. Over time, the 6MWT protocol was applied to the elderly as a measure of functional status¹⁷⁰. Although the information obtained from the 6MWT provided information beyond that of traditional indicators, when validating this measure against the gold standard (treadmill or cycle ergometry based

exercise stress tests), it was determined that the relationship between peak O₂ consumption and distance walked during the 6MWT was not linear¹⁶⁹; therefore, the convergent validity of this instrument could not be assumed.

The long distance corridor walk (LDCW) is a slight modification of the 6MWT protocol, and was developed to extend the range of self paced walking tests in older adults¹⁶³. As opposed to measuring the distance covered over a predetermined duration (6 minutes), the LDCW protocol assesses the total time necessary to walk a 400 meter course. The LDCW was developed based on the thought that an individual may be more intrinsically motivated to complete a predetermined distance that can be visualized, in as little time as possible, thus providing a more maximal effort¹⁶². A 2001 investigation directly compared the overall work effort, as indicated by walking speed, and ending heart rate (HR) and systolic blood pressure (SBP), from the 6MWT and LDCW, and results confirmed that a target distance encouraged individuals to walk closer to their maximal effort when compared to a time dependent protocol¹⁶².

The LDCW has been utilized in well-functioning healthy older individuals with promising results. Results from a cross-sectional investigation using the Health, Aging, and Body Composition study (Health ABC) suggested that walking performance was influenced by both clinical and subclinical diseases and was strongly related to anthropometric measures and self reported physical activity levels. Results from the follow-up Health ABC investigation suggested that exclusion or inability to complete the LDCW protocol was associated with an increased risk of mortality, incident CVD, and mobility limitation¹⁷¹. For those that completed the protocol, each additional minute of walk time was associated with a 29% higher rate of mortality, a 20% higher rate of incident CVD, and 52% higher rates of mobility limitation and

disability¹⁷¹. These findings suggest that measured parameters from the LDCW, particularly walk time, are useful for estimating risk of mortality and/or disease among older adults.

In addition to risk assessment, the use of the LDCW to estimate physical fitness levels was investigated¹⁷². The relationship between walk time from the LDCW and peak VO₂ measures obtained during a treadmill based protocol (modified Balke¹⁷³) were examined in 102 participants, aged 60 to 91, from the Baltimore Longitudinal Study of Aging (BLSA). The correlation between walk time and peak VO₂ was -0.79, indicating a strong relationship between the measured parameters. Therefore, in contrast to the 6MWT, the convergent validity of the LDCW to estimate fitness levels among older individuals can be assumed¹⁷².

It is fairly well established in the literature that the LDCW is a low cost alternative for estimating cardiovascular fitness levels and is useful for assessing mortality and incident disease risk in older individuals; however, little is known regarding the applicability of this test in middle-aged, postmenopausal women.

2.5 CONCLUSION

The literature provides strong evidence for the 1) association between physical activity and lipid levels, 2) positive role of lifestyle based interventions for CVD risk factor reduction and primary CVD prevention, and 3) usefulness of the LDCW to ascertain CVD risk. However, an examination of this literature also exposes the fact that several studies in this field have limitations in their design that can be addressed in future research. This project will address these shortcomings by using 1) both subjective and objective physical activity assessment tools, 2) direct measure of lipoprotein particle subclasses, 3) subclinical CVD measures, and 4)

measured parameters from the LDCW. The project will also examine the added influence of current and/or change in HT use on these relationships. With these improvements, we expect that this project will make a significant contribution to the existing literature.

2.5.1 Objectives of the Project

The proposed investigation will examine the 1) relationship between leisure physical activity, lipids, and lipoprotein subclass levels and investigate how current HT use may influence these associations, 2) effectiveness of a lifestyle intervention to attenuate unfavorable changes to CVD risk factors that result from HT discontinuation, and 3) associations between walking performance, physical activity levels, and subclinical CVD measures in 508 postmenopausal women, aged 52-62 years. Specifically, the study meets the following objectives:

Paper 1: Examine the cross-sectional relationship between physical activity levels and lipoprotein subclasses by hormone therapy status at baseline.

- a. It is hypothesized that leisure physical activity will be beneficially related to some of the lipoprotein sub-classes in postmenopausal women; however, there will be a few lipoprotein subclasses in which physical activity is only significantly related in women not taking hormone therapy.

Paper 2: To determine if a lifestyle intervention promoting weight and waist circumference reduction through beneficial physical activity and dietary practices can attenuate unfavorable CVD risk factor changes that are likely to occur as postmenopausal women discontinue hormone therapy (HT) use.

- a. It is hypothesized that discontinuation of hormone therapy has negative consequences on many CVD risk factors.

- b. It is further hypothesized that a lifestyle intervention will attenuate negative consequences of discontinuing hormone therapy with regards to many CVD risk factors.

Paper 3: To determine the utility of the LDCW as a measure of health status in middle-aged, postmenopausal women.

- a. Walking performance, more specifically walk time, will be significantly related to demographic factors, anthropometric measures, subjective and objective measures of physical activity, and CVD risk factors in postmenopausal women.

3 METHODS

3.1 BRIEF OVERVIEW OF THE WOMAN CLINICAL TRIAL

The WOMAN Study is a five-year randomized clinical trial designed to test whether an aggressive non-pharmacological intervention among postmenopausal women currently or previously on HT would modify or reduce measures of subclinical cardiovascular disease. Eligibility criteria for enrollment into the study included: age 52-62 years, waist circumference \geq 80 centimeters (cm), body mass index between 25-39.9 kilograms per meters squared (kg/m^2), not currently taking lipid lowering drugs, having a low density lipoprotein (LDL-C) level between 100-160 milligrams per deciliter (mg/dL), no physical limitation that would preclude walking, no known diabetes, and no diagnosed psychotic disorder and depression. Eligible WOMAN study participants (n=508) were randomized into one of two groups: lifestyle change (intervention) (n=253) and health education control (n=255).

Table 3.1 illustrates the measures central to this proposed plan and the number of WOMAN study participants that completed each measure. Those that completed the clinic visit also completed all measurements that were obtained during that visit including demographics, medication inventory (hormone therapy (HT) and other medication use), anthropometric measures (BMI and waist circumference), blood pressure, and fasting blood draw (plasma cholesterol, insulin, and glucose). It should be noted that the WOMAN study cohort represents a

higher than normal risk for CVD based on higher waist circumference and BMI criteria at entry. Changes in HT recommendations¹³ that were made during mid-recruitment resulted in a cohort of postmenopausal women with varied HT status. Therefore, the HT component of the WOMAN study was not randomized. Additionally, these changes in recommendations resulted in a number of women changing HT status as they progressed through the first 18 months of the 5-year long study.

Table 3-1: Time Line for WOMAN Study Measurements through the 18 Month Follow-Up

	Baseline/Screening Visit	6-Month Follow-up Visit	18-Month Follow-up Visit
Completed Clinic Visit (including demographic survey, medication inventory, anthropometric measures, blood pressure, and fasting blood draw)	x (n=508)	x (n=485)	x (n=455)
Physical Activity Measures			
Past Year MAQ	x (n=504)	x (n=484)	x (n=455)
Past Week MAQ	x (n=506)	x (n=467)	x (n=440)
Pedometer	x (n=173)		x (n=323)
Long Distance Corridor Walk			
	X (n=505)		
Cardiovascular Disease Risk Factors			
Lipoprotein Subclasses	x (n=493)	x (n=479)	x (n=454)
C-Reactive Protein	x (n=201)		x (n=201)
Subclinical Measures of Cardiovascular Disease			
Coronary Artery Calcification (EBCT)	x (n=507)		
Carotid Ultrasound	x (n=503)		

3.2. MEASURES

3.2.1. Physical Activity Measures

3.1.1.1 Past Year Modifiable Activity Questionnaire (MAQ)

Physical activity was measured using the MAQ, an interviewer administered, past-year questionnaire¹⁴⁴. The MAQ has been shown to be both reliable^{144, 174} and valid^{144, 174, 175} and has been used to assess physical activity levels in over 200 studies consisting of populations from all over the world. This questionnaire assesses current leisure and occupational activities, as well as extreme levels of inactivity due to disability. Study participants were asked to report if they participated in specific activities, such as walking for exercise, at least 10 times over the past year (12 months). For those that participated in a specific activity, they were asked which months they had participated in that specific activity over the past year and then estimated the number of times each month and length of time that they spent doing the specific activity. Physical activity levels were calculated as the product of the duration and frequency of each activity (in hours per week), weighted by an estimate of the metabolic equivalent (MET) of that activity and summed for all activities performed. One MET represents the energy expenditure for an individual at rest, whereas a 10-MET activity requires 10 times the resting energy expenditure¹⁷⁶. Physical activity data were expressed as metabolic equivalent hours per week (MET hr-wk).

For occupational activity, individuals were asked to list all jobs held during the past 12 months. For each job entry, data were collected for minutes per day walking or cycling to work, as well as the number of months per year, days per week, and hours per day spent working in that job. Job activity was determined by the number of hours spent sitting at work and the most

frequent activities performed when not sitting. Housewives, unemployed, physically challenged, and retired individuals were questioned about activities during a normal “40 hour work week”

144

Estimates of leisure and occupational activity were calculated separately as hours per week (h-wk) averaged over the past year. Total physical activity was the combination of leisure and occupational activity averaged over the past year.

3.1.1.2 Past Week Modifiable Activity Questionnaire (MAQ)

Physical activity was also assessed using a past week version of the MAQ. This questionnaire measures participation in leisure activities performed over the past 7 days. Study participants were given the past week MAQ during the eligibility visit and were asked to record leisure activities for the 7 days prior to their clinic assessment. Past week leisure physical activity levels were calculated similar to that used for the leisure section of the past year MAQ.

3.1.1.3 Pedometer

Physical activity was measured using the Accusplit Eagle (AE120) pedometer. At baseline, pedometer data was collected on a subgroup of women entering the study; however, was available to all participants at the 18 month clinic visit. The participant was instructed to wear the pedometer clipped to her waistband over the dominant hip for one week, and at the end of each day to record the number of steps taken in a diary. At the end of the week the participant returned the activity diary to the investigator. The number of steps recorded in the diary from the pedometer was averaged for the week to obtain a seven-day average of the number of steps taken per day.

3.1.2 Completed Clinic Visit

The proposed investigation examines the relationship between physical activity and cardiovascular risk factors in postmenopausal women during the first 18 months of the 5 year long study. The completed baseline and 18 month clinic visits will be critical for proposed examination. All relevant demographic and clinical measures (ie. anthropometrics, fasting blood draw) were collected during these time points.

3.1.3 Lipoprotein Subclasses

Participant blood samples were drawn after a 12 hour fast. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy (Liposcience Inc., Raleigh, NC), as previously described ¹⁷⁷. In brief, the lipoprotein subclasses were quantified using characteristic signals, which differ in frequency and shape depending on the diameter of the lipoprotein particle, as a basis for quantification. Each signal was derived from the total number of terminal methyl groups on the lipids contained within the particle core and in the surface shell. The intensity of each signal was proportional to the quantity of the subclass and was multiplied by a standard lipid amount to provide results in mg/dL of cholesterol for low density lipoprotein (LDL) and high density lipoprotein (HDL) and mg/dL of triglyceride for very low density lipoprotein (VLDL). The lipoprotein subclasses were categorized as large (60- to 200-nm), medium (35- to 60-nm), and small (27- to 35-nm) VLDL; IDL (23- to 27-nm), large (21.3- to 23.0-nm), medium (19.8- to 21.2-nm), small (18.3- to 19.7-nm), and very small (\leq 18.2-nm)

LDL; and large (8.8- to 13-nm), medium (8.2- to 8.8-nm), and small (7.3- to 8.2-nm) HDL. Particle concentrations (nmol/L for VLDL and LDL; $\mu\text{mol/L}$ for HDL) were calculated for each subclass standard by measuring the total concentration of core lipid and dividing the volume occupied by these lipids by the core volume per particle calculated from the diameter of that particle^{178, 179}.

3.1.4 Long Distance Corridor Walk

The LDCW consisted of 400 meter walk along a course consisting of 10 laps along a hallway with cones set 20 meters apart (40 meters per lap). Participants were instructed to walk “at a pace that you can maintain for the full 10 laps.” Standard encouragement by a trained clinician was given at each lap. Heart rate was monitored with a Polar Pacer hear monitor (Model 60905; Woodbury, NY). Persons with elevated blood pressure (BP $\geq 200/110$), resting heart rate (>110 or <40), recent exacerbation of chest pain, shortness of breath, or reporting a recent cardiac event or procedure were excluded for safety reasons. The LDCW was stopped if the participant’s heart rate exceeded 135 beats per minute (bpm) or if a participant reported chest pain or dyspnea during the test. Heart rate (HR) was recorded at rest before starting the walk, at completion, and at recovery 2 minutes later. Systolic blood pressure (SBP) was measured while seated prior to the walk and while standing at test completion. Based on these measures, cardiovascular response variables were generated. HR and SBP response were calculated by subtracting the resting values from those obtained immediately following completion. HR recovery was calculated by subtracting the HR obtained 2 minutes after LDCW completion from the value measured at completion.

3.1.5 Measures of Subclinical Disease

3.1.5.1 Electron Beam Computed Tomography (EBCT)

The participant was positioned supine on the table with the head toward the gantry; a bolster pillow was placed under the knees for comfort. After careful skin preparation, electrodes were placed and an optimum EKG tracing was obtained. The participant's body was next positioned within the gantry with arms over head and resting on the arm rests. The laser-guided light was positioned over the participant's xiphoid process. A second laser-guided light was used to adjust the table height so the participant was centered within the gantry. The participants had to hold their breath during the scanning. Each time the scanner was operated, they were instructed to take a breath in, let it out, take a second breath, let it out, and take a third breath, and hold it. The first scan was a preview scan, which served the purpose of calibrating to chest size of the given participant. The second scan imaged the entire heart, with cross-sectional images at every 3 mm. The pictures were taken during the diastolic phase of the cardiac cycle, one image during each heart beat. We obtained 30-40 contiguous 3mm thick transverse images from the level of the aortic root to the apex of the heart. Images were obtained during maximal breath holding using EKG triggering so that each 100m second exposure was obtained during the same phase of the cardiac cycle, 60% of the RR interval.

All EBCT studies were read at the University of Pittsburgh. Readings of coronary calcification were done using a DICOM workstation and software by Accuimage (San Francisco, CA). This software program implements the widely accepted Agaston scoring method¹⁸⁰. Coronary artery calcium was considered to be present when 3 contiguous pixels greater than 130 Hounsfield units were detected overlying the vessels of interest. Scoring results in a total calcium score as well as a total number of calcifications.

3.1.5.2 Carotid Ultrasound

The scanning procedure results in three primary carotid disease measures: average wall (intima-media) thickness, a measure of degree of focal plaque called the plaque index, and the ICA/CCA velocity ratio, a determination of whether or not plaque is interfering with blood flow in the internal carotid artery. Carotid ultrasound measurements were obtained using a Toshiba SSA-270A scanner in Pittsburgh, PA. Briefly, detailed B-mode images of the right and left common carotid artery, carotid bifurcation and the first centimeter of the internal carotid were obtained. Selected images were digitalized for later measurement of the intima-media thickness by central readers in Pittsburgh. After imaging, the sonographer obtained Doppler measures of blood flow velocity at mid common (2 cm proximal to the carotid bulb) and in the internal carotid at the point of the highest velocity distal to the flow divider. These were used to calculate the degree to which plaque may be interfering with blood flow. Plaque was defined as a distant focal area protruding into the vessel lumen. Plaque was assessed in 4 areas: proximal common, distal common, carotid bulb, and internal carotid. For each segment, the degree of plaque was graded using the following criteria: Grade 0 = no observable plaque; grade 1 = one small plaque (less than 30% of the vessel diameter); grade 2 = one medium plaque (between 30 and 50% of the vessel diameter) or multiple small plaques; grade 3 = one large plaque (greater than 50% of the vessel diameter) or multiple plaques with at least one medium plaque. The grades were then summed to create a plaque index, a measure of the extent of eccentric plaque.

Stiffness of the aorta was measured using the gold standard, carotid-femoral (or aortic) pulse wave velocity (aPWV), as previously described in detail^{181, 182}. Briefly, for each participant, 20 seconds of carotid and femoral pulse waveforms were collected simultaneously with non-directional Doppler probes and recorded to data files. Files were “scored” using

software developed by the Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging. For each file, the trained reader selected all clear waveforms for averaging into composite carotid and femoral waveforms, to determine the “foot” (or upstroke) of each. The transit time of the pulse wave was calculated as the foot-to-foot delay between the averaged carotid and femoral waveforms. The distance traveled by the pulse waveform between the carotid and femoral measurement sites was measured manually with a metal tape measure, above the surface of the participant’s torso. Aortic pulse wave velocity was calculated by dividing the distance traveled by the time differential between the two waveforms and expressed as distance/transit time (cm/sec). Results from all usable data collection runs (n = 3) for each participant are averaged. In our lab this measure has been demonstrated to have good reproducibility with an intraclass correlation of 0.72-0.83¹⁸¹.

3.3. STATISTICAL ANALYSIS

Briefly described below are the analytical procedures for papers 1-3. The specific methodologies are described in greater detail within the context of each respective paper.

Paper #1: The primary hypothesis of paper #1 was to determine if leisure physical activity is beneficially related to many of the lipoprotein sub-classes in postmenopausal women. A secondary hypothesis was that there are some lipoprotein subclasses in which physical activity is only significantly related in women not taking hormone therapy. To test the primary and secondary hypotheses, the following statistical procedures were performed.

Descriptive statistics were used to describe demographic, anthropometric measures, physical activity, and lipoprotein subclass levels in the entire cohort and stratified by HT use.

All variables were assessed for normality. Normally distributed variables were reported as mean \pm standard deviation; not normally distributed variables were reported as median with 25th and 75th percentiles. Depending upon the characteristics of the variable, t-tests, Wilcoxon Rank Sum, or Chi Square (χ^2) tests were used to compare HT users and non-users.

For each lipoprotein subclass, we evaluated four multivariate linear regression models. The first model examined the association between physical activity and lipoprotein subclasses after controlling for age and saturated fat/cholesterol intake. The second model added BMI and the third model added HT status as covariates. The fourth model evaluated the addition of a physical activity*HT interaction term to these models. For graphic representation, we evaluated the lipoprotein subclass levels across physical activity quartiles. Jonckheere-Terpstra tests were also used to estimate linear trends in mean lipoprotein subclass levels across physical activity quartiles stratified by HT status.

Paper #2: The primary hypothesis of paper #2 was that discontinuing hormone therapy may increase certain CVD risk factors and that a lifestyle intervention can attenuate the effect of discontinuing HT on CVD risk factors. To test the primary hypothesis, the following statistical procedures were performed.

The study population for this analysis consisted of a subgroup of the WOMAN study participants who were on HT at study entry. Descriptive statistics were used to describe baseline anthropometric measures, leisure physical activity levels, and CVD risk factor levels by HT group (those that continued versus discontinued use at the 18 month follow-up visit). Normally distributed variables were reported as mean \pm standard deviation; non-normally distributed variables were reported as median with 25th and 75th percentiles. Depending upon the

characteristics of the variable, t-tests or Wilcoxon Rank Sum tests were used to compare baseline CVD risk factor values between HT continuers and HT discontinuers.

The 18 month change in anthropometric, physical activity, and CVD risk factor variables over time were calculated as the difference in values between the 18 month follow-up and baseline. Change variables were reported and compared between HT continuers and HT discontinuers, stratified by randomized group assignment using t-tests or Wilcoxon Rank Sum tests. CVD risk factor change was also reported and compared between randomized groups, stratified by HT status at the 18 month clinic visit.

Further post-hoc analyses were conducted to determine the independent effect of healthy lifestyle behaviors that were promoted in the lifestyle intervention on CVD risk factor reduction using multivariate linear regression models. The multivariate model examined the longitudinal relationship between CVD risk factor and change in leisure physical activity, and saturated fat/cholesterol intake, after adjusting for HT status at 18 months and baseline levels of leisure physical activity, saturated fat/cholesterol intake, and relevant CVD risk factor.

Paper #3: The primary hypothesis of paper #3 was that walking performance obtained from the LDCW was related to physical activity levels and measures of subclinical CVD among postmenopausal women. A secondary hypothesis was that the cardiovascular response measures obtained from the LDCW was related to physical activity levels and measures of subclinical CVD. To test the primary and secondary hypotheses, the following statistical procedures were performed.

Univariate analyses were conducted on measured parameters from the LDCW, demographics, physical activity levels, and measures of subclinical CVD. Normally distributed variables were reported as mean \pm standard deviation, non-normally distributed variables were

reported as median with 25th and 75th percentile, and proportions were noted for categorical variables. Spearman rank order correlation coefficients were used to assess the bivariate associations between walk time and CV response measures from the LDCW, demographics, physical activity levels, and CVD risk factors and partial Spearman rank order correlations were used to examine these relationships adjusted for age and BMI. Descriptive statistics were used to illustrate demographics, physical activity levels, and CVD risk factors across quartiles of LDCW time. Depending upon the characteristics of the variable, ANOVA, Kruskal-Wallis, or Chi Square Test of Proportions was used to compare demographic factors, physical activity levels, clinical and subclinical CVD measures across quartiles of LDCW time in those who completed the 400-meter walk. Jonckheere-Terpstra tests were used estimate the linear trend in continuous variables and Cochran-Armitage Trend test were used to determine linear trend for categorical variables. To adjust for the high number of planned comparisons, a p value of <0.002 was used to denote statistical significance using the Bonferonni correction method.

3.4. CONCLUSION

Results from the proposed three papers will add to the growing body of evidence regarding strategies for primary prevention of CVD in postmenopausal women. The proposed investigation will add to the literature through the use of 1) both subjective and objective physical activity assessment measures, 2) direct measure of lipoprotein particle subclasses, 3) subclinical measures of CVD, and 4) measured parameters from the LDCW. Finally, the WOMAN study participants represent a unique cohort who were directly affected by the results

from the WHI¹³. The change in HT recommendations provides the opportunity to examine the health impact of the widespread discontinuation of HT.

With this information we will be able to: 1) examine the cross-sectional relationship between physical activity levels and lipoprotein subclasses by HT status at baseline, 2) determine if a lifestyle intervention can attenuate unfavorable CVD risk factor changes that are likely to result from HT discontinuation, and 3) determine the construct validity of the LDCW in postmenopausal women.

**4 THE RELATIONSHIP BETWEEN PHYSICAL ACTIVITY AND LIPOPROTEIN
SUB-CLASS LEVELS IN POST-MENOPAUSAL WOMEN: THE INFLUENCE OF
HORMONE THERAPY**

Accepted for Publication in Menopause January/February 2007

Kelley K. Pettee MS¹, Andrea M. Kriska PhD¹, B. Delia Johnson PhD¹, Molly B. Conroy^{1,2} MD,
Trevor J. Orchard¹ MD, Rachel H. Mackey¹, Lewis H. Kuller¹ MD

¹Department of Epidemiology

²Division of General Internal Medicine, Department of Medicine, University of Pittsburgh,
Pittsburgh, PA

4.1 ABSTRACT

OBJECTIVE: To determine if the association between physical activity and lipids and lipoprotein subclasses in postmenopausal women varies by hormone therapy (HT) use.

DESIGN: The cross-sectional relationship between physical activity and lipid and lipoprotein subclass relationship was examined prior to group randomization in 485 postmenopausal [mean age 56.9 (2.9 years)] Caucasian and African-American women from the Woman On the Move through Activity and Nutrition (WOMAN) Study. The WOMAN study is a randomized clinical trial designed to test whether a lifestyle intervention will reduce subclinical cardiovascular disease measures. **RESULTS:** HT users (n=286) were significantly ($p<0.05$) younger, less likely to be African American, reported higher levels of physical activity, large VLDL particles (VLDL-P), and medium HDL particles (HDL-P), had a larger mean HDL particle size, and lower levels of total cholesterol, LDL cholesterol (LDL-C), small HDL-P, and small VLDL-P than non users (n=196). Physical activity was significantly associated with favorable lipoprotein and lipid levels, regardless of HT use. Some relationships were found to vary significantly by HT use. In non-users, mean HDL and LDL particle size was significantly smaller and total and small LDL particles (LDL-P) were significantly lower as activity increased. These relationships were not found in HT users. **CONCLUSIONS:** Physical activity was significantly related to some lipoprotein subclasses regardless of HT. However, several key lipoprotein subclasses were associated with higher levels of activity only among non-HT users.

Key Words: physical activity, lipids, lipoprotein subclasses, hormone therapy, postmenopause

4.2 INTRODUCTION

Currently in the United States, cardiovascular disease (CVD) is the leading cause of death among older women (1). The cessation of ovarian function and the subsequent decrease in endogenous sex steroid hormone levels that occur as a result of the menopausal transition are associated with adverse lipid changes, which are thought to be largely responsible for the rising prevalence of CVD in postmenopausal women (2, 3). The menopausal transition is associated with increases in both total cholesterol and LDL cholesterol (LDL-C) and a decrease in HDL cholesterol (HDL-C) (4, 5).

Among postmenopausal women, hormone therapy (HT) has been shown to lower total and LDL-C and increase HDL-C (2). As a result, HT was widely prescribed lipid lowering and general CVD prevention in addition to menopausal symptom relief (6, 7). However, recent evidence from randomized clinical trials (8-11) has failed to confirm the cardio-protective benefits of HT that were suggested from earlier, observational studies. Since these results have been published, there have been significant changes in clinical practice regarding the prescription of HT. HT is no longer prescribed for lipid lowering and/or general CVD prevention. This clinical trend, combined with other documented risks of HT has caused prescription rates of HT use to plummet (12). This creates the need for other strategies to be employed to favorably alter the lipid profile and decrease CVD risk in postmenopausal women.

CVD risk attributable to dyslipidemia may be better quantified using specific lipoprotein subclass measurement as opposed to conventional methods (13). There is increasing evidence that subclasses of LDL, HDL, and VLDL (differentiated by particle size or density) may differentially predict CVD. Among postmenopausal women, the measurement of LDL subclasses may be particularly important. Past studies have suggested that smaller mean LDL

particle size, higher levels of total LDL particles (LDL-P) (14), and higher levels of small LDL-P are associated with incident CVD (15) and subclinical atherosclerosis (16) among postmenopausal women. Evidence also suggests that the associations between these key LDL lipoprotein subclasses and measures of subclinical CVD remain regardless of hormone therapy status (17). HDL subclass measures [e.g. larger mean HDL particle size or higher large HDL particles (HDL-P)] have also been shown to have incremental predictive value for coronary artery disease (CAD) and incident coronary heart disease (CHD) (18-20).

Past research does not clearly define the relationship between physical activity and the overall lipid profile in postmenopausal women (21). The purpose of the current investigation is to clarify these associations by including both specific lipoprotein subclass measures, as well as traditional lipid measures. A secondary aim is to examine how HT may modify the relationship between leisure physical activity and lipoprotein subclass and lipid levels in postmenopausal women.

4.3 METHODS

The Women On the Move through Activity and Nutrition (WOMAN) Study is a five year primary CVD prevention randomized clinical trial, designed to test whether an aggressive non-pharmacological lifestyle intervention among postmenopausal women will reduce measures of subclinical CVD. This study provides a unique opportunity to explore the relationship between physical activity, lipids, and nuclear magnetic resonance (NMR) spectroscopy-determined lipoprotein subclasses in postmenopausal women currently using and not using HT.

4.3.1 Study Population

Five hundred and eight postmenopausal women were recruited for the WOMAN study, primarily through direct mailing from selected zip codes in Allegheny County, Pennsylvania from April 2002 to October 2003. Eligibility criteria for enrollment into the study included waist circumference \geq 80 centimeters (cm), body mass index (BMI) between 25 – 39.9 kilograms per meters squared (kg/m^2), not currently taking lipid lowering drugs and having a low density lipoprotein cholesterol (LDL-C) level between 100 - 160 milligrams per deciliter (mg/dL), no physical limitations that would preclude walking, no known diabetes, and no diagnosed psychotic disorder or depression. All participants provided written informed consent and all protocols were approved by the institutional review board at the University of Pittsburgh. Results were based on data collected prior to randomization at the baseline clinic visit (2002-2003).

4.3.2 Physical Activity

Physical activity was measured using the Modifiable Activity Questionnaire (MAQ), an interviewer-administered, past-year questionnaire (22). This questionnaire assesses current leisure and occupational activities, as well as extreme levels of inactivity due to disability. Physical activity levels were calculated as the product of the duration and frequency of each activity (in hours per week), weighted by an estimate of the metabolic equivalent (MET) of that activity and summed for all activities performed. For the purposes of this investigation, only leisure physical activity estimates were used. Leisure physical activity data were expressed as

metabolic equivalent hours per week (MET hr-wk). The MAQ has been shown to be both reliable (22, 23) and valid (22-24).

4.3.3 Hormone Therapy Status

HT status was obtained through self-report in addition to a medication inventory that was completed at the baseline clinic visit. Participants were classified as being either current HT users or non-users.

4.3.4 Lipid and Lipoprotein Subclass Measures

Total cholesterol, HDL-C, and triglycerides were determined by conventional methods from fasting (12 hour) blood samples. LDL-C was estimated by the Friedewald equation. Lipoprotein subclass particle concentrations and mean particle diameters were measured using an automated nuclear magnetic resonance (NMR) spectroscopic assay (LipoScience, Inc., NC) as previously described (25) in detail. Unlike conventional lipid measures, which quantify lipoproteins according to the amounts of lipid (cholesterol or triglyceride) carried by all of the particles in the major class, the NMR spectroscopy assay determines concentrations of lipoprotein particles according to particle size (diameter). Results are then grouped into small, medium, and large subclasses for HDL-P and VLDL-P. For LDL, the particle concentrations are reported for small and large LDL-P in addition to intermediate density lipoprotein particles (IDL-P). Subclasses are summed to provide total LDL-P, HDL-P, and VLDL-P. Mean LDL and HDL particle sizes are calculated as weighted-averages (i.e. the diameter of each subclass multiplied by its relative mass percentage).

4.3.5 Other Measures

Demographic factors, such as age, saturated fat and cholesterol intake (fat intake index), body mass index (BMI) were considered confounding variables. BMI was calculated from height and weight measured with a stadiometer and calibrated balance beam scale, respectively. Fat intake index was assessed using the Connor Diet Habit Survey, which has been shown to be both a reliable and valid measure for the rapid assessment of eating habits and diet composition (26).

4.3.6 Analytic Procedures

Descriptive statistics were used to describe demographic, anthropometric measures, physical activity, and lipoprotein subclass levels in the entire cohort and stratified by HT use. Normally distributed variables were reported as mean \pm standard deviation; non-normally distributed variables were reported as median with 25th and 75th percentiles. Depending upon the characteristics of the variable, t-tests, Wilcoxon Rank Sum, or Chi Square (χ^2) tests were used to compare HT users and non-users.

For each lipoprotein subclass, we evaluated four multivariate linear regression models. The first model examined the association between physical activity and lipoprotein subclasses after controlling for age and saturated fat/cholesterol intake. The second model added BMI. The third model added HT status. The fourth model evaluated the addition of a physical activity*HT interaction term to the models. For graphic representation, we evaluated the lipoprotein subclass levels across leisure physical activity quartiles by HT status. Activity quartiles represented the distribution of leisure physical activity levels reported in the WOMAN study. Jonckheere-

Terpstra tests were used estimate the linear trend in mean lipoprotein subclass levels across physical activity quartiles by HT status.

4.4 RESULTS

Twenty-six women (5.1%) had incomplete data and were excluded from these analyses. Of the remaining 482 WOMAN study participants with complete data, 59.3% (n = 286) reported taking HT and 40.7% (n = 196) of the women reported not taking HT at the baseline assessment. Of those women who reported taking HT at baseline, 120 (42% of HT users) women took estrogen therapy (ET), while the remaining 166 (58% of HT users) took estrogen plus progestogen therapy (EPT). The mean age of the participants was 56.9 ± 2.9 years, and 11.6% were African American (Table 4.1). Study participants had a mean BMI of 30.7 ± 3.8 kg/m² and waist circumference of 105.7 ± 11.2 centimeters. Only 6.2% of women reported being current smokers. The median physical activity levels reported in the WOMAN study cohort at baseline were similar to those recommended by the Surgeon General for physical activity and health²¹

Compared to non users, HT users were significantly younger ($p < 0.05$), were less likely to be African American, and reported higher levels of physical activity (Table 4.1). In addition, HT users had significantly higher large VLDL particles (VLDL-P), and medium HDL-P levels. HT users also had a significantly larger mean HDL particle size, and lower levels of total cholesterol, LDL-C, small HDL-P and small VLDL-P than non-users. No additional significant differences were found between HT groups for the remaining lipid or lipoprotein levels (Table 4.1).

In separate multivariable linear regression models in the entire cohort, after adjustment for age and fat intake index, leisure physical activity was significantly related to higher levels of

HDL-C ($p=0.001$) and large HDL-P ($p=0.02$) and lower total and medium VLDL-P ($p=0.001$; $p=0.003$ respectively), and triglycerides ($p=0.03$). However, for the entire cohort, after adjustment for age and fat intake, leisure physical activity was not significantly related to mean HDL or LDL particle size, total, small LDL-P, total cholesterol, total, medium, or small HDL-P, IDL-P, LDL-C, large LDL-P, or large or small VLDL-P (data not shown).

When BMI was added to the model results were similar. BMI was a significant covariate in most models ($p<0.01$ to <0.001). Although BMI attenuated the relationship between leisure physical activity and HDL-C, large HDL-P, and triglycerides, physical activity remained a statistically significant covariate for each of these lipid and lipoprotein subclass variables. It should be noted that results were similar when waist circumference was substituted in the model for BMI (data not shown).

Similarly when HT was added to the multivariate model, results were similar. Activity levels were significantly related to higher levels of HDL-C ($p=0.01$) and large HDL-P ($p=0.008$) and lower levels of total and medium VLDL-P ($p=0.003$, $p=0.005$ respectively), and triglycerides ($p=0.006$), (Table 4.2). Physical activity was not significantly related to mean HDL or LDL particle size, total, small LDL-P, total cholesterol, total, medium, or small HDL-P, IDL-P, LDL-C, large LDL-P, or large or small VLDL-P (data not shown). HT was a significant covariate only for lower HDL-C levels ($p<0.01$), but not for other lipoproteins. Moderate alcohol intake was also considered as a possible confounding factor. However, the addition of this factor to the models did not significantly change the results; therefore, it was not included in final multivariate models.

After adjusting for potential confounders, the physical activity*HT interaction term was only statistically significant for mean HDL and LDL particle size, total and small LDL-P.

Therefore, we further evaluated the relationship between leisure physical activity and those four key lipoprotein subclass measures after stratifying by HT use (Figure 4.1). Among HT users, there was no significant association between physical activity and these lipoprotein subclasses (Figure 1). In contrast, among HT non-users, higher leisure physical activity was significantly associated with lower total and small LDL-P and larger mean LDL and HDL particle sizes. Furthermore, among HT non-users, these relationships remained statistically significant after adjustment for age, body mass index, and saturated fat/cholesterol intake (Table 4.3).

4.5 DISCUSSION

The present investigation was the first to investigate the associations between lipids, physical activity, and HT using specific lipoprotein subclasses. In this large cohort of overweight postmenopausal women, we found that leisure physical activity was significantly related to a favorable lipid and lipoprotein subclass profile (i.e., higher levels of HDL-C and large HDL-P, and lower levels of triglycerides, and total and medium VLDL-P), regardless of HT use. However, we saw no association between leisure physical activity and LDL-C, which agrees with previous reports. The beneficial association that was observed in our study between leisure physical activity and higher large HDL-C and lower total and medium VLDL-P levels are congruent with the higher HDL-C and lower triglyceride levels, since those are the primary lipids carried by those particles, respectively. Generally, past investigations in postmenopausal women have shown that physical activity levels are beneficially related to both HDL-C and

triglyceride levels, and these associations remained after adjustment for factors such as body mass index and HT status (28, 29).

Findings from the current investigation also suggest that for several key lipoprotein subclass measures, the relationship with physical activity differed by HT use. After stratification by HT use, physical activity was independently related to larger mean HDL and LDL particle size, and lower levels of total and small LDL-P among non-HT users, but not among women currently taking HT. As we and others have shown, these particular lipoprotein subclass measures, particularly total LDL-P, are independently associated with coronary calcification (16) and predict incident CVD (14, 15) among postmenopausal women. Furthermore, in a study of healthy postmenopausal women, we have previously shown that higher levels of total and small LDL-P and small mean LDL particle size are associated with coronary artery calcification, for both HT users and non-users (17). Therefore, the results of the current study, showing that among HT users, higher levels of leisure physical activity was not associated with any improvements in these specific lipoprotein subclasses are particularly important. In HT users, the pharmacological effects of the hormones appears to have masked or interfered with the potential benefits of leisure physical activity levels on important facets of the lipoprotein subclass profile.

Past research exploring the relationship between physical activity and lipids in postmenopausal women has generated contradictory results (21). As previously mentioned, it has been suggested that estrogen may mask the response of lipid levels to participation in physical activity in postmenopausal women taking HT (30). Therefore, one possible reason for the divergent results of previous studies investigating the relationship between physical activity and lipid levels among postmenopausal women may be explained by the inconsistent selection of

the study population with regard to HT use. Results of the present investigation illustrate that the independent relationship between physical activity and certain lipoprotein subclasses, such as mean HDL and LDL particle size, total, and small LDL-P, may only become evident after stratification by HT status. It is, therefore, imperative for future work to consider HT use when examining the relationship between physical activity and lipids in postmenopausal women.

The present analysis utilized a questionnaire that assessed structured physical activity levels and demonstrated that leisure physical activity was related to many lipid and lipoprotein subclasses. Although questionnaires have been shown to accurately assess higher intensity, structured physical activities, they typically do a poor job when measuring lower intensity, unstructured lifestyle physical activities, such as household chores, childcare, and housework (22, 31). Future work should examine whether total physical activity levels, including both structured and unstructured activities as measured by an objective assessment tool, follows the same trends as what was observed in the present investigation. Also, the addition of an objective physical activity measure would allow investigators the opportunity to validate activity estimates obtained through subjective measures.

When interpreting the findings of the present investigation, a number of limitations need to be considered. Data from only one point in time, the baseline visit, was used in the analyses. Although informative, this cross-sectional study analysis is limited in that it does not provide information pertaining to the direction of association or allow us to determine how the relationship between physical activity and lipoprotein subclasses changes as a woman changes her physical activity levels, HT status, or both. In addition, the results were adjusted for lifestyle factors (age, BMI, dietary saturated fat and cholesterol intake) that have been demonstrated to be related to both physical activity and lipid and lipoprotein subclass levels. The adjustment of

results by these lifestyle factors helps to ensure that any significant relationship that was noted between physical activity and lipid and lipoprotein subclass levels is not the result of confounding by a third factor. Also, the results are limited by our small sample size which may reduce confidence in our findings. Specifically, post-hoc power analyses revealed that the power to examine the interaction between physical activity levels and hormone therapy status ranged from 61- 75%. However, despite having relatively low power, the results were strong enough to detect a statistical significant difference. Finally, women were classified as current HT users or non-users; the type, dosage, and/or duration of HT usage were not considered in these analyses. Therefore, future work is needed to further investigate the complex relationship between HT, and mean lipoprotein subclass and physical activity levels.

In conclusion, the literature has been inconsistent with regards to the relationship between physical activity and lipids and lipoproteins in postmenopausal women. Findings from the present work confirmed earlier studies suggesting that, regardless of HT use, physical activity levels were directly related to HDL-C levels and indirectly related to triglyceride levels. However, when the results were stratified by HT use, physical activity was associated with key lipoprotein subclasses in HT non-users which have been shown to be related to both incident and subclinical CVD. These findings raise the important question as to whether the beneficial effect of physical activity on the lipid profile in postmenopausal women is similar between HT users and non-users.

As HT is being prescribed less frequently and for shorter periods of time, we need to be aware of other strategies to favorably alter the overall lipid profile in postmenopausal women. Despite the fact that these data are cross-sectional in nature, findings from the current

investigation suggest that the promotion of physical activity may be a safe and effective alternative to improve lipids and reduce risk of CVD in postmenopausal women.

Acknowledgements: The authors would like to acknowledge the contributions of the staff of the WOMAN study. This research was funded by National Heart, Lung, and Blood Institute contract R01-HL-66468.

4.6 REFERENCES

1. Association AH. *Heart Disease and Stroke Statistics - 2005 Update*. Dallas, TX; 2004.
2. Rosano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. *Cardiol Rev*. Jan-Feb 2002;10(1):51-60.
3. Kuller LH, Meilahn EN. Risk factors for cardiovascular disease among women. *Curr Opin Lipidol*. Aug 1996;7(4):203-208.
4. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. *N Engl J Med*. Sep 7 1989;321(10):641-646.
5. Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. *Am J Epidemiol*. Mar 15 2000;151(6):584-593.
6. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. *Jama*. Jan 7 2004;291(1):47-53.
7. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. *Jama*. Oct 27 2004;292(16):1983-1988.
8. Hulley S GD, Bush T, Furberg C, Herrington D Riggs B Vittinghoff E. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. *Journal of the American Medical Association*. 1998;280(7):605-613.
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama*. Jul 17 2002;288(3):321-333.
10. Manson JE HJ, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen Plus Progestin and the Risk of Coronary Heart Disease. *The New England Journal of Medicine*. 2003;349(6):523-534.
11. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *Jama*. Apr 14 2004;291(14):1701-1712.
12. Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. A population-based study. *J Gen Intern Med*. Nov 2005;20(11):1026-1031.

13. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. *Am J Cardiol.* Oct 17 2002;90(8A):22i-29i.
14. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. *Circulation.* Oct 8 2002;106(15):1930-1937.
15. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol.* Jul 1 2002;22(7):1175-1180.
16. Mackey RH S-TK, Vaitevicius PV, Sakkinen PA, Lyles MF, Spurgeon HA, Lakatta EG, Kuller LH. Correlates of Arterial Stiffness in Elderly Individuals: A Subgroup of the Cardiovascular Health Study. *American Journal of Hypertension.* 2002;15:16-23.
17. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. *Arch Intern Med.* Mar 14 2005;165(5):510-515.
18. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol.* Jul 15 2002;90(2):89-94.
19. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. *Arterioscler Thromb Vasc Biol.* Oct 2005;25(10):2185-2191.
20. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. *Arterioscler Thromb Vasc Biol.* Nov 2004;24(11):2181-2187.
21. Haddock BL H-MH, Manson JJ, Blix G. The Effect of Hormone Replacement Therapy and Exercise on Cardiovascular Disease Risk Factors in Postmenopausal Women. *Sports Medicine.* 2000;29(1):39-49.
22. Pereira MA, FitzGerald SJ, Gregg EW, et al. A collection of Physical Activity Questionnaires for health-related research. *Med Sci Sports Exerc.* Jun 1997;29(6 Suppl):S1-205.
23. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. *Diabetes Care.* Apr 1990;13(4):401-411.

24. Schulz LO HI, Smith CJ, Kriska AM, Ravussin E. Energy intake and physical activity in Pima Indians: comparison with energy expenditure measured by doubly-labeled water. *Obes Res.* 1994;2:541-548.
25. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. *Clin Chem.* Jul 2004;50(7):1189-1200.
26. Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-Wild S, Connor WE. The Diet Habit Survey: a new method of dietary assessment that relates to plasma cholesterol changes. *J Am Diet Assoc.* Jan 1992;92(1):41-47.
27. Services USDoHaH. *Surgeon General's Report on Physical Activity and Health.* Washington, DC: U.S. Government Printing Office; 1996.
28. Haddock BL, Hopp HP, Mason JJ, Blix G, Blair SN. Cardiorespiratory fitness and cardiovascular disease risk factors in postmenopausal women. *Med Sci Sports Exerc.* Jun 1998;30(6):893-898.
29. Hagberg JM, McCole SD, Ferrell RE, et al. Physical activity, hormone replacement therapy and plasma lipoprotein-lipid levels in postmenopausal women. *Int J Sports Med.* Jan 2003;24(1):22-29.
30. Klebanoff R, Miller VT, Fernhall B. Effects of exercise and estrogen therapy on lipid profiles of postmenopausal women. *Med Sci Sports Exerc.* Jul 1998;30(7):1028-1034.
31. Jacobs DR, Jr., Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation of 10 commonly used physical activity questionnaires. *Med Sci Sports Exerc.* Jan 1993;25(1):81-91.

Table 4-1: Participant Characteristics Stratifying by Current Hormone Therapy Use in the WOMAN Study

	Entire Cohort n=482	Hormone Therapy Users n=286 (59.3%)	Non-Hormone Therapy Users n=196 (40.7%)	p value
Age (years)	56.9 (2.9)	56.6 (2.9)	57.3 (2.9)	0.0079
Leisure Physical Activity (MET hr-wk)	11.1 (5.3, 20.2)	12.8 (6.2, 21.5)	9.1 (4.3, 18.6)	0.0128
Body Mass Index (kg/m ²)	30.7 (3.8)	30.7 (3.6)	30.8 (4.1)	0.8054
Waist Circumference (cm)	105.7 (11.2)	105.8 (10.6)	105.5 (12.0)	0.7489
% High School Graduate	98.7	99.0	98.5	0.6426
% African American	11.6	6.6	18.9	<0.0001
% Married	66.8	69.6	62.8	0.1180
% Current Smokers	6.2	4.9	8.2	0.1474
Lipids				
Total Cholesterol, mg/dL	216.4 (28.1)	211.9 (26.6)	223.0 (29.1)	<0.0001
LDL Cholesterol, mg/dL	128.2 (25.0)	122.1 (22.8)	137.0 (25.5)	<0.0001
HDL Cholesterol, mg/dL	59.8 (13.9)	60.7 (13.8)	58.8 (14.0)	0.0828
Triglyceride, mg/dL	142.2 (74.7)	146.1 (81.0)	136.6 (64.2)	0.1733
NMR Lipoprotein Particle Measures				
Total LDL-P, nmol/L	1394.1 (310.4)	1390.1 (296.2)	1400.0 (330.6)	0.7370
IDL, nmol/L	42.8 (36.3)	41.5 (35.7)	44.7 (37.2)	0.3423
Large LDL-P, nmol/L	640.5 (219.9)	632.3 (213.2)	652.5 (229.3)	0.3277
Small LDL-P, nmol/L	710.8 (419.3)	716.3 (399.4)	702.8 (447.8)	0.7326
LDL Size, nm	21.4 (0.7)	21.4 (0.7)	21.4 (0.7)	0.7348
Total HDL-P, μmol/L	35.0 (5.4)	35.4 (5.5)	34.6 (5.2)	0.1022
Large HDL-P, μmol/L	7.6 (3.2)	7.7 (3.3)	7.4 (3.1)	0.2878
Medium HDL-P, μmol/L	2.8 (3.3)	3.5 (3.6)	1.8 (2.3)	<0.0001
Small HDL-P, μmol/L	24.6 (5.3)	24.1 (5.4)	25.3 (5.2)	0.0130
HDL Size, nm	9.1 (0.5)	9.1 (0.4)	9.0 (0.5)	0.0100
Total VLDL-P, nmol/L	83.3 (37.3)	80.8 (37.5)	87.0 (36.9)	0.0743
Large VLDL-P, nmol/L	4.9 (5.9)	5.3 (6.5)	4.3 (4.8)	0.0499
Medium VLDL-P, nmol/L	31.7 (24.7)	30.9 (24.9)	32.8 (24.4)	0.3970
Small VLDL-P, nmol/L	46.7 (17.9)	44.5 (17.5)	49.8 (18.2)	0.0016

Age, BMI, Waist Circumference, and Lipoprotein Subclasses represented as mean (standard deviation). Leisure Physical Activity represented as

median (25th, 75th percentile). p value = hormone therapy users vs. non-hormone therapy users.

Table 4-2: Final Multivariate Linear Regression Model for Leisure Physical Activity and Lipoprotein Subclasses for the Entire Cohort (n=482)

	HDL-C (mg/dL)	Large HDL-P (μ mol/L)	Total VLDL-P (nmol/L)	Medium VLDL-P (nmol/L)	Triglycerides (mg/dL)
Leisure PA (MET hr-wk)	1.05 \pm 0.39**	0.24 \pm 0.08**	-3.11 \pm 1.05**	-1.96 \pm 0.70**	-5.78 \pm 2.08**
Age (years)	-0.26 \pm 0.21	-0.04 \pm 0.05	0.04 \pm 0.58	-0.11 \pm 0.38	-0.22 \pm 1.15
Body Mass Index (kg/m ²)	-0.54 \pm 0.17**	-0.14 \pm 0.04***	0.75 \pm 0.46	0.23 \pm 0.30	2.45 \pm 0.91**
Cholesterol/Saturated Fat Intake Index	-0.09 \pm 0.05	-0.00 \pm 0.01	0.05 \pm 0.14	0.07 \pm 0.09	0.13 \pm 0.28
Hormone Therapy Status	-1.72 \pm 1.28**	-0.19 \pm 0.30	4.97 \pm 3.46	1.34 \pm 2.31	-7.07 \pm 6.90
R ²	0.049919	0.052433	0.33568	0.020394	0.036905

Final model adjusted for age, body mass index, cholesterol/saturated fat intake, and hormone therapy. *p<0.05; **p<0.01; ***p<0.001;

****p<0.0001.

Table 4-3: Multivariate Linear Regression Model for Leisure Physical Activity and Lipoprotein Subclasses for Hormone Therapy Users and Non-Hormone Therapy Users

		Mean HDL Particle Size (nm)	Mean LDL Particle Size (nm)	Total LDL-P (nmol/L)	Small LDL-P (nmol/L)
Model II Stratified by Hormone Therapy					
Non-Hormone Therapy Users (n=196)	Leisure PA (MET hr-wk)	0.05 ± 0.02**	0.06 ± 0.03*	-35.15 ± 14.47*	-46.41 ± 19.45*
	Age (years)	-0.01 ± 0.01	-0.00 ± 0.02	0.72 ± 7.90	2.77 ± 10.62
	Body Mass Index (kg/m ²)	-0.02 ± 0.01**	-0.02 ± 0.01	10.78 ± 5.85	13.98 ± 7.86
	Cholesterol/Saturated Fat Intake Index	0.00 ± 0.00	0.01 ± 0.00	-1.02 ± 1.98	-3.54 ± 2.66
	R ²	0.097946	0.076803	0.065444	0.079416
Hormone Therapy Users (n=286)	Leisure PA (MET hr-wk)	-0.01 ± 0.02	-0.02 ± 0.03	8.38 ± 10.85	8.33 ± 14.64
	Age (years)	-0.01 ± 0.01	0.01 ± 0.01	-0.95 ± 6.03	-4.54 ± 8.13
	Body Mass Index (kg/m ²)	-0.03 ± 0.01***	-0.03 ± 0.01*	11.54 ± 5.01*	14.39 ± 6.76*
	Cholesterol/Saturated Fat Intake Index	-0.00 ± 0.00	0.00 ± 0.00	-0.16 ± 1.44	-0.63 ± 1.95
	R ²	0.053346	0.022870	0.020586	0.019779

Multivariate models adjusted for age, BMI, and cholesterol/saturated fat intake. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.




Figure 4-1: Mean Lipoprotein Subclass Levels by Leisure Physical Activity, stratified by Current Hormone Therapy Use. Quartile 1: <5.3 MET hr-wk; Quartile 2: >5.3 to <11.3 MET hr-wk; Quartile 3: >11.3-20.4 MET hr-wk; Quartile 4: >20.4 MET hr-wk

**5 CAN A LIFESTYLE INTERVENTION ATTENUATE THE EFFECT OF
DISCONTINUING HORMONE THERAPY ON CARDIOVASCULAR RISK
FACTORS?**

For Future Publication

Kelley K. Pettee PhD¹, Andrea M. Kriska PhD¹, Molly B. Conroy^{1,2} MD, B. Delia Johnson PhD¹,
Trevor J. Orchard¹ MD, Bret H. Goodpaster² PhD, Frani M. Averbach¹ MPH, Lewis H. Kuller¹

MD

¹ Department of Epidemiology

² Division of General Internal Medicine, Department of Medicine, University of Pittsburgh,

Pittsburgh, PA

5.1 ABSTRACT

OBJECTIVE: To determine if a lifestyle intervention consisting of physical activity and dietary modifications can counteract unfavorable CVD risk factor changes that are predicted to occur as postmenopausal women discontinue hormone therapy (HT) use. **DESIGN:** Participants from the Woman On the Move through Activity and Nutrition (WOMAN) study were randomized at baseline to either a health education (HE) or lifestyle change (LC) group. The impact of a lifestyle intervention on CVD risk factor reduction was examined in the 231 postmenopausal [mean age 58.3 (2.9 years)] women who were initially on HT at baseline and either remained on HT (n=106) or discontinued use (n=125) by the 18 month follow up visit. **RESULTS:** In general, lifestyle intervention had a beneficial impact on CVD risk factor reduction regardless of HT status at 18 months. Women randomized to the LC group decreased weight, BMI, WC, insulin and triglyceride levels and improved glucose levels when compared to the HE group. Within the HE arm, women who discontinued HT had significantly ($p<0.01$) higher increases in total and LDL-C as compared to HT continuers, whereas no such differences were observed in the LC arm. **CONCLUSIONS:** A lifestyle based intervention comprised of physical activity and diet was effective for CVD risk factor reduction among postmenopausal women. Negative lipid consequences of discontinuing HT were noted only in the HE group and not among women randomized to the LC group. These findings suggest that a lifestyle behavioral approach can successfully attenuate increases in total and LDL-C that result from HT discontinuation.

5.2 INTRODUCTION

After menopause, women experience an increased incidence of cardiovascular disease (CVD) (1). The increase in CVD incidence is likely due to detrimental changes in related risk factors, such as dyslipidemia, abdominal adiposity, hypertension, and insulin resistance that often worsen during the menopausal transition (2, 3). Hormone therapy (HT) use has been shown to favorably alter CVD risk factors (4) and, until recently, was widely prescribed for both the relief of menopausal symptoms and general CVD prevention in postmenopausal women (5, 6).

Past observational studies have consistently suggested an inverse association between exogenous HT use and CVD (7, 8), due in part to the beneficial impact of HT on CVD risk factors. The Postmenopausal Estrogen/Progestin Interventions (PEPI) study was a randomized clinical trial exploring the impact of four HT regimens (placebo control vs. unopposed estrogen or one of three estrogen/progestin combinations) on selected CVD risk factors in healthy postmenopausal women (9). Results from the PEPI trial suggest that, regardless of type of HT, HT users had increased HDL cholesterol (HDL-C) and decreased LDL cholesterol (LDL-C) and fasting glucose levels when compared to the placebo control group (9).

In contrast to observational studies, evidence from recent clinical trials, such as the Women's Health Initiative (WHI) (10, 11) and Heart and Estrogen/progestin Replacement Study (HERS) (12) have failed to confirm the cardio-protective benefits of hormone therapy (HT) (7, 8). Following the publication of the WHI results, many HT users were advised by their physicians to taper doses and/or discontinue use (5). Unfortunately, there is little information regarding the health impact of the widespread discontinuation of HT.

The Women On the Move through Activity and Nutrition (WOMAN) study is a five year randomized clinical trial of primary CVD prevention among postmenopausal women designed to test whether an aggressive non-pharmacological lifestyle intervention will modify or reduce measures of subclinical CVD. Approximately midway through the WOMAN study recruitment process, results were publicized from the estrogen/progestin (E+P) arm of the WHI trial indicating adverse effects among HT users (11). Women who had already been randomized into the WOMAN study were advised by their health care provider to taper and/or discontinue HT use according to the new guidelines based upon the WHI results. The WOMAN study provides a unique opportunity to explore the impact of HT discontinuation and the possible attenuation of this impact by healthy lifestyle behaviors on CVD risk factors after 18 months of a behavioral lifestyle intervention.

Based on results from previous studies (9), it is hypothesized that HT discontinuation will negatively impact certain CVD risk factors such as lipids. The purpose of this current longitudinal investigation is to determine if a lifestyle intervention consisting of healthy physical activity and dietary practices can lessen unfavorable CVD risk factor changes that are hypothesized to occur as women discontinue HT use after 18 months of study participation.

5.3 METHODS

5.3.1 Study Population

Five hundred and eight postmenopausal women were recruited for the WOMAN study, primarily through direct mailing from selected zip codes in Allegheny County, Pennsylvania from April

2002 to October 2003. Eligibility criteria for enrollment into the study included waist circumference (WC) \geq 80 centimeters (cm), body mass index (BMI) between 25 – 39.9 kilograms per meters squared (kg/m^2), not currently taking lipid lowering drugs and having a low density lipoprotein (LDL-c) level between 100 - 160 milligrams per deciliter (mg/dL), no physical limitations that would preclude walking, no known diabetes, and no diagnosed psychotic disorder or depression. All participants provided written informed consent and all protocols were approved by the institutional review board at the University of Pittsburgh. Results from the current investigation were generated from data collected at baseline and at the 18 month clinic visit.

5.3.2 Group Randomization: Intervention Design

Eligible women were randomized to a Health Education (HE) comparison group or a Lifestyle Change (LC) group using a block randomized design prepared by a statistician. Briefly, women in the HE group received educational lectures while women randomized to the LC group received group and individualized intervention which focused on body weight and WC reduction through healthy lifestyle changes. The healthy lifestyle behaviors promoted in the LC included 150 minutes per week of moderate intensity physical activity similar to brisk walking and a caloric intake of 1300-1500 calories per day, emphasizing an eating pattern low in total (<17%) and saturated fat (<7%).

5.3.3 Physical Activity

Physical activity was measured using the past year version of the Modifiable Activity Questionnaire (MAQ), an interviewer administered questionnaire (13). This questionnaire assesses leisure and occupational activities, as well as extreme levels of inactivity due to disability. For the purposes of this investigation, we will focus on the leisure physical activity estimate as there was little reported occupational physical activity in our study population. Study participants were asked to identify if they participated in a variety of specific activities, such as walking for exercise, at least 10 times over the past year (12 months). For each activity identified, they were asked which months they had participated in that specific activity over the past year and then estimated the number of times each month and length of time that they spent doing the specific activity. Physical activity levels were calculated as the product of the duration and frequency of each activity (in hours per week), weighted by an estimate of the metabolic equivalent (MET) of that activity and summed for all activities performed. One MET represents the energy expenditure for an individual at rest, whereas a 10-MET activity requires 10 times the resting energy expenditure (14). Leisure physical activity data were expressed as metabolic equivalent hours per week (MET hr-wk). The MAQ has been shown to be both reliable (13, 15) and valid (13, 15, 16). In the WOMAN study, baseline and 18 month physical activity estimates obtained from the MAQ were positively and significantly ($p < 0.0001$) correlated with step counts obtained from a pedometer step counter ($\rho = 0.30$ and 0.36 , respectively).

5.3.4 Hormone Therapy Groups

Information on HT use was obtained through self-report in addition to a medication inventory that was completed at both the baseline and 18 month clinic visit. Following the publication of the WHI results, study participants were allowed to enter the trial after recently terminating HT use; however, only those who were identified as current HT users at baseline were included in the current report. These women were classified into one of two HT groups: 1). HT Continuers (HT user at baseline and 18 months) and 2). HT Discontinuers (HT user at baseline and non-user at 18 months).

5.3.5 Clinical Measures

All clinical measures were obtained at the baseline and 18 month follow-up clinic visit. Clinical measures included height, body weight, waist circumference, and a fasting (12 hour) blood draw. BMI was calculated from height and weight measured with a stadiometer and calibrated balance beam scale by dividing the participant's weight in kilograms by the square of her height in meters. Waist circumference (WC) was measured at the navel (horizontal plane at the center of the navel) using a fiberglass retractable tape measure. Total cholesterol, HDL-C, triglycerides, and glucose were determined by conventional methods. LDL-C was estimated by the Friedewald equation and insulin was measured via radioimmunoassay.

5.3.6 Other Measures

In addition to the clinical measures, a saturated fat/cholesterol intake index score was calculated using the Connor Diet Habit Survey, which has been shown to be both a reliable and valid measure for the rapid assessment of eating habits and diet composition. The saturated fat and cholesterol score is generated by summing the scores for 20 questions related to cholesterol and saturated fat intake (17).

5.3.7 Statistical Methods

Descriptive statistics were used to describe baseline anthropometric measures, leisure physical activity levels, and CVD risk factor levels by HT use at the 18 month follow-up visit. Normally distributed variables were reported as mean \pm standard deviation; non-normally distributed variables were reported as median with 25th and 75th percentiles. Depending upon the characteristics of the variable, t-tests or Wilcoxon Rank Sum tests were used to compare baseline CVD risk factor values between HT continuers and HT discontinuers.

The 18 month change in anthropometric, physical activity, and CVD risk factor levels variables over time was calculated as the difference in values between the 18 month follow-up and baseline. Change variables were compared between HT continuers and HT discontinuers, stratified by treatment group assignment using t-tests or Wilcoxon Rank Sum tests. CVD risk factor change was also reported and compared between randomized groups, stratified by HT status at the 18 month clinic visit.

Further post-hoc analyses were conducted to determine the independent effect of healthy lifestyle behaviors that were promoted in the lifestyle intervention on CVD risk factor reduction

using multivariate linear regression models. The multivariate model examined the longitudinal relationship between CVD risk factor and change in leisure physical activity, and saturated fat/cholesterol intake, after adjusting for HT status at 18 months and baseline levels of leisure physical activity, saturated fat/cholesterol intake, and relevant CVD risk factor.

5.4 RESULTS

Of the 508 women randomized into the WOMAN study, 455 (90%) completed the 18 month clinic visit. Of these 455 women, 182 reported not using HT at baseline and were excluded from these analyses. Also excluded were 16 women initiating a lipid lowering medication during the 18 month interval and 26 with incomplete physical activity, clinical, or diet quality data. Women not using HT at baseline were more likely to be African American, had lower reported leisure physical activity levels, and higher baseline total cholesterol, LDL-C, insulin, and glucose levels when compared to women who were HT users at baseline ($p < 0.05$).

The 231 women included in the present analyses had a mean age of 58.3 (2.9 years). The mean BMI was 28.5 (4.3) kg/m^2 and average WC was 98.4 (11.9) cm. Additionally, 98.7% had at least a high school degree, 6.9% were African American, and 4.8% were current smokers. One hundred and six (106; 46%) of the 231 women were HT continuers and the remaining 125 (54%) women were HT discontinuers at 18 months. Of the HT discontinuers, 61% had HT discontinued prior to the 6 month follow-up visit. There were no significant differences between HT continuers and HT discontinuers with regards to education, race, or smoking status (data not shown).

Table 5.1 describes and compares CVD risk factor levels between HT continuers vs. HT discontinuers at baseline. Women in the HT continuer group were significantly ($p < 0.05$) younger than women who discontinued HT. However, the two HT groups did not significantly differ in anthropometric and clinical measures, leisure physical activity, saturated fat/cholesterol intake, lipid, or glucose levels. One notable exception was that women who continued HT at 18 months had lower baseline insulin levels when compared to HT discontinuers.

The lifestyle intervention was successful and had a positive impact on many CVD risk factors among both HT continuers and HT discontinuers (Table 5.2). More specifically, when compared to the HE group, the LC group significantly decreased weight, BMI, average WC, and saturated fat and cholesterol intake and increased leisure physical activity levels (significant in HT discontinuers only). With regards to CVD risk factor change, women in the LC group had improved insulin (significant in HT continuers only), triglyceride and glucose levels (significant in HT discontinuers only) when compared to the HE group. There were no significant differences at 18 months between randomized groups with regards to changes in HDL-C, systolic and diastolic blood pressure levels in either HT continuers or HT discontinuers.

In contrast, there was marked differences by randomized group assignment between HT continuers and HT discontinuers with regards to two key CVD risk factors; total cholesterol and LDL-C (Figure 5.1). When comparing total cholesterol and LDL-C change within the HE arm, women who had discontinued HT use had significantly higher increases in these two measures as compared to HT continuers [total cholesterol: 21.4 vs. 3.5 mg/dL ($p = 0.0063$) and LDL-C: 21.7 vs. 4.0 mg/dL ($p = 0.0017$)]. The significant differences in total and LDL cholesterol change between HT continuers and HT discontinuers were not replicated in the LC arm [total cholesterol: 5.8 vs. 4.7 mg/dL ($p = 0.8225$) and LDL-C: 6.1 vs. 7.4 mg/dL ($p = 0.7572$)]. There

were no other differences between HT groups with regards to CVD risk factor change in either the HE or LC group.

Since it appeared that lifestyle intervention had a major impact on CVD risk factors in postmenopausal women, post-hoc analysis was performed to begin to examine the role of the specific components of the lifestyle intervention on risk factor reduction. Specifically, the effect of leisure physical activity and diet on CVD risk factor reduction was examined in the entire cohort (Table 5.3). After adjustment for HT use at the 18 month clinic visit, baseline leisure physical activity, saturated fat and cholesterol intake, and relevant CVD risk factor level (i.e. adjustment for baseline HDL-C when exploring HDL-C change), an increase in leisure physical activity was significantly related ($p<0.05$) to decreases in triglyceride levels and increases in HDL-C levels as well as decreases in LDL-C and glucose levels ($p<0.10$). With regards to dietary behavior, an improvement in saturated fat and cholesterol intake was significantly related to decreases in total cholesterol, LDL-C, triglyceride, insulin, and glucose levels ($p<0.05$).

5.5 DISCUSSION

The present investigation explored the effect of lifestyle intervention on CVD risk factors in postmenopausal women that were on HT at baseline and either continued or discontinued use after 18 months of study participation. Prior to the WOMAN study, the beneficial effect of a lifestyle intervention for CVD risk factor reduction had not been examined in women who had recently discontinued HT. When considering the current controversies regarding HT use, the findings from the present report are timely.

Regardless of HT status at 18 months, women randomized to the LC group increased leisure physical activity levels, improved saturated fat and cholesterol intake and glucose levels, and decreased weight, BMI, WC, insulin and triglyceride levels when compared to the HE group. The overall success of the WOMAN study lifestyle intervention was in line with the findings from previous reports suggesting the efficacy of lifestyle based approaches for risk factor reduction and chronic disease prevention in populations at risk for diabetes (18-21) and heart disease (22). Specifically in older women, lifestyle intervention was demonstrated to prevent weight gain (23) and to determine a rise in LDL-C levels (24) during the menopausal transition.

However, previous reports did not account for concurrent changes in HT status, an issue which has become particularly relevant in the post-WHI era. The WOMAN study provided the unique opportunity to examine the effect of a lifestyle intervention on CVD risk factor reduction by change in HT status. Based on findings from previous investigations, it was assumed that HT discontinuation would result in unfavorable changes to CVD risk factors (9). As predicted, the WOMAN study documented that HT discontinuation at 18 months resulted in increases in total cholesterol and LDL-C levels in the HE group. In contrast, in the LC group, there were no observed differences between HT groups with regards to these particular lipids. These findings suggest that a lifestyle intervention, consisting of physical activity, dietary behavior modification, and weight loss can successfully attenuate unfavorable changes to CVD risk factors that result from HT discontinuation. These results have important public health implications and suggest that a non-pharmacological approach is both a safe and effective strategy for CVD risk factor reduction in postmenopausal women, especially for women that discontinued HT use.

The WOMAN study was not designed to determine the independent contribution of the specific intervention components on CVD risk factors. However, post-hoc analyses were conducted to begin to examine the role of the specific components of the lifestyle intervention for CVD risk factor reduction. Increases in leisure physical activity were independently related to increases in HDL-C and decreases in triglyceride levels. Likewise, improved saturated fat and cholesterol intake was independently related to decreases in total cholesterol, LDL-C, triglyceride, insulin, and glucose levels. The independent contribution of physical activity and diet on these particular lipid measures was similar in both HT continuers and discontinuers.

CVD continues to be the leading cause of morbidity and mortality among women in westernized countries (1). However, CVD in women has been underappreciated by the public (25) and under treated by health care providers (24, 27). Recent public health campaigns, such as the American Heart Association's "Go Red for Women" campaign (28) have raised public health awareness of the disease. However, concern and confusion about the risks associated with HT has left women and their health care providers searching for safe and effective means to reduce CVD risk factors.

In this era of uncertainty, one potential consequence of diminished HT use for CVD risk factor reduction is increased use of supplementary pharmacological agents, such as statins and aspirin; however, both are associated with side effects (29, 30). In addition, trial data suggests that aspirin does not protect women from CVD in a similar fashion to men (31). Furthermore, the majority of statin research to date has been conducted in men (32, 33). However, based on the promising findings of the current investigation, special attention should be paid to encouraging efficacious lifestyle strategies that are likely to impart more benefit and less risk than drug therapies.

When interpreting the findings from the present investigation, a number of limitations need to be considered. The present analyses utilized self-reported estimates of leisure physical activity levels and dietary intake which may be subject to recall bias. Also, since this was a behavioral intervention, there may have been a differential reporting bias with the intervention group reporting what they should be doing rather than what they are doing. However, it should be noted that the leisure physical activity estimates obtained via the MAQ were validated with pedometer step counts in the WOMAN study population. In addition, WOMAN study participants were not randomized to continue or discontinue HT use at 18 months, which may influence the findings of the current report. In addition, the duration of prior HT usage and/or time since discontinuation were not considered in these analyses. Finally, for the purposes of this report, saturated fat and cholesterol intake was used as general measure of diet composition. Therefore, future work is needed to investigate the overall contribution of diet on CVD risk factor reduction.

In conclusion, little data has been available regarding the widespread impact of the WHI results on CVD risk factor change in postmenopausal women. The current report confirmed previous findings suggesting that a lifestyle based approach is effective for general CVD risk factor reduction. In addition, lifestyle interventions incorporating physical activity and dietary modification can successfully attenuate negative changes to lipids that result from HT discontinuation. More research and improved delivery systems are needed to facilitate dissemination and maintenance of healthy lifestyle programs in postmenopausal women.

Acknowledgements: The authors would like to acknowledge the 508 dedicated WOMAN study participants and the contributions of the WOMAN study staff, including Alhaji Buhari, Eileen Cole, Phyllis Jones, Laura Kinzel, Barbara Kolodziej, Wm. Scott Pappert, and Darcy Underwood. This research was funded by National Heart, Lung, and Blood Institute contract R01-HL-6646.

5.6 REFERENCES

1. Association AH. *Heart Disease and Stroke Statistics - 2005 Update*. Dallas, TX; 2004.
2. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. *N Engl J Med*. Sep 7 1989;321(10):641-646.
3. Carr MC. The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab*. Jun 2003;88(6):2404-2411.
4. Rosano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. *Cardiol Rev*. Jan-Feb 2002;10(1):51-60.
5. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. *Jama*. Jan 7 2004;291(1):47-53.
6. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. *Jama*. Oct 27 2004;292(16):1983-1988.
7. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. *Prev Med*. Jan 1991;20(1):47-63.
8. Hu FB, Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. *Am J Cardiol*. Jul 3 2002;90(1A):26F-29F.
9. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *Jama*. Jan 18 1995;273(3):199-208.
10. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *Jama*. Apr 14 2004;291(14):1701-1712.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama*. Jul 17 2002;288(3):321-333.
12. Hulley S GD, Bush T, Furberg C, Herrington D Riggs B Vittinghoff E. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. *Journal of the American Medical Association*. 1998;280(7):605-613.

13. Pereira MA, FitzerGerald SJ, Gregg EW, et al. A collection of Physical Activity Questionnaires for health-related research. *Med Sci Sports Exerc.* Jun 1997;29(6 Suppl):S1-205.
14. Medicine ACoS. *ACSM's Guidelines for Exercise Testing and Prescription.* 6th ed. Baltimore, MD: Lippincott, Williams & Wilkins; 2000.
15. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. *Diabetes Care.* Apr 1990;13(4):401-411.
16. Schulz LO HI, Smith CJ, Kriska AM, Ravussin E. Energy intake and physical activity in Pima Indians: comparison with energy expenditure measured by doubly-labeled water. *Obes Res.* 1994;2:541-548.
17. Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-Wild S, Connor WE. The Diet Habit Survey: a new method of dietary assessment that relates to plasma cholesterol changes. *J Am Diet Assoc.* Jan 1992;92(1):41-47.
18. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* Feb 7 2002;346(6):393-403.
19. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care.* Apr 1997;20(4):537-544.
20. Eriksson KF LF. Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical activity. *Diabetologia.* 1991;34:891-898.
21. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med.* May 3 2001;344(18):1343-1350.
22. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. *Jama.* Dec 16 1998;280(23):2001-2007.
23. Simkin-Silverman LR, Wing RR, Boraz MA, Kuller LH. Lifestyle intervention can prevent weight gain during menopause: results from a 5-year randomized clinical trial. *Ann Behav Med.* Dec 2003;26(3):212-220.
24. Kuller LH S-SL, Wing, RR, Meilahn EN, Ives DG. Women's Healthy Lifestyle Project: A Randomized Clinical Trial - Results at 54 Months. *Circulation.* 2001;103:32-37.

25. Mosca L, Ferris A, Fabunmi R, Robertson RM. Tracking women's awareness of heart disease: an American Heart Association national study. *Circulation*. Feb 10 2004;109(5):573-579.
26. Vittinghoff E, Shlipak MG, Varosy PD, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. *Ann Intern Med*. Jan 21 2003;138(2):81-89.
27. King KB, Mosca L. Prevention of heart disease in women: recommendations for management of risk factors. *Prog Cardiovasc Nurs*. Spring 2000;15(2):36-42.
28. Association AH. Go Red for Women Campaign. <http://www.goredforwomen.org/>. Accessed June 7, 2006, 2006.
29. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol*. Apr 17 2006;97(8A):89C-94C.
30. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. *Am J Med*. Sep 6 2004;117 Suppl 5A:72S-78S.
31. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. Mar 31 2005;352(13):1293-1304.
32. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. Oct 8 2005;366(9493):1267-1278.
33. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. *Ann Intern Med*. Mar 7 2006;144(5):326-336.

Table 5-1: Baseline Cardiovascular Disease Risk Factor Levels between HT Continuers and HT Discontinuers

	HT Continuers (n=106)	HT Discontinuers (n=125)	P value
Age, years	57.9 (2.8)	58.7 (2.9)	0.04
Weight, lbs.	178.2 (24.7)	180.4 (25.3)	0.51
Body Mass Index, kg/m ²	30.4 (3.5)	30.8 (3.8)	0.41
Waist Circumference, cm	105.5 (10.1)	107.1 (11.2)	0.27
Leisure Physical Activity, MET hr- wk	13.6 (6.7, 20.6)	10.9 (4.9, 20.2)	0.11
Saturated Fat/Cholesterol Intake Index	62.1 (12.5)	60.8 (12.7)	0.42
Systolic Blood Pressure, mmHg	124.7 (13.6)	122.8 (13.3)	0.28
Diastolic Blood Pressure, mmHg	76.4 (9.1)	76.0 (7.8)	0.71
Total Cholesterol, mg/dL	212.8 (23.7)	207.2 (26.0)	0.09
LDL Cholesterol, mg/dL	122.4 (21.1)	118.7 (20.8)	0.18
HDL Cholesterol, mg/dL	62.0 (14.5)	60.8 (13.1)	0.52
Triglyceride, mg/dL	141.9 (69.0)	137.4 (74.4)	0.64
Insulin, mg/dL	11.6 (4.6)	13.6 (7.2)	0.02
Glucose, mg/dL	92.3 (7.7)	94.3 (9.9)	0.10

Baseline leisure physical activity levels presented as median (25th, 75th percentile); the remaining variables as mean (SD).

Table 5-2: 18 Month Change in Cardiovascular Risk Factors by Hormone Therapy Group and Randomized Group Assignment (n=231)

	HT Continuers (n=106)			HT Discontinuers (n=125)		
	HE (n=45)	LC (n=61)	P value	HE (n=57)	LC (n=68)	P value
Weight, lbs.	-5.3 (13.2)	-17.0 (13.7)	< 0.0001	4.3 (11.8)	-18.3 (17.7)	< 0.0001
Body Mass Index, kg/m ²	-0.9 (2.1)	-3.0 (2.4)	< 0.0001	-0.9 (2.1)	-3.2 (3.1)	< 0.0001
Waist Circumference, cm	-5.3 (6.4)	-10.6 (7.6)	0.0002	-3.8 (6.4)	-11.0 (8.5)	< 0.0001
Leisure Physical Activity, MET hr-wk	0.4 (-6.4, 9.3)	3.7 (-2.2, 12.0)	0.1955	0.8 (-4.8, 6.0)	7.2 (1.2, 12.7)	0.0012
Saturated Fat/Cholesterol Intake Index	8.3 (11.1)	18.4 (14.1)	< 0.0001	5.2 (8.6)	20.3 (16.6)	< 0.0001
CVD Risk Factors						
Insulin, mg/dL	1.2 (4.1)	-0.5 (4.0)	0.0402	1.1 (8.4)	-0.1 (5.1)	0.3461
Triglyceride, mg/dL	-10.0 (43.8)	-11.0 (53.5)	0.9192	1.6 (50.9)	-16.9 (48.2)	0.0399
Glucose, mg/dL	5.2 (7.6)	2.2 (9.6)	0.0778	8.5 (13.0)	3.9 (9.0)	0.0264
HDL Cholesterol, mg/dL	1.5 (11.6)	1.9 (10.1)	0.8619	-0.3 (11.2)	-0.2 (10.9)	0.9389
Systolic Blood Pressure, mmHg	-1.8 (18.2)	-2.7 (14.3)	0.7842	-2.6 (11.9)	-3.6 (14.3)	0.6750
Diastolic Blood Pressure, mmHg	-0.09 (9.8)	-0.1 (9.1)	0.9820	-1.0 (7.2)	-1.9 (7.9)	0.5217
Total Cholesterol, mg/dL	3.5 (31.5)	5.8 (25.8)	0.6871	21.4 (32.9)	4.7 (30.3)	0.0041
LDL Cholesterol, mg/dL	4.0 (26.1)	6.1 (22.5)	0.6607	21.7 (29.4)	7.4 (25.0)	0.0045

18 month change in leisure physical activity levels presented as median (25th, 75th percentile); the remaining 18 month change variables as mean (SD).

Table 5-3: 18 Month Change in Cardiovascular Risk Factors after Adjustment (MLR Models) (n=231)

	Total Cholesterol, mg/dL	LDL Cholesterol, mg/dL	HDL Cholesterol, mg/dL	Triglycerides, mg/dL	Insulin, mg/dL (n=208)	Glucose, mg/dL (n=230)
Hormone Therapy Use at 18 Months	3.8 ± 3.5	5.8 ± 3.0†	-2.1 ± 1.3†	1.4 ± 6.0	1.1 ± 0.7	3.1 ± 1.2**
△ Leisure Physical Activity (LPA), MET hr-wk	-2.1 ± 2.0	-3.3 ± 1.7†	2.9 ± 0.7****	-9.0 ± 3.5**	-0.5 ± 0.4	-1.2 ± 0.7†
△ Saturated Fat/Cholesterol Intake Score	-0.7 ± 0.1****	-0.5 ± 0.1****	-0.04 ± 0.05	-0.7 ± 0.2****	-0.1 ± 0.02****	-0.1 ± 0.04**
Baseline LPA, MET hr-wk	-0.5 ± 1.1	-1.5 ± 1.0	1.6 ± 0.4****	-1.4 ± 1.9	-0.2 ± 0.2	-0.8 ± 0.4*
Baseline Saturated Fat/Cholesterol Intake Score	-0.1 ± 0.1	-0.08 ± 0.1****	-0.07 ± 0.05	0.1 ± 0.2	-0.07 ± 0.03**	-0.05 ± 0.05
Baseline CVD Risk Factor Level	-0.5 ± 0.07****	-0.6 ± 0.07****	-0.3 ± 0.05****	-0.2 ± 0.04****	-0.5 ± 0.06****	-0.5 ± 0.07****
R ²	0.317	0.318	0.274	0.212	0.349	0.252

*All models were adjusted for HT use at 18 months, change (△) in leisure physical activity levels, △ in saturated fat/cholesterol intake score, baseline leisure physical activity levels, baseline saturated fat/cholesterol intake score, and baseline levels of relevant CVD risk factor. †<0.10; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.




Figure 5-1: 18 Month Change in Total Cholesterol and LDL-C by Randomized Group Assignment and HT group (**p<0.01)

**6 ASSOCIATIONS BETWEEN WALKING PERFORMANCE DETERMINED BY
THE LONG DISTANCE CORRIDOR WALK, PHYSICAL ACTIVITY LEVELS,
AND SUBCLINICAL MEASURES OF CARDIOVASCULAR DISEASE IN
POSTMENOPAUSAL WOMEN**

For Future Publication

Kelley K. Pettee PhD¹, Beth M. Larouere PhD², Andrea M. Kriska PhD¹, B. Delia Johnson
PhD¹, Bret H. Goodpaster³ PhD, Trevor J. Orchard¹ MD, Rachel H. Mackey PhD¹, Molly B.
Conroy^{1,3} MD, Darcy A. Underwood BS¹, Lewis H. Kuller¹ MD

¹ Department of Epidemiology

² Department of Health, Physical and Recreational Education

³ Division of General Internal Medicine, Department of Medicine, University of Pittsburgh,
Pittsburgh, PA

6.1 ABSTRACT

OBJECTIVE: To examine the association between the long distance corridor walk (LDCW), physical activity levels, and measures of subclinical cardiovascular disease (CVD) in order to determine the construct validity of the LDCW to estimate health and functional status in middle-aged, postmenopausal women. **DESIGN:** The cross-sectional relationships between walk time from the LDCW, physical activity levels, and subclinical CVD measures were examined prior to group randomization in 492 [mean age 57.0 (2.9 years)] Caucasian and African-American women from the Woman On the Move through Activity and Nutrition (WOMAN) study. The WOMAN study is a randomized clinical trial involving overweight, middle-aged, postmenopausal women. **RESULTS:** Longer walk times were significantly associated with higher BMI ($p<0.0001$) and WC ($p<0.0001$) and lower subjective and objective physical activity levels ($p<0.003$). The proportion of detectable coronary artery calcification (CAC) and median aortic pulse wave velocity (aPWV) levels, both subclinical measures of CVD, were significantly higher among those with slower walk times ($p<0.002$ and $p<0.001$, respectively). **CONCLUSIONS:** Total walk time from the LDCW was significantly associated with both physical activity levels and measures of subclinical CVD. These findings support the utility of the LDCW to monitor patient progress in physical activity programs and/or identify those individuals who may warrant additional CVD screening.

6.2 INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death among women in the United States, claiming approximately 500,000 lives each year (1). A large proportion of deaths attributable to CVD occur in women with no prior symptoms (2, 3). Therefore, the identification of high risk, asymptomatic women who may benefit from primary CVD prevention would have important public health implications.

Past epidemiological studies have suggested that exercise capacity and/or cardiovascular fitness is an independent predictor of cardiovascular events and death among asymptomatic women (3, 4), thereby providing a general indicator of cardiovascular health status (5). Maximal oxygen uptake (VO_2 max) is the most accurate assessment technique to evaluate cardiovascular fitness and is typically measured using treadmill based protocols (5). However, VO_2 max protocols may not be practical in large epidemiological studies due to time constraints, staff burden, high equipment costs, and safety concerns (6). In instances where VO_2 max tests are not feasible, tests of walking endurance have been substituted for this gold standard measure to estimate fitness levels and overall health status (7-9).

Walking endurance protocols, such as the 6-minute walk test and long distance corridor walk (LDCW) were developed, and have been primarily used, in diseased and/or in older populations as a crude measure of fitness and health and functional status. The 6-minute walk test has primarily been used to estimate health status in populations with debilitating conditions such as chronic obstructive lung disease, heart failure, and left ventricular dysfunction (10-12), but has also been used to estimate functional status in older adults (13). The LDCW is a modification of the 6-minute walk test and uses a predetermined distance (400 meters) rather than duration (9). Time based tests of walking endurance evolved into distance based protocols

based on the notion that an individual may be more intrinsically motivated to complete a predetermined distance in as little time as possible, thus, providing a more maximal effort (9).

In contrast to the 6 minute walk test which is primarily used in diseased populations, the LDCW has been utilized in well-functioning, healthy older individuals with promising results. Results from a cross-sectional investigation suggested that walking performance was influenced by both clinical and subclinical disease and was strongly related to anthropometric measures and self reported physical activity levels (14). The usefulness of the LDCW to provide a general indicator of overall health in older adults was confirmed in the follow-up, longitudinal investigation. Results from this report suggested that exclusion or inability to complete the LDCW protocol was associated with an increased risk of mortality, incident CVD, and mobility limitation (7). Furthermore, among those that completed the protocol, each additional minute of walk time was associated with a 29% higher rate of mortality, a 20% higher rate of incident CVD, and 52% higher rates of mobility limitation and disability (7). In addition, unlike the 6 minute walk test, the LDCW has been shown to be a valid estimate of peak VO_2 (8) in older adults. These findings suggest that measured parameters from the LDCW, particularly walk time, are useful for estimating fitness levels as well as risk of mortality and/or disease among older adults.

It is fairly well established in the literature that the LDCW can be used as a low cost alternative for estimating fitness levels, functional status, and future morbidity and/or mortality in older individuals; however, little is known regarding the applicability of this test in younger populations. Thus, the primary purpose of the current report was to determine the construct validity of walk time from the LDCW against subjective and objective physical activity

assessments and measures of subclinical CVD in order to determine the utility of the LDCW to estimate functional status in middle-aged, postmenopausal women.

6.3 METHODS

6.3.1 Study Population

Five hundred and eight postmenopausal women were recruited for the Women On the Move through Activity and Nutrition (WOMAN) study, primarily through direct mailing from selected zip codes in Allegheny County, Pennsylvania from April 2002 to October 2003. The (WOMAN) study is a five year primary CVD prevention randomized clinical trial, designed to test whether an aggressive non-pharmacological lifestyle intervention among postmenopausal women will reduce measures of subclinical CVD. Eligibility criteria for enrollment into the study included waist circumference ≥ 80 centimeters (cm), body mass index (BMI) between 25 – 39.9 kilograms per meters squared (kg/m^2), not currently taking lipid lowering drugs and having a low density lipoprotein cholesterol (LDL-C) level between 100 - 160 milligrams per deciliter (mg/dL), no physical limitations that would preclude walking, no known diabetes, and no diagnosed psychotic disorder or depression. All participants provided written informed consent and all protocols were approved by the institutional review board at the University of Pittsburgh. Results were based on data collected prior to randomization at the baseline clinic visit (2002-2003).

6.3.2 Demographic and Clinical Measures

Demographic factors and clinical measures were obtained at the baseline clinic visit. Clinical measures included height, body weight, average waist circumference (WC), and a fasting (12 hour) blood draw. Body mass index (BMI) was calculated from height and weight measured with a stadiometer and calibrated balance beam scale by dividing the participant's weight in kilograms by the square of her height in meters. Average WC was measured at the navel (horizontal plane at the center of the navel) using a fiberglass retractable tape measure. Total cholesterol, HDL-C, triglycerides, and glucose were determined by conventional methods. LDL-C was estimated by the Friedewald equation and insulin was measured via radioimmunoassay.

6.3.3 Long Distance Corridor Walk

The LDCW was a 400 meter course which consisted of 10 laps along a hallway with cones set 20 meters apart (40 meters per lap). Participants were instructed to walk "at a pace that you can maintain for the full 10 laps." Standard encouragement by trained staff was given at each lap. Heart rate was monitored with a Polar Pacer heart monitor (Model 60905; Woodbury, NY). Persons with elevated blood pressure (BP $\geq 200/110$) or resting heart rate (>110 or <40) or reporting exacerbation of chest pain, shortness of breath, or cardiac event or procedure within the past three months were excluded for safety reasons. The LDCW was stopped if the participant's heart rate exceeded 135 beats per minute (bpm) or if a participant reported chest pain or dyspnea during the test. Heart rate (HR) was recorded at rest before starting the walk, at completing, and at recovery 2 minutes later. Systolic blood pressure (SBP) was measured while seated prior to

the walk and standing at test completion. Based on these measures, cardiovascular (CV) response variables were generated. HR and SBP response were calculated by subtracting the resting values from those obtained immediately following completion. HR recovery was calculated by subtracting the HR obtained 2 minutes after LDCW completion from the value measured at completion. On average, the entire LDCW protocol takes approximately 8-10 minutes to administer.

6.3.4 Physical Activity Measures

Physical activity levels were assessed using both subjective and objective measurement tools. Physical activity was measured subjectively using a past year and past week version of the Modifiable Activity Questionnaire (MAQ) and objectively with the pedometer step counter.

In brief, the interviewer-administered, past year version of the Modifiable Activity Questionnaire (MAQ) questionnaire assesses current leisure and occupational activities, as well as extreme levels of inactivity due to disability (15). Physical activity levels were calculated as the product of the duration and frequency of each activity (in hours per week), weighted by an estimate of the metabolic equivalent (MET) of that activity and summed for all activities performed. Physical activity data were expressed as metabolic equivalent hours per week (MET hr-wk). The MAQ has been shown to be both a reliable (15, 16) and valid (15-17) assessment measure.

Physical activity was also assessed using a past week version of the MAQ. This questionnaire measures participation in leisure activities performed over the past 7 days. Study participants were given the past week MAQ during the eligibility visit and were asked to record

leisure activities for the 7 days prior to their clinic assessment. Past week leisure physical activity levels were calculated similar to that used for the leisure section of the past year MAQ.

At baseline, objective assessments of physical activity were obtained with the Accusplit Eagle AE120 (Accusplit Inc., Pleasanton, CA) pedometer in a subgroup of WOMAN study participants (n=170; 33.5%). The participants were instructed to wear the pedometer clipped to their waistband over the dominant hip for one week, and at the end of each day to record the number of steps taken in a diary. At the end of the week the participant returned the activity diary to the investigator. The number of steps recorded in the diary from the pedometer was averaged for the week to obtain a seven-day average of the number of steps taken per day.

6.3.5 Subclinical CVD Measures

Electron beam tomography, with an Imatron C-150 Scanner (Imatron, San Francisco, CA) was used to obtain 30-40 contiguous 3-mm-thick images of the heart, as previously described (18). Coronary artery calcification (CAC) scores were calculated according to the Agatston method. The reproducibility of the electron beam tomographic scans from this laboratory has an interclass correlation of 0.99 (18).

Detailed B-mode images of the right and left common carotid artery (CCA), carotid bifurcation, and the first 1.5 cm of the internal carotid artery (ICA) were obtained using a Toshiba SSA-270A ultrasound scanner (Toshiba America Inc., New York, New York) equipped with a 5-MHz linear array imaging probe. To measure the average intima-media thickness (IMT) of each segment, lines were electronically drawn along 1-cm segments of the lumen-intima interface and the media-adventitia interface of the near and far walls of the distal CCA

and along the far walls of the carotid bulb and ICA. The average of these was recorded for each location. The mean of all average readings across the eight locations (four on each side) was calculated.

Stiffness of the aorta was measured using the gold standard, carotid-femoral (or aortic) pulse wave velocity (aPWV), as previously described in detail (19, 20). Briefly, for each participant, 20 seconds of carotid and femoral pulse waveforms were collected simultaneously with non-directional Doppler probes and recorded to data files. Files were “scored” using software developed by the Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging. For each file, the trained reader selected all clear waveforms for averaging into composite carotid and femoral waveforms, to determine the “foot” (or upstroke) of each. The transit time of the pulse wave was calculated as the foot-to-foot delay between the averaged carotid and femoral waveforms. The distance traveled by the pulse waveform between the carotid and femoral measurement sites was measured manually with a metal tape measure, above the surface of the participant’s torso. Aortic pulse wave velocity was calculated by dividing the distance traveled by the time differential between the two waveforms and was expressed as distance/transit time (cm/sec). Results from all usable data collection runs ($n = 3$) for each participant were averaged. In our lab this measure has been demonstrated to have good reproducibility with an intraclass correlation of 0.72-0.83 (19).

6.3.6 Statistical Methods

Univariate analyses were conducted on measured parameters from the LDCW, demographics, physical activity levels, and measures of subclinical CVD. Normally distributed variables were reported as mean \pm standard deviation, non-normally distributed variables were reported as

median with 25th and 75th percentile, and proportions were noted for categorical variables. Spearman rank order correlation coefficients were used to assess the bivariate associations between walk time and CV response measures from the LDCW, demographics, physical activity levels, and CVD risk factors. Partial Spearman rank order correlations were used to further examine these relationships adjusted for age, age and BMI, and past year leisure physical activity levels. Descriptive statistics were used to illustrate demographics, physical activity levels, and CVD risk factors across quartiles of LDCW time. Depending upon the characteristics of the variable, ANOVA, Kruskal-Wallis, or Chi Square Test of Proportions was used to compare demographic factors, physical activity levels, clinical and subclinical CVD measures across quartiles of LDCW time in those who completed the 400-meter walk. Jonckheere-Terpstra tests were used estimate the linear trend in continuous variables and Cochran-Armitage Trend test were used to determine linear trend for categorical variables. Due to the high number of planned comparisons across quartiles of walk time, a p value of <0.002 will be used to denote statistical significance using the Bonferonni correction method.

6.4 RESULTS

Of the 508 women, 3 had missing walk time, 1 had an invalid walk time, and 1 woman did not complete the 10 laps due to elevated HR. Of those 503 (99%) women that completed the entire protocol, 11 (2%) had incomplete physical activity and/or coronary artery calcium (CAC) data and were excluded from the present analyses [8 of the 11 were missing past year leisure physical activity, 2 were missing past week leisure physical activity, and 1 woman had a missing CAC

score]. The current report will focus on the remaining 492 WOMAN study participants with complete data.

At baseline, the mean age of the participants was 57.0 (range: 52 - 62.8) years, 11.8% were African American, and 59.4% (n = 292) reported taking HT at baseline. Study participants had a mean BMI of 30.8 (range: 23.3 – 41.3) kg/m² and waist circumference of 106.0 (range: 80.8 – 138.5) centimeters. Only 6.1% of women reported being current smokers at baseline. With regards to the measured parameters from the LDCW, on average the WOMAN study participants completed the walk in 301.2 seconds (approximately 5 minutes). Mean HR and SBP increased from resting by 36.8 bpm and 4.3 mmHg, respectively. At the end of the 2 minute recovery period, HR decreased by 20.4 bpm, which was approximately 55% of the HR response (Table 6.1).

Correlations between walk time and demographics, physical activity levels, CV response measures from the LDCW, and CVD risk factors are presented in table 6.2. Longer walk times were significantly (p<0.05) associated with older age and higher BMI and average WC levels. Walk time was inversely related to both subjective and objective assessments of physical activity levels as well as the CV response (HR and SBP) to the 400 meter walk. Longer walk times were related to higher resting HR and SBP, triglyceride, insulin, glucose, CAC score (continuous) and aPWV levels and lower HDL-C levels. The results were similar when the associations with walk time were adjusted for age alone (data not shown). However, when the results were adjusted for age and BMI, higher walk time was no longer significantly correlated with higher resting SBP, triglyceride, insulin levels or CAC score nor was walk time related to lower HDL-C levels. Adjusting for past year leisure physical activity levels did not substantially change the relationship between walk time and CVD risk factors (data not shown).

Table 6.3 describes the characteristics of the study population across quartiles of LDCW time. With regards to demographic factors, mean age, BMI, and WC significantly increased as time to complete the 400 meter course increased. In addition, the proportion of African American women was significantly higher in the slower walk time categories. The relationship between current HT use and walk time was not statistically significant. Regardless of whether activity was measured subjectively or objectively, median physical activity levels decreased across increasing walk time quartiles. Finally, relationships between walk time and CVD risk factors were investigated. The SBP and HR response to the LDCW and HR recovery decreased as mean walk time increased. Resting HR and SBP, LDL-C, insulin, and glucose levels increased as time to complete the 400 meter walk increased (significant at $p < 0.002$ for resting HR, glucose, and insulin only). With regards to subclinical CVD measures, the proportion of detectable CAC (>0) was significantly higher among those with slower walk times. Median aortic PWV levels also significantly increased across increasing walk time quartiles. The association between walk time and IMT levels was not statistically significant.

6.5 DISCUSSION

In this large cohort of healthy postmenopausal women, 99% of study participants completed the LDCW testing protocol without complications. The high completion rate that was achieved in the current investigation confirms previous work suggesting that the LDCW protocol is practical to administer in large population studies. Furthermore, the significant trends that were observed between walk time and physical activity levels and measures of subclinical CVD indicate that the

LDCW has important psychometric properties among healthy, middle-aged, postmenopausal women.

In a practical sense, the LDCW protocol may be appealing in primary care settings due to the relative cost and time effectiveness, lack of required medical supervision, space and/or equipment, and patient familiarity of the activity mode (walking). Based on the findings from the current report, total walk time from the LDCW could be considered both a proxy measure for physical activity as well as an objective assessment of physical function and performance. The use of the LDCW protocol in clinical practice may allow health care providers to more effectively prescribe physical activity for their patients and/or monitor progress in healthy lifestyle based programs. In addition, when screening for CVD risk factors, poor performance during the LDCW could potentially identify those individuals who may warrant follow-up (cardiac) testing and evaluation.

In the current report, total walk time from the LDCW was inversely associated with physical activity levels as determined by the pedometer as well as past year and past week versions of the MAQ (15). Unlike past studies that estimated physical activity levels using subjective questionnaires, the present investigation also included an objective measure of physical activity, the pedometer step counter. Although subjective physical activity measures have been shown to accurately assess higher intensity, structured leisure physical activities, they typically do a poor job when measuring lower intensity, unstructured lifestyle physical activities, such as household chores, childcare, and housework (15, 21). In contrast, objective measures have the ability to capture both structured and unstructured activities thus providing a complete picture of an individual's total physical activity levels (22). The decrease in physical activity levels that was observed across increasing walk times was similar regardless of the method that

was used to collect activity data (ie. subjective vs. objective assessment). Finally, when comparing the subjective activity assessments (past year vs. past week MAQ), the relationship with walk time was stronger with the past year measure as it may reflect more typical activity when compared to the past week estimate which may be subject to acute changes in health status.

When interpreting the findings of the present investigation, a number of limitations need to be considered. Data from only one point in time, the baseline visit, was used in the analyses. Although informative, this cross-sectional study analysis is limited in that it does not provide information pertaining to the direction of association or allow us to determine how the relationship between walking performance, physical activity, and CVD risk factors may change over time. In addition, maximal oxygen uptake (max VO_2) was not measured in the current investigation; therefore, the usefulness of the LDCW to estimate fitness levels in this population cannot be assumed. Finally, the ability to complete the LDCW and timed performance were found to be important prognostic factors for total mortality, CVD, and functional ability in older adults (7). Future work is needed to determine the predictive value of the LDCW for future morbidity and mortality in middle-aged, postmenopausal women.

As we move towards promoting physical activity for primary CVD prevention, quick and inexpensive tools are needed in order to ensure safe participation and/or evaluate progress in healthy lifestyle based programs. The evidence from the current report supports the utility of the LDCW to estimate the functional status of middle-aged, postmenopausal women. The information obtained during the LDCW protocol may allow health care providers to identify those individuals who may necessitate additional CVD screening.

Acknowledgements: The authors would like to acknowledge the contributions of the staff as well as the 508 dedicated participants of the WOMAN study. This research was funded by National Heart, Lung, and Blood Institute contract R01-HL-66468.

6.6 REFERENCES

1. Association AH. *Heart Disease and Stroke Statistics - 2005 Update*. Dallas, TX; 2004.
2. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. *Circulation*. Oct 7 1997;96(7):2468-2482.
3. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. *Circulation*. Apr 29 2003;107(16):2096-2101.
4. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. *Circulation*. Sep 30 2003;108(13):1554-1559.
5. Medicine ACoS. *ACSM's Guidelines for Exercise Testing and Prescription*. 6th ed. Baltimore, MD: Lippincott, Williams & Wilkins; 2000.
6. Wilson PW, Paffenbarger RS, Jr., Morris JN, Havlik RJ. Assessment methods for physical activity and physical fitness in population studies: report of a NHLBI workshop. *Am Heart J*. Jun 1986;111(6):1177-1192.
7. Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. *Jama*. May 3 2006;295(17):2018-2026.
8. Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk. *J Am Geriatr Soc*. Jan 2006;54(1):127-132.
9. Simonsick EM, Montgomery PS, Newman AB, Bauer DC, Harris T. Measuring fitness in healthy older adults: the Health ABC Long Distance Corridor Walk. *J Am Geriatr Soc*. Nov 2001;49(11):1544-1548.
10. Swerts PM, Mostert R, Wouters EF. Comparison of corridor and treadmill walking in patients with severe chronic obstructive pulmonary disease. *Phys Ther*. Jul 1990;70(7):439-442.
11. Lucas C, Stevenson LW, Johnson W, et al. The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. *Am Heart J*. Oct 1999;138(4 Pt 1):618-624.
12. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. *Jama*. Oct 13 1993;270(14):1702-1707.

13. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: a quick measure of functional status in elderly adults. *Chest*. Feb 2003;123(2):387-398.
14. Newman AB, Haggerty CL, Kritchevsky SB, Nevitt MC, Simonsick EM. Walking performance and cardiovascular response: associations with age and morbidity--the Health, Aging and Body Composition Study. *J Gerontol A Biol Sci Med Sci*. Aug 2003;58(8):715-720.
15. Pereira MA, FitzerGerald SJ, Gregg EW, et al. A collection of Physical Activity Questionnaires for health-related research. *Med Sci Sports Exerc*. Jun 1997;29(6 Suppl):S1-205.
16. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. *Diabetes Care*. Apr 1990;13(4):401-411.
17. Schulz LO HI, Smith CJ, Kriska AM, Ravussin E. Energy intake and physical activity in Pima Indians: comparison with energy expenditure measured by doubly-labeled water. *Obes Res*. 1994;2:541-548.
18. Kuller LH MK, Sutton-Tyrrell K, Edmundowicz D, Bunker CH. Coronary and Aortic Calcification Among Women 8 Years After Menopause and Their Premenopausal Risk Factors: The Healthy Women Study. *Arterioscler Thromb Vasc Biol*. 1999;19:2189-2198.
19. Sutton-Tyrrell K, Mackey RH, Holubkov R, Vaitkevicius PV, Spurgeon HA, Lakatta EG. Measurement variation of aortic pulse wave velocity in the elderly. *Am J Hypertens*. May 2001;14(5 Pt 1):463-468.
20. Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, et al. Correlates of aortic stiffness in elderly individuals: a subgroup of the Cardiovascular Health Study. *Am J Hypertens*. Jan 2002;15(1 Pt 1):16-23.
21. Jacobs DR, Jr., Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation of 10 commonly used physical activity questionnaires. *Med Sci Sports Exerc*. Jan 1993;25(1):81-91.
22. Kriska A. Ethnic and cultural issues in assessing physical activity. *Res Q Exerc Sport*. Jun 2000;71(2 Suppl):S47-53.

Table 6-1: Baseline Characteristics of the WOMAN Study Cohort (n=492)

Corridor Walk Variables	
Corridor Walk Time, sec	301.2 (37.5)
HR at End of LDCW, bpm	107.0 (12.5)
SBP at End of LDCW, mmHg	128.5 (18.0)
2 Minute Recovery HR, bpm	86.6 (13.0)
SBP Response, mmHg	4.3 (13.1)
HR Response, bpm	36.8 (12.0)
2 Minute HR Recovery, bpm	20.4 (10.2)
Demographics	
Age, years	57.0 (2.9)
BMI, kg/m ²	30.8 (3.8)
Average WC, cm	106.0 (11.3)
% African American	11.8%
% HS Education	98.6%
% Hormone Therapy Use	59.4%
% Current Smokers	6.1%
Physical Activity Measures	
Past Year Leisure Activity, MET hr-wk	11.5 (5.2, 20.5)
Past Week Leisure Activity, MET hr-wk	11.2 (5.3, 19.3)
Pedometer, steps/day (n=170)	6446.9 (4801.4, 8721.6)
CVD Risk Factors	
Resting Heart Rate, bpm	70.2 (9.2)
Systolic Blood Pressure, mmHg	124.2 (16.3)
Diastolic Blood Pressure, mmHg	76.8 (8.3)
Total Cholesterol, mg/dL	216.4 (28.1)
LDL-C, mg/dL	128.0 (25.1)
HDL-C, mg/dL	60.0 (14.2)
Triglycerides	142.1 (74.3)
Insulin, mg/dL (n=432)	13.6 (6.7)
Glucose, mg/dL (n=486)	95.4 (9.3)
% Coronary Artery Calcification	
0	49%
0-10	32.1%
11-100	13.6%
101+	5.3%
IMT (n=485)	0.71 (0.65, 0.76)
Pulse Wave Velocity, cm/sec (n=467)	846.2 (737.6, 988.8)

Normally distributed variables presented as mean (SD); non-normally distributed variables presented as median (25th, 75th percentile).

Table 6-2: Spearman Rank Order Correlations Between Walk Time from the Long Distance Corridor Walk (LDCW) and Related Factors

Walk Time (sec)		Unadjusted	Adjusted for age and BMI
Demographics	Age, yrs	0.13**	--
	BMI, kg/m ²	0.36****	--
	Average WC	0.29****	--
Physical Activity (PA) Levels	Past Year Leisure Activity	-0.23****	--
	Past Week Leisure Activity	-0.18****	--
	Pedometer Steps (n=170)	-0.25****	--
Cardiovascular Response to LDCW	SBP Response, mmHg	-0.13****	-0.22****
	HR Response, bpm	-0.31**	-0.38****
	HR Recovery, bpm	-0.44****	-0.48****
CVD Risk Factors	Resting Heart Rate, bpm	0.17***	0.15***
	Systolic Blood Pressure (BP), mmHg	0.10*	0.01
	Diastolic BP, mmHg	0.01	-0.04
	Total Cholesterol, mg/dL	0.08 [†]	0.06
	LDL-C, mg/dL	0.08 [†]	0.06
	HDL-C, mg/dL	-0.11**	-0.06
	Triglycerides, mg/dL	0.09*	0.04
	Insulin, mg/dL (n=432)	0.26****	0.15**
	Glucose, mg/dL (n=486)	0.13**	0.05
	CAC	0.16***	0.01
	IMT (n=485)	0.04	-0.04
Pulse Wave Velocity (n=467)	0.16***	0.12**	

[†]<0.10; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001

Table 6-3: Characteristics of Study Participants by Quartiles of Walk Time (n=492).

	Quartiles of Walk Time (sec)				p value	p for linear trend
	Quartile 1 (n=120)	Quartile 2 (n=123)	Quartile 3 (n=124)	Quartile 4 (n=125)		
Demographics						
Age, yrs	56.6 (2.8)	56.6 (3.0)	57.3 (2.9)	57.3 (2.8)	0.04	0.01
% African American	7.5	4.1	15.3	20	0.0003	0.0002
% Hormone Therapy users	43.3	31.7	42.7	44.8	0.14	0.42
Body Mass Index, kg/m ²	29.3 (3.3)	30.1 (3.2)	30.7 (3.6)	32.9 (4.1)	<0.0001	<0.0001
Average Waist Circumference, cm	102.4 (10.5)	104.1 (10.0)	106.7 (10.8)	110.5 (12.2)	<0.0001	<0.0001
Physical Activity (PA)						
Past Year Leisure PA, MET hr-wk	15.7 (7.5, 27.0)	11.6 (5.5, 23.2)	10.6 (4.2, 17.5)	8.7 (4.0, 16.4)	<0.0001	<0.0001
Past Week Leisure PA, MET hr-wk	13.3 (7.7, 22.2)	11.7 (6.4, 22.6)	9.8 (5.0, 16.7)	9.9 (3.0, 15.5)	0.01	0.0007
Pedometer, steps/day	7285.2 (5670.7, 10427.6) n=36	6523.1 (5112.1, 8686.7) n=49	7132.5 (4864.6, 8426.4) n=42	5482.3 (4204.3, 6581.4) n=43	0.02	0.003
Cardiovascular Response						
Systolic Blood Pressure (BP) Response, mmHg	6.4 (13.6)	4.6 (11.7)	4.0 (12.7)	2.5 (14.0)	0.14	0.0041
Heart Rate Response, bpm	42.6 (12.0)	37.3 (10.5)	34.6 (10.9)	32.9 (12.4)	<0.0001	<0.0001
Heart Rate Recovery, bpm	27.1 (9.6)	21.0 (9.8)	18.2 (8.8)	15.6 (9.0)	<0.0001	<0.0001
CVD Risk Factors						
Heart Rate, bpm	68.1 (9.3)	69.8 (8.3)	71.3 (9.5)	71.6 (9.3)	0.01	0.0005
Systolic BP, mmHg	122.7 (13.2)	123.8 (13.8)	123.7 (13.5)	126.6 (13.8)	0.14	0.05
Diastolic BP, mmHg	77.1 (8.0)	76.1 (8.7)	76.7 (7.7)	77.2 (8.8)	0.69	0.76
Total Cholesterol, mg/dL	213.1 (24.2)	215.5 (26.7)	218.5 (29.4)	218.5 (31.6)	0.36	0.08
LDL-C, mg/dL	124.3 (21.7)	127.7 (24.3)	129.1 (26.2)	130.9 (27.8)	0.22	0.0510
HDL-C, mg/dL	60.9 (13.8)	60.1 (13.7)	61.4 (14.5)	57.6 (14.7)	0.15	0.06
Triglycerides, mg/dL	137.2 (75.5)	140.6 (79.2)	139.9 (72.1)	150.3 (70.3)	0.53	0.07
Insulin, mg/dL	12.0 (5.6)	11.7 (4.4)	14.4 (7.2)	16.1 (8.0)	<0.0001	<0.0001
Glucose, mg/dL	93.8 (7.6)	94.4 (8.3)	95.7 (9.5)	97.7 (11.0)	0.006	0.002
% Detectable CAC	40.8	51.2	49.2	62.4	0.0008	0.002
Intima Medial Thickness	0.70 (0.65, 0.77) n=115	0.70 (0.65, 0.77) n=123	0.70 (0.65, 0.75) n=123	0.72 (0.65, 0.78) n=124	0.62	0.48
Pulse Wave Velocity (cm/sec)	834.0 (726.7, 958.4) n=112	843.3 (721.7, 945.0) n=119	824.4 (731.6, 981.3) n=115	916.3 (791.0, 1087.1) n=121	0.002	0.0009

Normally distributed variables presented as mean (SD); non-normally distributed variables presented as median (25th, 75th percentile).
 Quartile 1: <267.6 seconds; Quartile 2: ≥ 267.6 to <305.4 seconds; Quartile 3: ≥ 305.4 to <319.2 seconds; Quartile 4: ≥ 319.2

7 DISCUSSION

Heart disease is the leading cause of death among American women. Overall, cardiovascular disease (CVD) claims the lives of more than ½ million women each year⁴. Furthermore, nearly 2/3 of all CVD related deaths occur in women with no previous symptoms, making early detection and diagnosis particularly challenging in this population^{1, 2}. The present investigation focused on non-pharmacological strategies and inexpensive screening measures to facilitate effective primary CVD prevention in postmenopausal women.

7.1 SUMMARY OF FINDINGS

The findings from the current report confirm previous studies suggesting the overall benefit of physical activity, either separately or as part of a lifestyle intervention, on CVD risk factor reduction in postmenopausal women. However, previous investigations examining the beneficial role of physical activity and/or lifestyle intervention for primary CVD prevention have not adequately accounted for the added influence of HT, which is particularly relevant following the publication of the results from the Women's Health Initiative (WHI) and Heart and Estrogen/progestin Replacement Study (HERS). The WOMAN study provided the unique opportunity to examine the separate and combined role of physical activity as part of a lifestyle intervention for CVD risk factor reduction by current and varying HT use (paper 1 and 2). The

utility of the long distance corridor walk (LDCW) to estimate health status and as a crude measure of physical fitness was also examined using the WOMAN study cohort (paper 3). The specific findings from each of the three papers included in this report are provided in the following sections.

7.1.1 Paper 1

The purpose of paper 1 was to clarify the cross-sectional associations between leisure physical activity and lipids in postmenopausal women using specific lipoprotein subclass measures. In addition, paper 1 examined how current HT use may influence these relationships. Results of paper 1 suggested that baseline leisure physical activity levels were significantly associated with higher levels of HDL-C and large HDL-P, and lower levels of triglycerides, and total and medium VLDL-P, regardless of HT use. However, for several key lipoprotein subclass measures, the relationship with physical activity differed by HT use. After stratification by HT use, physical activity was independently related to larger mean HDL and LDL particle size, and lower levels of total and small LDL-P among non-HT users, but not among women currently taking HT.

7.1.2 Paper 2

The primary purpose of paper 2 was to determine the effectiveness of a lifestyle intervention to attenuate unfavorable CVD risk factor changes that were hypothesized to occur as result of HT discontinuation. In general, the lifestyle intervention was successful and had a positive impact on many CVD risk factors among both HT continuers and HT discontinuers. When compared to

the HE group, women randomized to the LC group increased leisure physical activity levels and improved saturated fat and cholesterol intake. Women in the intervention also made beneficial improvements with regards to a number of important CVD risk factors including weight, WC, insulin, glucose, and triglyceride levels. There were no significant differences at 18 months between randomized groups with regards to changes in HDL-C, systolic and diastolic blood pressure levels in either HT continuers or HT discontinuers.

In contrast, there was marked differences by randomized group assignment between HT continuers and HT discontinuers with regards to two key CVD risk factors; total cholesterol and LDL-C. When comparing total cholesterol and LDL-C change within the HE arm, women who had discontinued HT use had significantly higher increases in these two measures as compared to HT continuers. The significant differences in total and LDL cholesterol change between HT continuers and HT discontinuers were not replicated in the LC arm, suggesting that the lifestyle intervention successfully attenuated an increase in total cholesterol and LDL-C that likely would have occurred with HT discontinuation.

7.1.3 Paper 3

The purpose of paper 3 was to determine the utility of the long distance corridor walk (LDCW) in postmenopausal women. More specifically, paper 3 examined the associations between measured parameters from the LDCW and related factors such as physical activity subclinical CVD levels. Results from paper 3 suggested that walking performance was related to demographics factors such as age and race, anthropometric measures including BMI and WC, and physical activity levels. Walk time was also strongly related to detectable coronary artery calcification (CAC) as well as aortic pulse wave velocity (aPWV), both subclinical measures of

CVD, suggesting that the LDCW protocol is a useful, inexpensive measure among postmenopausal women using construct validity.

7.2 PUBLIC HEALTH SIGNIFICANCE AND CLINICAL IMPLICATIONS

In the post-WHI era, concern and confusion about the risks associated with HT has left women and their health care providers searching for safe and effective means to reduce CVD risk factors. There is a growing body of evidence to support that physical activity, and physical activity as part of a lifestyle intervention, is important for primary CVD prevention in women. However, prior to this report little was known regarding how the relationship between healthy lifestyles practices, more specifically physical activity, and CVD risk factors may be influenced by current (paper 1) or changing (paper 2) HT use. Data from the WOMAN study provided the unique opportunity to clarify these relationships. The public health significance and clinical implications that are specific to each of the three papers included in this report are provided in the following sections.

7.2.1 Paper 1

Paper 1 was the first to investigate the associations between lipids, physical activity, and hormone therapy (HT) using specific lipoprotein subclasses in postmenopausal women. The findings from paper 1 suggested that leisure physical activity was associated with favorable lipoprotein and lipid levels, regardless of HT use. However, some relationships were found to vary by HT. When the results were stratified by current HT use, physical activity was associated

with key lipoprotein subclasses in HT non-users which have been shown to be related to both incident and subclinical CVD. The results from paper 1 raise the important question as to whether the beneficial effect of physical activity on the lipid profile in postmenopausal women is similar between HT users and non-users. As HT is being prescribed less frequently and for shorter periods of time, we need to be aware of other strategies to favorably alter the overall lipid profile in postmenopausal women. Findings from this report suggested that the promotion of physical activity may be a safe and effective alternative to improve lipids and reduce risk of CVD in postmenopausal women.

7.2.2 Paper 2

At 18 months, we were able to examine the effectiveness of a lifestyle intervention for CVD risk factor reduction in postmenopausal women who were on HT at baseline and either continued or discontinued use. We were also able to investigate the additional benefit of lifestyle among women discontinuing HT (paper 2). A lifestyle intervention was shown to attenuate increases in total and LDL-C levels that resulted from HT discontinuation. In this era of uncertainty, one potential consequence of diminished HT use for CVD risk factor reduction is increased use of supplementary pharmacological agents, such as statins and aspirin; however, both are associated with side effects^{183, 184}. In addition, trial data suggests that aspirin does not protect women from CVD in a similar fashion to men¹⁸⁵. Furthermore, the majority of statin research to date has been conducted in men^{186, 187}. Based on the promising findings of paper 2, special attention should be paid to encouraging efficacious lifestyle strategies that are likely to convey more benefit and less risk than drug therapies. To date, few data was available regarding the widespread impact of the

WHI results on CVD risk factor change in postmenopausal women. The findings from the current report suggest that a lifestyle based approach is effective for general CVD risk factor reduction and can effectively attenuate negative changes to lipids that result from HT discontinuation.

7.2.3 Paper 3

As we move towards promoting physical activity in the community for primary CVD prevention, quick and inexpensive tools are needed to provide objective information regarding general functional and/or health status that would otherwise not be captured through subjective means. The findings presented in paper 3 supported previous efforts suggesting the practicality of the LDCW in large population studies. The direct relationship that was observed between walk time and subclinical CVD measures is particularly important and supports the utility of this measure in postmenopausal women. Based on these promising findings, the parameters measured during the LDCW may provide health care providers with additional, necessary information to appropriately ascertain CVD risk in apparently healthy, asymptomatic postmenopausal women.

7.3 LIMITATIONS

The WOMAN study provided the unique opportunity to investigate the role of lifestyle, including physical activity, for CVD risk factor reduction in postmenopausal women by varying HT use. However, several general limitations are applicable to all three papers and need to be considered when interpreting the findings from the current report.

1. Hormone Therapy: The WOMAN study participants were not randomized to HT use at baseline nor were they randomized to either continue or discontinue HT use at 18 months. Thus, the inability to randomize the HT component of the WOMAN study may influence the findings of papers 1 and 2.
2. Study Population: The WOMAN study cohort consisted primarily of healthy, well-educated, Caucasian women. Thus, the results from the current investigation may not be generalizable to women of lower socio-economic status and/or women representing minority populations.
3. Study Design: The WOMAN study was also not designed to investigate the independent contributions of the specific intervention components for CVD risk factor reduction. Therefore, the independent effect of physical activity, diet, and/or weight loss on CVD risk factors would be difficult to separate out from the overall effect of the lifestyle intervention.
4. Sample Size: A larger and more diverse study cohort would have provided more statistical power to perform more detailed subgroup analyses.
5. Assessment of Physical Activity: Although both subjective and objective physical activity assessments were included in the WOMAN study, the findings from the current report were based primarily from leisure physical activity estimates obtained from the past year version of the Modifiable Activity Questionnaire (MAQ)¹⁴⁴. Self-reported physical activity estimates are subject to response bias which may influence the precision in measures of physical activity and related energy expenditure^{188, 189}. While subjective measures accurately assess moderate to higher intensity activities, focusing

solely on higher intensity activities may not be valid among women who may acquire the bulk of their physical activity in lower intensity activities^{144, 190}. Thus, the lack of incorporating the objective measure of physical activity (pedometer) into the analyses may affect the findings of paper 1 and 2.

The limitations that are specific to each of the three papers included in this report are provided in the following sections:

7.3.1 Paper 1

When interpreting the findings from paper 1, a number of limitations need to be considered. Data from only one point in time, the baseline visit, was used in the analyses. Although informative, this cross-sectional study analysis is limited in that it does not provide information pertaining to the direction of association or allow us to determine how the relationship between physical activity and lipoprotein subclasses changes as a woman changes her physical activity levels, HT status, or both. In addition, the results were adjusted for lifestyle factors (age, BMI, dietary saturated fat and cholesterol intake) that have been demonstrated to be related to both physical activity and lipid and lipoprotein subclass levels. Finally, women were classified as current HT users or non-users; the type, dosage, and/or duration of HT usage were not considered in these analyses.

7.3.2 Paper 2

The limitations of paper 2 should also be recognized. Given that this was a behavioral intervention, there may be a differential reporting bias with the intervention group reporting what

they should have been doing rather than what they were actually doing. For the purposes of paper 2, women were classified as HT continuers or HT discontinuers at 18 months; therefore, the duration of prior HT usage and/or time since discontinuation were not considered in these analyses. Finally, saturated fat and cholesterol intake was used as general measure of diet composition; therefore, other diet quality data was not considered in these analyses.

7.3.3 Paper 3

Paper 3 was a cross-sectional investigation and was; therefore, subject to the same study design limitations that were previously described for paper 1. In addition, VO_2 max, the current gold standard for assessing cardiovascular fitness, was not measured in this population. Therefore, the validity (convergent) of the LDCW to estimate fitness levels cannot be assumed. Finally, the LDCW was a tool developed to assess fitness levels and physical function in an older population. In younger individuals the time taken to complete the 400 meter course may be overestimated due to the fact that those walking at higher speeds may need to slow down in order to navigate around turns. In a previous investigation, it was suggested that walk time was not accurate in estimating peak VO_2 in individuals who walked at speeds of 3.75 mph (<240 seconds) and higher¹⁷². However, it should be noted that only two of the 492 (0.4%) women included in the present investigation completed the test protocol in less than 240 seconds.

7.4 FUTURE RESEARCH

The limitations that were identified in the previous section can be used to guide future research efforts. Although the WOMAN study cohort included women representing minority populations, 88% of the participants were of Caucasian descent. In addition, over 98% had achieved at least a high school degree, indicating that the cohort was of higher socio-economic status. Therefore, future efforts need to focus on translating the WOMAN lifestyle intervention into more diverse community settings with less manpower and a smaller budget. Future work should also examine whether total physical activity levels, including both structured and unstructured activities as measured by an objective assessment tool, follows the same trends as what was observed in the current report. An objective measure of physical activity would also provide the opportunity to validate the activity estimates that were obtained via subjective questionnaires. Finally, the ability to complete the LDCW and timed performance were found to be important prognostic factors for total mortality, CVD, and functional ability in older adults. Future work is needed to determine the predictive value of the LDCW for future morbidity and mortality in middle-aged, postmenopausal women.

7.5 CONCLUSION

In the current report, strategies for primary CVD prevention in postmenopausal women were examined. At baseline, leisure physical activity levels were shown to be beneficially related to improved lipid and lipoprotein subclass levels with many of these associations influenced by current HT use. Physical activity, as part of a lifestyle intervention, was also shown to be

effective for general CVD risk factor reduction regardless of HT continuation or discontinuation at 18 months. In addition, the lifestyle based intervention attenuated increases in total and LDL-C levels that apparently resulted from HT discontinuation. Finally, findings from the current report also suggested that a simple test of walking endurance may provide supplemental information when ascertaining CVD risk in women.

In conclusion, the development of primary CVD prevention strategies to decrease the burden from incident CVD in women has important public health implications. Currently, there is much concern and confusion about the risks associated with HT use and discontinuation of use. The findings from the current report suggest that a non-pharmacological, healthy lifestyle approach for CVD risk factor reduction is a safe and effective strategy for primary CVD prevention in healthy, middle-aged, postmenopausal women.

APPENDIX A: WOMAN STUDY PARTICIPANT INFORMATION FORM

WOMAN Study

Participant Information

Please only complete lines where there are changes from last visit.

ID: _____

Date: ____ / ____ / ____ (MM/DD/YY)

Staff: _____

Name: _____

Address: _____

Phone #: (Home)_(____)_____

(Work)_(____)_____

(Other)_(____)_____

Email: _____

Alternative Contact: _____ **Phone (Home):** _(____)_____

(Preferably somebody who does not live with you)

Relation to Participant: _____ **(Work):** _(____)_____

Emergency Contact: _____ **Phone (Home):** _(____)_____

Relation to Participant: _____ **(Work):** _(____)_____

Primary Physician's Name: _____

Address: _____

PCP Phone #:_(____)_____

ID _____
Date _____

The WOMAN on the Move Study

HEIGHT, WEIGHT, AND WAIST MEASUREMENTS:

- Standing Height**- Record to nearest half-inch (round up) without shoes: _____ **inches**
_____ **cm**
- Weight** - record to nearest half-pound, (round up) clothed, without shoes: _____ **lbs.**
_____ **kg.**

WAIST MEASUREMENTS (cm) - Record to nearest (.1) cm
1st reading _____ 2nd reading _____ 3rd reading _____

If first 2 readings are within 2 cm, average the 2. If not, do a third measurement and average the 2 measures within range (2 cm). If even after 3 measures there are no matches, take the average of the 2 closest measurements.

- Average waist circumference _____ cm
(≥ 80 cm–eligible)

HEART RATE

- Beats in 30 seconds: _____ X2 = _____

BLOOD PRESSURE MEASUREMENTS:

Cuff Size: _____ Regular _____ Large _____ Pediatric _____ Thigh
Arm: _____ Left _____ Right

- First Reading _____ / _____
Systolic Diastolic
- Second Reading _____ / _____
Systolic Diastolic
- Average of blood pressure Readings _____ / _____
Systolic Diastolic

ID _____

BLOOD DRAW (12 HOUR FAST)

8. When did you last have anything other than water to eat or drink? _____ a.m./p.m.

Note: If less than 10 hours from clinic appointment, participant should be rescheduled for the blood draw.

Time Blood Drawn: _____ a.m./p.m.

Difficult blood draw? 1. Yes 2. No

Was blood sample collected? 1. Yes 2. No, specify reason

Tubes collected: (✓ if completed)

EDTA 10mL: _____

Serum 15 mL: _____

Serum 10 mL: _____

Na Nitrate 5mL: _____

MEDICATION(S) LIST

9. Over the past 2 weeks have you taken any prescribed medications?

1. Yes 2. No

Office Use Only

meds _____

Medication 1:

Medication 2:

Medication 3:

Type _____

Type _____

Type _____

Date began _____ mo/yr

Date began _____ mo/yr

Date began _____ mo/yr

Dose _____ mg

Dose _____ mg

Dose _____ mg

Freq. _____ x /day

Freq. _____ x /day

Freq. _____ x /day

Reason _____

Reason _____

Reason _____

Medication 4:

Medication 5:

Medication 6:

Type _____

Type _____

Type _____

Date began _____ mo/yr

Date began _____ mo/yr

Date began _____ mo/yr

Dose _____ mg

Dose _____ mg

Dose _____ mg

Freq. _____ x /day

Freq. _____ x /day

Freq. _____ x /day

Reason _____

Reason _____

Reason _____

Medication 7:
Type _____

Date began _____ mo/yr

Dose _____ mg

Freq. _____ x /day

Reason _____

Medication 8:
Type _____

Date began _____ mo/yr

Dose _____ mg

Freq. _____ x /day

Reason _____

Medication 9:
Type _____

Date began _____ mo/yr

Dose _____ mg

Freq. _____ x /day

Reason _____

- 9a. Do you take aspirin (not Tylenol): (0) daily
(1) 1-6 times/week
(2) less than once/week
(3) rarely
(4) never (go to blood results)

9b. When you take aspirin, how many on the average do you take per day? _____ per day

9c. How many aspirin have you taken in the last 48 hours _____ aspirin
(00 if none)

HORMONE REPLACEMENT USE

10. Are you currently taking hormone therapy? 1. Yes (if yes, proceed to #11) 2. No

10a. If no, what was the date that you stopped taking HRT? _____ (MM/YY) (proceed to #13)

11. What are the hormones that you are taking?

Hormone 1: (Please circle one)

Oral Patch Injection Other

Name _____
Date Began _____ (MM/YY)
Dose _____ mg
Days/Month _____
Months Taken _____

Hormone 2: (Please circle one)

Oral Patch Injection Other

Name _____
Date Began _____ (MM/YY)
Dose _____ mg
Days/Month _____
Months Taken _____

Hormone 3: (Please circle one)

Oral Patch Injection Other

Name _____
Date Began _____ (MM/YY)
Dose _____ mg
Days/Month _____
Months Taken _____

Hormone 4: (Please circle one)

Oral Patch Injection Other

Name _____
Date Began _____ (MM/YY)
Dose _____ mg
Days/Month _____
Months Taken _____

12. Have you stopped taking your hormones in the past year for more than 1 week?
1. Yes 2. No ⇒ **Go to #14**
 a. If yes, how many occasions did you stop taking your hormones? _____ (Proceed to #14)
13. What were the primary reasons you stopped taking hormone replacement therapy? (Check all that apply)
- Directed by physician
 - Needed second opinion from another doctor
 - Felt like I didn't need it
 - Thought the medication was harmful
 - The cost of the medication
 - Developed a new health problem
 - Heard about the Women's Health Initiative HRT results and decided to stop because of health risks
 - Had undesirable side effects (check all that apply below):

_____ Weight gain	_____ Depression/mood swings
_____ Bleeding	_____ Flu-like symptoms
_____ Breast lumps	_____ Headaches
_____ Breast tenderness	_____ Other _____
 - Other (please specify) _____
14. Have you experienced any side effects while on HRT?
1. Yes 2. No
- (if yes, ↓ check all that apply below)
- | | |
|-------------------------|------------------------------|
| _____ Weight gain | _____ Depression/mood swings |
| _____ Bleeding | _____ Flu-like symptoms |
| _____ Breast lumps | _____ Headaches |
| _____ Breast tenderness | _____ Other _____ |
15. Do you currently smoke?
1. Yes 2. No
16. Have you had a mammogram in the last year?
1. Yes 2. No 1a. **If yes, Date:** _____/_____**mo/yr**
If no, explain importance of mammography and where to have them done
17. Have you ever been diagnosed by a physician with cancer?

1. Yes 2. No (If no, proceed to #18)

17a. If yes, Date: _____/_____/____ mo/yr

17b. If yes, which type?

- Breast
- Uterine (Endometrium)
- Ovary
- Other, describe _____

18. Have you had a cardiovascular event since the start of your participation in this study?

1. Yes 2. No (If no, questionnaire, go to #19)

18a. If yes, which type of event?

- Myocardial infarction; Date: _____/_____/____ mo/yr
- Stroke; Date: _____/_____/____ mo/yr
- Venous thrombosis: Date: _____/_____/____ mo/yr
- Aneurysm, in what location (e.g., aortic)? _____; Date: _____/_____/____ mo/yr
- Other?, describe _____; Date: _____/_____/____ mo/yr

19. Has your doctor ever told you that you have:

- | | | |
|------------------|---------------------------------|--------------------------------|
| Arthritis | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |
| Diabetes (Sugar) | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |
| Lung Disease | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |
| Kidney Disease | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |
| Pancreatitis | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |
| Gallstone | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |
| Thyroid Disease | 1. <input type="checkbox"/> Yes | 2. <input type="checkbox"/> No |

20. Have you ever had gastric bypass surgery?

1. Yes 2. No

If yes; Date: _____/_____/____ mo/yr

Corridor WalkExclusion Questions

Script: “The following tests will assess your physical fitness by having you walk 1/4 mile at a steady pace. First I need to ask you a few questions to see if you should try the test.”

- a. Does the participant use a walking aid, such as a cane? Yes No
- b. Within the past 3 months, have you had a heart attack? Yes No
- c. Within the past 3 months, have you had angioplasty? Yes No
- d. Within the past 3 months, have you had heart surgery? Yes No
- e. Within the past 3 months, have you had any new or worsening heart pain or angina? Yes No

Demonstration

- a. Attachment for heart rate monitor:

Script: “This device measures your pulse, or how often your heart beats.”

400-Meter Walk Test Performance

Script: “You will be walking 10 complete laps around the course, about 1/4 mile. We would like you to walk at a normal pace you can maintain over the 10 laps. After you complete the 10 laps I will tell you to stop, and measure your blood pressure and heart rate. “STOP” symptoms Script: “Please tell me if you feel any chest pain, tightness or pressure in your chest, if you become short of breath or if you feel faint, lightheaded or dizzy, or if you feel knee, hip, calf, or back pain. If you feel any of these symptoms, you may slow down or stop. Do you have any questions?” (Start walking when I say ‘GO’ and try to complete 10 laps at a pace you can maintain. Ready, go.”)

- a. Baseline heart rate: _____ bpm
- b. Cross off as each lap is completed: **1 2 3 4 5 6 7 8 9 10**
- c. Number of laps completed: _____ laps
- d. Did participant complete all 10 laps 1. Yes 2. No
- e. Record time at 400m or at stop: _____ : _____ . _____
(Min:sec.hundreths/sec)

ID _____

- f. Did the heart rate exceed 135 bpm at any time during the 400-meter walk? 1. Yes 2. No
- g. Heart rate at 400m or at stop: _____ bpm
- h. Blood pressure at 400m or at stop: _____ / _____ mmHg
- i. Heart rate **2 minutes** after completion of 400m walk: _____ bpm
- j. Did the participant complete the 400-meter walk? 1. Yes 2. No

Reason walk was incomplete or not done:

- Excluded based on criteria
- Refused
- Heart rate > 135 bpm during 2-minute walk
- Heart rate < 40 bpm
- Symptoms reported during walk:
Specify reason _____
- Stopped by technician:
Specify reason _____
- Other:
Specify reason _____

While you were walking, did you have any of the following symptoms?

- Chest pain? Yes No Don't Know
- Shortness of breath? Yes No Don't Know
- Knee pain? Yes No Don't Know
- Hip pain? Yes No Don't Know
- Calf pain? Yes No Don't Know
- Foot pain? Yes No Don't Know
- Numbness or tingling
in your legs or feet? Yes No Don't Know
- Leg cramps? Yes No Don't Know
- Back pain? Yes No Don't Know
- Other symptoms*? Yes No Don't Know

**Please specify:* _____

APPENDIX B: WOMAN STUDY PHLEBOTOMY FORM

WOMAN Phlebotomy/Processing Form

DATE _____ Phlebotomist ID: _____ ID: _____

PHLEBOTOMY

Participant Questions:

1. Do you bleed or bruise easily?
 No: _____ Yes: _____ Don't Know: _____
2. Have you ever been told you have a disorder related to blood clotting or coagulation?
 No: _____ Yes: _____ Don't Know: _____
3. Have you ever experienced fainting spells while having blood drawn?
 No: _____ Yes: _____ Don't Know: _____
4. Do you have diabetes?
 No: _____ Yes: _____ Don't Know: _____
5. Are you fasting?
 No: _____ Yes: _____ **If yes, how long?** _____

Was any blood drawn: (circle one) Yes No Time Drawn: _____
 If no, reason not drawn: _____

Venipuncture:

Venipuncture time elapsed: _____ minutes
 Time elapsed until tourniquet released: _____ (2 min optimum)
 Quality of venipuncture: C (Clean) T (Traumatic - please specify)
 A. Vein collapse B. Hematoma C. Vein Hard to get D. Multiple sticks
 E. Excessive duration of draw F. Leakage at venipuncture site

Site of venipuncture: _____

Position of participant during blood drawing: supine sitting

Blood drawing:

Blood Volume per Tube:	Fill (✓)	Other (specify volume)
1. EDTA 10mL	_____	_____
2. Serum 15mL	_____	_____
3. Serum 10mL	_____	_____
4. Na citrate 5mL	_____	_____
5. Li Heparin 4mL	_____	_____

PROCESSING

Processor ID: _____

Centrifuge after 30 minutes:

Indicate after centrifugation complete whether plasma is Lipemic (L), Icteric (I), Hemolyzed (H), or clotted (C).

Tube	(✓)	*	Suggested	Aliquot	Blind
	Done	Lab	Tube	dupl. (✓)	Comment
			Number vol(ml)		
#1 NMR EDTA	()	L	_____	2ml	Cryovial () _____
#2 DNA EDTA	()	S	_____	1ml	Cryovial () _____
#3 Extra EDTA	()	S	_____	1ml	Cryovial () _____
#4 Extra EDTA	()	S	_____	1ml	Cryovial () _____
#5 Na citrate	()	V	_____	1ml	Cryovial () _____
#6 Na citrate	()	V	_____	1ml	Cryovial () _____
#7 Serum	()	H	_____	3ml	Cryovial () _____
#8 Serum L(a)	()	H	_____	1ml	Cryovial () _____
#9 Serum CRP	()	V	_____	1ml	Cryovial () _____
#10 Serum IL-6	()	V	_____	1ml	Cryovial () _____
#11 Serum Est. Met. ()	()	I	_____	1ml	Cryovial () _____
#12 Serum TSH	()	I	_____	1ml	Cryovial () _____
#13 Extra Serum ()	()	S	_____	1ml	Cryovial () _____
#14 Extra Serum ()	()	S	_____	1ml	Cryovial () _____

*L=Lipomed V=University of Vermont H=Heinz Lab S=Storage

CBAL Use Only

Received Date: _____ Time: _____ Frozen: _____
 Comment: _____

APPENDIX C: WOMAN STUDY PHYSICAL ACTIVITY MEASURES

THE MODIFIABLE ACTIVITY QUESTIONNAIRE (MAQ)

1. Please circle all activities listed below that you have done more than 10 times in the past year from _____ to _____.

- | | | |
|--|-------------------------------------|-----------------------------|
| 1 Jogging (outdoor, treadmill) | 14 Football/Soccer | 27 Stair Master |
| 2 Swimming (laps, snorkeling) | 15 Raquetball/Squash | 28 Fencing |
| 3 Bicycling (indoor, outdoor) | 16 Horseback Riding | 29 Hiking |
| 4 Softball/Baseball | 17 Hunting | 30 Tennis |
| 5 Volleyball | 18 Fishing | 31 Golf |
| 6 Bowling | 19 Aerobic Dance/Step Aerobic | 32 Canoeing/Rowing Kayaking |
| 7 Basketball | 20 Water Aerobics | 33 Water Skiing |
| 8 Skating (roller, ice, blading) | 21 Dancing (square, line, ballroom) | 34 Jumping Rope |
| 9 Martial Arts (karate, judo, kendo) | 22 Gardening or Yardwork | 35 Snow Skiing (x-country) |
| 10 Tai Chi | 23 Badminton | 36 Snow Skiing (downhill) |
| 11 Calisthenics/Toning Exercises | 24 Strength/Weight Training | 37 Snow Shoeing |
| 12 Wood Chopping | 25 Rock Climbing | 38 Yoga |
| 13 Elliptical Trainer | 26 Scuba Diving | 39 Other |
| 40 Walking for Exercise (outdoor, indoor at a mall or fitness center, treadmill) | | |

List each activity that you circled in the "activity" box below, check the months that you did each activity over the past year and then estimate the average amount of time spent in that activity. If participant did not participate in any activities, please check the box below marked none.

None

ACTIVITY	Activity #	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEPT	OCT	NOV	DEC	Average # of Times per Month	Average # of Months Each Time

2. Excluding time at work, in general how many HOURS per DAY do you usually spend watching television or walking on the computer? _____ hours

3. Over this past year, have you spent more than one week confined to a bed or chair as a result of an injury, illness, or surgery? Yes _____ No _____

If yes, how many weeks over the past year were you confined to a bed or chair? _____ weeks

4. Do you have difficulty doing any of the following activities?
- | | | |
|---|-----------|----------|
| a. getting in or out of a bed or chair? | Yes _____ | No _____ |
| b. walking across a small room without resting? | Yes _____ | No _____ |
| c. walking for 10 minutes without resting? | Yes _____ | No _____ |

5. Did you ever compete in an individual or team sport (not including any time spent in sports performed during school physical education classes)? Yes _____ No _____
 If yes, how many total years did you participate in competitive sports? _____ years

6. Have you had a job for more than one month over the past year, from last _____ to this _____?

List all JOBS that the individual held over the past 12 months for more than one month. Account for all 12 months of the past year. IF unemployed/disabled/homemaker/student during all or part of the past 12 months, list as such and probe for job activities of a normal 8 hour day, 5 day week.

Job Name	Job Code	Walk or bicycle to/from work Min/Day	Average Job Schedule			Out of the total # of "hrs/day" the individual reported working at this "job", how much of this time was usually spent sitting? Enter this # in "hrs sitting" column, then place a check in the category that best describes their job activities when they are not sitting.			
						Hrs. spent sitting at work	Check the category that best describes job activities when not sitting		
			Mos/Yr	Days/Wk	Hrs/Day	Hrs Sitting	A	B	C

Category A
 (Includes all sitting activities)

- Sitting
- Standing still w/o heavy lifting
- Light cleaning
- Driving a bus, taxi, tractor
- Jewelry making/weaving
- General Office Work
- Occasional/short distance walking

Category B
 (Includes most indoor activities)

- Carrying light loads
- Continuous walking
- Heavy cleaning
- Gardening
- Painting/Plastering
- Plumbing/Welding
- Sheep Herding

Category C
 (heavy industrial work, outdoor construction, farming)

- Carrying moderate to heavy loads
- Heavy construction
- Farming
- Digging ditches, shoveling
- Chopping (ax), sawing wood
- Tree/pole climbing
- Water/Coal/Wood Hauling

JOB CODES

Not employed outside of the home:

1. Student
2. Home Maker
3. Retired
4. Disabled
5. Unemployed

Employed (or volunteer):

6. Armed Services
7. Office Worker
8. Non-Office Worker



Seven Day
Physical Activity Diary

ID _____

Dates Recorded

____ / ____ / ____ to
____ / ____ / ____

Phone (____) _____

Reviewer Initials _____

Directions

Please complete your log the week following your clinic visit. This log consists of two parts 1). the pedometer and 2). activity diary. We are asking you to wear the pedometer and record your activities every day for a full seven-day period. For each of the seven days, please check the day of the week (ex. Monday) and write in the date. Each of the seven days is to be recorded on a separate sheet.

Pedometer Instructions: The monitor is to be clipped snugly to your clothes or on a belt at the waist. First thing every morning, just before you put on the monitor, push the reset button and make sure the monitor reads “zero”. **Record the time** you put on the monitor in your activity log and circle am or pm. Keep the monitor on all day, except when swimming or bathing. Remove the monitor at night just before bedtime and record **the number of steps per day** along with the **time that it was removed** in the activity log and circle am or pm. Please repeat these steps for the next seven days.

Activity Diary Instructions: **Only include activities or exercises you do for 10 minutes or longer***. Please include **only** the time that you are actually active. Examples of physical activity includes brisk walking, gardening or yardwork, aerobics, swimming, stairclimbing, dancing, golf, weight training, etc. List each activity that you did during the day as well as the amount of time you spent doing that particular activity.

Day 1:

Sunday
 Monday
 Tuesday
 Wednesday
 Thursday
 Friday
 Saturday

Date: ___/___/___
(month) (day) (year)

Time you put the monitor on in the morning: ___ : ___ am or pm

Time you took the monitor off in the evening: ___ : ___ am or pm

The number of steps taken today from the pedometer: _____

Did you remove the monitor for longer than **30 minutes** for any reason today such as bathing, swimming, or water aerobics? If YES, please fill in the time that the monitor was taken off and the time it was put back on.

Activity	YES	NO	Time Monitor Removed	Time Monitor Put Back On
Bathing	<input type="checkbox"/>	<input type="checkbox"/>	___ : ___ am or pm	___ : ___ am or pm
Swimming/Water Aerobics	<input type="checkbox"/>	<input type="checkbox"/>	___ : ___ am or pm	___ : ___ am or pm

Leisure Physical Activity Done Today for 10 minutes or more

Activity/Exercise	Total Minutes/Day	Activity Code
WALKING	_____	_____
2. _____	_____	_____
3. _____	_____	_____
4. _____	_____	_____
5. _____	_____	_____
6. _____	_____	_____

*NOTE: This form is replicated for an additional 6 days to obtain 7 days of pedometer step counts and reported leisure physical activity levels.

APPENDIX D: WOMAN STUDY DIETARY MEASURES

CONNOR DIET HABIT SURVEY

Meat, Fish, and Poultry

Consider your eating habits during the last month.

For each question, circle all numbers that apply.

1. Which type of ground meat do you usually eat?
 1. Regular hamburger (30% fat)
 2. "Lean" ground beef (25-27% fat)
 3. Ground chuck (20% fat)
 4. Ground round or ground sirloin, other than Giant Eagle's ground sirloin, ground turkey (15% fat)
 5. "Extra lean", "Ultra lean" or "93/7" (4-10% fat), Giant Eagle's ground sirloin (7-10% fat), ground turkey breast, ground chicken breast
 6. Eat no ground meat

2. Which best describes your typical lunch? "Lunch meat" means ham, bologna, salami, pastrami, etc.
 1. Cheeseburger, pizza, typical cheeses, egg dishes (egg salad, quiche, frittata, etc.)
 2. Sandwich (regular lunch meat, hamburger, grilled cheese), meat/fried chicken entrée, regular hot dog
 3. Skip lunch or sandwich (tuna, fish, peanut butter, chicken or turkey lunch meat/light mayo, etc), turkey hot dog, vegetarian dishes
 4. Tuna sandwich (w/mayo: 1 gm fat or less/Tbsp), veggie burger (e.g. Harvest, Garden, Boca), entrée (fish [not fried], small bits of chicken or meat), low-fat yogurt
 5. Salad (low cal dressing), low-fat vegetarian dishes, low fat or fat-free hot dog (0-2 gm fat), deli meats/fat free sandwich (w/mayo: 1 gm fat or less/Tbsp), bagel (light cream cheese)
 6. Fat free vegetarian dishes, salad (fat free dressing), veggie dog, garden vegan (fat free soy burger), nonfat yogurt, dry cereal (skim milk), bagel (fat free cream cheese)

3. Circle all of the choices that reflect your entrée at your main meal.
 1. Cheese (cheddar, jack, etc.), eggs, organ meats (liver, etc), pizza, regular (not low fat) vegetarian dishes once a week or more.
 2. Beef, lamb, pork, or ham once a week or more
 3. Very lean red meat (top round or flank steak), rabbit, veal, or venison once a week or more
 4. Chicken, turkey, crab, lobster or shrimp twice a week or more
 5. Fish, scallops, oysters, clams, low-fat vegetarian dishes twice a week or more
 6. Fat free vegetarian dishes, fat free seafood dishes every day

4. Estimate the number of ounces of meat, cheese, fish and poultry you eat in a typical day. Include all meals and snacks.

To guide you in your estimate (a piece the size of a deck of cards = 3 oz)

<i>1 hot dog = 1 ½ oz</i>	<i>1 chicken thigh = 2-3 oz</i>	<i>1 slice cheese = 1 oz</i>
<i>4 strips of bacon = 1 oz</i>	<i>½ chicken breast = 3 oz</i>	<i>1-inch cube cheese = 1 oz</i>
<i>1 sm. burger patty = 3-4 oz</i>	<i>average T-bone steak = 8 oz</i>	<i>most sandwich meat = 2-3 oz</i>

 1. eleven or more ounces a day
 2. nine to 10 ounces a day
 3. six to 8 ounces a day
 4. four to 5 ounces a day
 5. up to 1 ounce cheese or 3 oz lean meat, poultry, shrimp, crab, lobster or 6 oz fish, clams, oysters, scallops a day
 6. none or up to 3 oz shrimp, crab, lobster or 6 oz fish, clams, oysters, scallops a day

5. Which of these have you eaten in the past month?
1. bacon, sausage
 2. Canadian bacon, turkey, or chicken sausage
 4. vegetarian sausage (e.g. Morningstar links or patties, other soy sausage)
 6. none

Dairy Products and Eggs

Consider your eating habits during the last month.

For each question, circle all numbers that apply

6. Which do you usually use for drinking (don't forget lattes/mochas) or cooking? (most lattes/mochas contain whole milk unless you request otherwise).
1. whole milk
 2. two percent milk
 4. one percent milk, buttermilk, nondairy beverages (edensoy, rice dream, etc)
 5. none or skim (non-fat) milk, light nondairy beverages (edensoy light, rice dream light, etc)
7. Which toppings do you use?
1. sour cream (real or imitation), whipped cream
 2. ligh/lowfat sour cream, cool whip, redid- whip aerosol dairy topping
 3. cool whip light, regular cottage cheese, whole milk yogurt
 4. low fat yogurt, 2% lowfat cottage cheese, reddi-whip aerosol nondairy
 5. 1% fat cottage cheese, cool whip free, soy yogurt
 6. none or nonfat sour cream, nonfat yogurt, nonfat cottage cheese
8. Which frozen desserts are you most likely to eat at least once a month?
1. ice cream (5 to 18 g fat per ½ cup)
 2. light ice cream (4 g fat per ½ cup)
 3. ice milk, most soft ice cream, frozen yogurt (cream added), tofutti
 4. sherbet, lowfat frozen yogurt, soy delicious
 5. none or nonfat frozen yogurt, sorbets, popsicles
9. Which kind of cheese do you use?
2. cheddar, swiss, jack, brie, feta, monrchet, blue, jarisbert, whole milk mozzarella, Neufchatel or regular cream cheese, processed cheese (velveeta, American, cheese whiz), kraft deluxe slices, parmesan
 6. part skim mozzarella, light cream cheese, light cheddar, light jack, (kraft light naturals, alpine lace-lo, velveeta light, or other part-skim cheeses), string cheese
 8. jarlsberg light, athenos reduced fat feta cheese, 2% milk processed cheese slices
 10. light part skim mozzarella, low fat and light ricotta, lite line, nonfat parmesan, soy/rice cheese (cheddar, mozzarella)
 12. none or fat free cheeses (cheddar, jack, ricotta, cream cheese, healthy choice, alpine lace, etc), soy(tofu rella)
10. Circle the type and number of “visible” eggs you eat (scrambled, fried, etc).
1. six or more whole eggs a week
 2. three to five whole eggs a week
 3. one to two whole eggs a week
 4. one whole egg a month
 5. none or egg whites, egg substitute (nulaid, egg beaters, scramblers, second nature, etc.)

11. Circle the type of eggs usually used in food prepared at home or bought in a grocery stores.
1. whole eggs or mixes containing whole eggs (complete pancake mix, slice and bake cookies, etc)
 3. combination of egg whites, egg substitute and whole eggs
 5. none or egg whites, egg substitute

Fats and Oils

Consider your eating habits during the last month.
For each question, circle all numbers that apply

12. Which kinds of fats are used most often to cook your food (vegetables, meats, etc)?
1. butter, shortening (with animal fat), lard, bacon grease, chicken fat
 2. shortening (with vegetable fat), vegetable oil (cottonseed)
 3. tub or stick margarine (all except those made from canola oil), vegetable oil (soybean, olive)
 4. vegetable oil (sunflower, corn), tub or stick margarine (made from canola oil)
 5. vegetable oil (canola, safflower)
 6. non or use nonstick cooking spray

Margarine brand(s) used most often: 1) _____ 2) _____

13. How much of these “added” fats do you eat in a typical day: peanut butter, margarine, mayonnaise, or salad dressing (including those made with olive oil)? Do not count fat free products.

Examples of amounts people often use (None: 3 tsp = 1 Tbsp)

- | | |
|---|--|
| <ol style="list-style-type: none"> <u>1.</u> ten teaspoons or more <u>2.</u> eight to 9 teaspoons <u>3.</u> six to 7 teaspoons <u>4.</u> four to 5 teaspoons <u>5.</u> three teaspoons <u>6.</u> none | <p>on toast: 2 tsp margarine
 on salads: 12 tsp (=1/2 cup) salad dressing
 on sandwiches: 6 tsp mayonnaise, 2 tsp margarine
 on potatoes: 3 tsp margarine
 on vegetables: 3 tsp margarine
 on pasta, rice: 3 tsp margarine or oil or 6 tsp pesto</p> |
|---|--|
14. How often do you eat potato chips, corn or tortilla chips, fried chicken, fish sticks, French fries, doughnuts, croissants or Danish pastries, or other foods? Do not count fat free products.
1. two or more times a day
 2. once a day
 3. two to 4 times a week
 4. once a week
 5. less than twice a month
 6. never
15. Which best describes the amount of margarine, butter, peanut butter, mayonnaise or cream cheese that you put on bread, muffins, bagels, etc? Do not count fat free products
1. average
 2. lightly spread (can see the bread through it)
 4. “scrape” (can barely see the spread)
 5. none

16. Which kind of salad dressings do you use?
1. real mayonnaise
 2. miracle whip, light mayonnaise (5 gm fat per Tbs), Caesar dressing, thousand island dressing
 3. ranch, French, blue cheese or Roquefort, vinegar and oil, Italian, Russian, low fat mayonnaise dressing, miracle whip light dressing and Italian dressings
 4. Ranch dressing (mix and light mayo)
 5. low cal salad dressing, ranch dressing (mix and low fat yogurt), low fat mayonnaise (1 gm fat per Tbs)
 6. Use no salad dressing or fat free mayonnaise, miracle whip fat free, fat free salad dressings, ranch dressing (mix and nonfat dairy or yogurt/sour cream, vinegar, lemon juice)

Sweets and Snacks

Consider your eating habits during the last month.
For each question, circle all numbers that apply

17. How often do you eat desserts or baked goods (sweet rolls, doughnuts, muffins, scones, cookies, cakes)?
1. once a day
 2. five to 6 times a week
 3. three to 4 times a week
 4. two times a week
 5. one time a week or less
 6. never
18. Which of the following desserts or snacks have you eaten in the last month?
1. croissants, cheesecake, typical cakes with frosting
 2. pies, cookies, cupcakes, muffins, scones, frosted doughnuts
 3. granola bars (nature valley, quaker chewy)
 4. low fat muffins, desserts made using lowfat recipes, lowfat cookies (fig bars, ginger snaps, snackwell's) low fat granola bars (power bar, quaker chewy)
 5. fat free desserts including angel food cake, fat free cookies
 6. never eat baked goods listed above or eat fruit for dessert
19. Which of the following snacks have you eaten in the last month?
1. chocolate, commercial (movie) popcorn, poppy cock popcorn, caramel corn
 2. nuts, potato chips, corn chips, Doritos chips, microwave popcorn, homemade popcorn with butter, cracker jack, French fries, peanut butter, party/snack crackers (ritz)
 4. tortilla chips, baked potato chips, pretzels, light microwave popcorn, lightly buttered popcorn (1 tsp margarine for 3 cups popcorn), low fat crackers (soda, graham)
 5. baked tortilla chips, homemade popcorn with no fat, fat free soda crackers and other fat free crackers
 6. do not eat snacks or eat fruits and vegetables as snacks

Grains, Beans, Fruits and Vegetables

Consider your eating habits during the last month. For this part of the survey, note that the time frame varies for the foods listed; some questions ask you to think about how much per day, others per week.

20. How many pieces of fruit or cups of fruit juice do you consume a day (do not include "fruit flavored" drinks) _____ cups or pieces

21. How many cups of vegetables do you eat a day (tossed salad, cooked vegetables, soups, casseroles, etc)? (A typical serving size for tossed salad is 1 to 1 ½ cups)
 _____ cups
22. How many cups of legumes do you eat a week (refried beans, split peas, white beans, black beans, black-eyed peas, lentils, chili, etc)? _____ cups
23. How much of the following do you eat a week? (A typical cereal bowl holds 1 to 2 cups; people typically eat 9 to 12 cups of popcorn, which is about what is in one full bag of microwave popcorn)

Amounts eaten per week

- | | | |
|---------------------------|-------|---------------|
| Cooked cereal | _____ | bowls/week |
| Ready to eat cereal | _____ | bowls/week |
| English muffin | _____ | number/week |
| Hamburger bun | _____ | number/week |
| Bagel (plain or flavored) | _____ | number/week |
| Pita or pocket bread | _____ | number/week |
| Eight inch tortilla | _____ | number/week |
| Plain popcorn | _____ | servings/week |
| Fat free or lowfat muffin | _____ | muffins/week |
| Cornbread | _____ | pieces/week |

Amounts eaten per week

- | | | |
|--------------------------------------|-------|---------------------|
| Bread or toast | _____ | slices/week |
| Dinner or hard roll | _____ | rolls/week |
| French/sourdough bread | _____ | slices/week |
| Four inch pancake | _____ | pancakes/week |
| Lowfat crackers such as soda, graham | _____ | servings/week |
| Regular sized rice cakes | _____ | servings/week |
| Mini sized rice cakes | _____ | servings/week |
| Pretzels (1 cup or 1 large soft) | _____ | cups or number/week |

24. How much of the following do you eat a week? Be sure to count these foods when they are in a mixed dish (casserole, pierogies, burrito, etc). This includes breakfast, lunch, and dinner.

Number of servings eaten per week

- | | |
|---|-------|
| Macaroni, spaghetti and other pastas (½ cup/serving) | _____ |
| Mashed potato (½ cup/serving) | _____ |
| Baked potato (1 medium/serving) | _____ |
| Cooked rice, corn, bulger, barley, other grains (½ cup/serving) | _____ |

Beverages

Consider your eating habits during the last month.
For each question, circle all numbers that apply

25. Which of the following reflects your habits regarding alcohol beverages?

1 drink = 12 ounce beer
1 ½ ounces whiskey, gin, rum, etc.
4 ounces of wine
1 ounce liquor

- 1. one or more drinks a day
- 2. four to 6 drinks a week
- 3. three drinks a week
- 4. one to 2 drinks a week
- 5. one to 3 drinks a month
- 6. do not drink alcohol beverages

26. Which of the following reflects your habits regarding soda pop, sweetened selzers, sports drinks, fruit punch, etc? *Do not count sugar free (diet drinks)*

1 can = 12 ounces
big gulp = 32 ounces
1 liter = 33 ounces
2 liters = 67 ounces

- 1. more than 48 ounces
- 2. 33-48 ounces
- 3. 25-32 ounces
- 4. 12-24 ounces
- 5. none or less than 12 ounces a week

27. How much coffee do you drink? This includes espressos, lattes, mochas, etc.

Guidelines for Espresso Drinks

“short” = 8 – 10 ounces
small “tall” = 12 ounces
medium “grande” = 16 ounces
large “venti” = 20 ounces

- 1. more than 40 ounces (more than 5 cups) a day
- 3. 25-40 ounces (4 to 5 cups) a day
- 4. 6 – 24 ounces (1 to 3 cups) a day
- 5. none or less than 1 cup a day

Salt

Consider your eating habits during the last month.
For each question, circle all numbers that apply

28. Which type of salt do you normally use?
1. regular salt, sea salt, flavoring salts (seasoned, garlic, onion, celery salt, lemon pepper etc), regular soy sauce
 3. combination of regular and lite salt
 4. lite salt, lower sodium soy sauce, reduced sodium flavoring salts
 5. none or salt substitute (100% potassium chloride), salt free products (Mrs. Dash, etc)
29. How often do you add salt to your food at the table?
1. always
 2. frequently
 4. occasionally
 5. never
30. Which type of salt and how much do you use in cooking potatoes, rice, pasta, vegetables, meat, casseroles, hot cereals, and soups
1. regular salt (typical amount) or eat in restaurants 4 or more times a week
 2. regular salt (½ typical amount) or lite salt (typical amount)
 4. lite salt (½ typical amount)
 5. none or salt free products (Mrs. Dash, etc) salt substitute
31. Which type of cereals do you use?
1. typical dry cereals (sweetened or unsweetened) or cereals cooked with regular salt (typical amount)
 3. combination of typical dry cereals and salt-free dry cereals (shredded wheat, puffed wheat, puffed rice) or cereals cooked with regular salt (½ typical amount) or lite salt (typical amount)
 5. do not eat cereal or eat salt-free dry cereals (shredded wheat, puffed wheat, puffed rice, ec) or cereals cooked without salt.
32. How often do you use typical canned, bottled, or packaged foods such as:
- | | | |
|---------------|--------------------------|----------------------|
| salsa | salad dressing | boxed noodle entrees |
| Picante sauce | soups (chicken broth) | frozen entrees |
| BBQ sauce | chili | canned beans |
| ketchup | cured meats (lunch meat) | canned vegetables |
1. more than 15 times a week or eat in restaurants 4 or more times a week
 2. ten to 14 times a week
 3. six to 9 times a week
 5. five times a week or less

Restaurants and Recipes

Consider your eating habits during the last month.
For each question, circle all numbers that apply

33. How often do you eat breakfast at a restaurant or cafeteria (this includes coffee shops)?
1. more than twice a week
 2. once or twice a week
 3. once a week and you eat low fat (unbuttered toast or English muffin, oatmeal)
 4. less than once a month
 5. never

Where do you eat breakfast out most frequently?

1) _____ 2) _____

34. How often do you eat lunch at a restaurant or cafeteria or eat “take out”?

- 1. daily
- 2. five days a week
- 3. two to 4 days a week
- 4. once a week
- 5. less than once a month
- 6. never

Where do you eat lunch out most frequently?

1) _____ 2) _____

35. How often do you eat dinner at a restaurant or cafeteria or eat “take out”?

- 1. more than 3 times a week
- 2. two to 3 times a week
- 3. once a week
- 4. once or twice a month
- 5. less than once a month
- 6. never

Where do you eat dinner out most frequently?

1) _____ 2) _____

36. Check the choices you make when eating in restaurants or cafeterias (you may check more than one)

- Select restaurants that offer low-fat choices and order these choices
- Order toast, muffins, cereal, pancakes, waffles for breakfast
- Order soup (not cream), salad or other meatless, cheeseless entrees for lunch
- Order vegetarian pizzas with half the cheese
- Avoid cheese, eggs, bacon on salads and avoid potato and macaroni salads
- Put garbanzo or kidney beans on salad at the salad bar
- Use a very small amount of salad dressing
- Order a fish, shellfish, chicken, or lean red meat entrée (but not fried)
- Use no more than 1 pat of margarine at any meal
- Order fruit, sorbet, sherbet, frozen yogurt or skip dessert

37. How often do you eat foods made using low fat recipes or cook low fat without recipes?

- 1. once a month or less
- 2. one to 2 times a week
- 3. three to 4 times a week
- 4. five to 6 times a week
- 5. everyday

Seafood

Consider your eating habits during the last month.
For each question, circle all numbers that apply

38. How often do you eat fish? (tuna, snapper, perch, sole, halibut, cod, salmon, shrimp/prawns, crab, lobster, scallops, clams, oysters, sardines, etc)
- 1. do not eat fish or eat fish less than once a month
 - 2. one to 3 times a month
 - 3. once a week
 - 4. two times a week
 - 5. three or more times a week or eat vegetarian with no added fat
39. Which fish (fresh, frozen, or canned) have you eaten in the last month?
- 1. ate no fish in the last month
 - 2. clams, scallops, lobster, crab, perch, cod, sole, snowcrab (surimi)
 - 3. tuna, halibut, snapper, catfish, shrimp (prawns), squid
 - 4. salmon (pink, silver, coho, red), trout, steelhead, oysters
 - 5. salmon (Chinook or king), sardines, herring, mackerel, or eat vegetables with no added fat

Where do you most often buy your fish and seafood?

1) _____ 2) _____

Fiber

Consider your eating habits during the last month.
For each question, circle only one number

****Please note change in instructions above****

<p>40. How often do you eat Rice Krispies, Special K, Grapenuts, and/or Corn Flakes?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>	<p>41. How often do you eat Wheaties, Shredded Wheat, All Bran, and/or Raisin Bran?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>
<p>42. How often do you eat Cheerios, Oatmeal, and/or Quaker Oat Flakes?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>	<p>43. How often do you eat Oat Bran (cooked)</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>
<p>44. How often do you eat All Bran's "Bran Buds"?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>	<p>45. How often do you eat English muffins, white bread, white pita, cornbread, and/or whole wheat bread?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>
<p>46. How often do you eat Rye and/or Pumpernickel bread?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>	<p>47. How often do you eat melon, banana, blueberries, grapes, nectarines, and/or pineapple?</p> <p style="text-align: center;"> <u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more </p>

<p>48. How often do you eat prunes, fresh or canned peaches, kiwi, apples, mango, and/or canned pears?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>	<p>49. How often do you eat dried apricot, fresh grapefruit, plums, and/or strawberries?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>
<p>50. How often do you eat fresh apricot, orange, and/or fresh pears?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>	<p>51. How often do you eat cauliflower, bean sprouts, corn, cucumber, and/or V- 8 juice?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>
<p>52. How often do you eat cabbage, celery, kale, turnips, spinach, canned tomato, zucchini, and/or snow peas?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>	<p>53. How often do you eat asparagus, carrots, green beans, okra, peas, broccoli, and/or sweet potatoes?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>
<p>54. How often do you eat Brussel's sprouts?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>	<p>55. How often do you eat lentils and/or black-eyed peas?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>
<p>56. How often do you eat chick peas (garbanzos), white (Great Northern), lima, and/or butter beans?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>	<p>57. How often do you eat broad beans, black, navy, and/or kidney beans?</p> <p><u>1</u> Never <u>2</u> Once a week or less <u>3</u> 1-2 times a week <u>4</u> 3-4 times a week <u>5</u> 5-6 times a week <u>6</u> Once a <u>day</u> or more</p>

BIBLIOGRAPHY

1. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. *Circulation*. Oct 7 1997;96(7):2468-2482.
2. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. *Circulation*. Apr 29 2003;107(16):2096-2101.
3. Rosano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. *Cardiol Rev*. Jan-Feb 2002;10(1):51-60.
4. Association AH. *Heart Disease and Stroke Statistics - 2005 Update*. Dallas, TX; 2004.
5. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. *N Engl J Med*. Sep 7 1989;321(10):641-646.
6. Carr MC. The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab*. Jun 2003;88(6):2404-2411.
7. Binder EF, Birge SJ, Kohrt WM. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. *J Am Geriatr Soc*. Mar 1996;44(3):231-236.
8. Klebanoff R, Miller VT, Fernhall B. Effects of exercise and estrogen therapy on lipid profiles of postmenopausal women. *Med Sci Sports Exerc*. Jul 1998;30(7):1028-1034.
9. Lobo RA. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. *J Clin Endocrinol Metab*. Nov 1991;73(5):925-930.
10. Vadlamudi S, MacLean P, Israel RG, et al. Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins. *Metabolism*. Oct 1998;47(10):1222-1226.
11. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. *Prog Cardiovasc Dis*. Nov-Dec 1995;38(3):199-210.

12. Hulley S GD, Bush T, Furberg C, Herrington D Riggs B Vittinghoff E. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. *Journal of the American Medical Association*. 1998;280(7):605-613.
13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama*. Jul 17 2002;288(3):321-333.
14. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *Jama*. Apr 14 2004;291(14):1701-1712.
15. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. *Jama*. Jan 7 2004;291(1):47-53.
16. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. *Jama*. Oct 27 2004;292(16):1983-1988.
17. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. *Ann Intern Med*. May 17 2005;142(10):855-860.
18. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. *Metabolism*. Sep 1993;42(9):1153-1158.
19. Lindheim SR, Notelovitz M, Feldman EB, Larsen S, Khan FY, Lobo RA. The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women. *Obstet Gynecol*. Feb 1994;83(2):167-172.
20. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med*. Aug 7 2003;349(6):523-534.
21. Services USDoHaH. *Surgeon General's Report on Physical Activity and Health*. Washington, DC: U.S. Government Printing Office; 1996.
22. Thompson. Exercise and Physical Activity in the Prevention and Treatment of Atherosclerotic Cardiovascular Disease. *Arterioscler Thromb Vasc Biol*. 2003;23:1319-1321.
23. Bauman AE. Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003. *J Sci Med Sport*. Apr 2004;7(1 Suppl):6-19.

24. Richardson CR, Kriska AM, Lantz PM, Hayward RA. Physical activity and mortality across cardiovascular disease risk groups. *Med Sci Sports Exerc.* Nov 2004;36(11):1923-1929.
25. Eriksson KF LF. Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical activity. *Diabetologia.* 1991;34:891-898.
26. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care.* Apr 1997;20(4):537-544.
27. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med.* May 3 2001;344(18):1343-1350.
28. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* Feb 7 2002;346(6):393-403.
29. Breslow RA, Ballard-Barbash R, Munoz K, Graubard BI. Long-term recreational physical activity and breast cancer in the National Health and Nutrition Examination Survey I epidemiologic follow-up study. *Cancer Epidemiol Biomarkers Prev.* Jul 2001;10(7):805-808.
30. Slattery ML, Potter JD. Physical activity and colon cancer: confounding or interaction? *Med Sci Sports Exerc.* Jun 2002;34(6):913-919.
31. Meyer T, Broocks A. Therapeutic impact of exercise on psychiatric diseases: guidelines for exercise testing and prescription. *Sports Med.* Oct 2000;30(4):269-279.
32. Dunn AL, Trivedi MH, O'Neal HA. Physical activity dose-response effects on outcomes of depression and anxiety. *Med Sci Sports Exerc.* Jun 2001;33(6 Suppl):S587-597; discussion 609-510.
33. Unger JB, Johnson CA, Marks G. Functional decline in the elderly: evidence for direct and stress-buffering protective effects of social interactions and physical activity. *Ann Behav Med.* Spring 1997;19(2):152-160.
34. Brach JS, FitzGerald S, Newman AB, et al. Physical activity and functional status in community-dwelling older women: a 14-year prospective study. *Arch Intern Med.* Nov 24 2003;163(21):2565-2571.
35. Services USDoHaH. Health Behaviors of Adults: United States, 1999-2001. *Vital Health Statistics.* 2004;10(219):39-53.

36. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. *Annu Rev Public Health*. 1987;8:253-287.
37. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. *Sports Med*. 2004;34(6):371-418.
38. Press V, Freestone I, George CF. Physical activity: the evidence of benefit in the prevention of coronary heart disease. *Qjm*. Apr 2003;96(4):245-251.
39. Bouchard C DJ, Tremblay A. Exercise and obesity. *Obesity Research*. 1993;1:133-147.
40. Powers SK HE. *Exercise Physiology: Theory and Application to Fitness and Performance*. 4th ed. Boston, MA: McGraw Hill; 2001.
41. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *Jama*. Jan 18 1995;273(3):199-208.
42. Bouchard C. *Physical Activity and Prevention of Cardiovascular Disease*. Champaign, IL: Human Kinetics; 1997.
43. Sesso HD, Paffenbarger RS, Ha T, Lee IM. Physical activity and cardiovascular disease risk in middle-aged and older women. *Am J Epidemiol*. Aug 15 1999;150(4):408-416.
44. LaCroix AZ, Leveille SG, Hecht JA, Grothaus LC, Wagner EH. Does walking decrease the risk of cardiovascular disease hospitalizations and death in older adults? *J Am Geriatr Soc*. Feb 1996;44(2):113-120.
45. Folsom AR, Arnett DK, Hutchinson RG, Liao F, Clegg LX, Cooper LS. Physical activity and incidence of coronary heart disease in middle-aged women and men. *Med Sci Sports Exerc*. Jul 1997;29(7):901-909.
46. Kushi LH, Fee RM, Folsom AR, Mink PJ, Anderson KE, Sellers TA. Physical activity and mortality in postmenopausal women. *Jama*. Apr 23-30 1997;277(16):1287-1292.
47. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. *N Engl J Med*. Sep 5 2002;347(10):716-725.
48. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. *N Engl J Med*. Aug 26 1999;341(9):650-658.
49. Lee IM RK, Cook NR, Manson JE, Buring JE. Physical Activity and Coronary Heart Disease in Women. *Journal of the American Medical Association*. 2001;285:1447-1454.

50. Owens JF MK, Raikkonen K, Kuller LH. It Is Never Too Late: Change in Physical Activity Fosters Change in Cardiovascular Risk Factors in Middle-Aged Women. *Preventative Cardiology*. 2003;6:22-28.
51. Haddock BL, Marshak HP, Mason JJ, Blix G. The effect of hormone replacement therapy and exercise on cardiovascular disease risk factors in postmenopausal women. *Sports Med*. Jan 2000;29(1):39-49.
52. Stevenson ET, Davy KP, Seals DR. Hemostatic, metabolic, and androgenic risk factors for coronary heart disease in physically active and less active postmenopausal women. *Arterioscler Thromb Vasc Biol*. May 1995;15(5):669-677.
53. Ready AE, Naimark B, Ducas J, et al. Influence of walking volume on health benefits in women post-menopause. *Med Sci Sports Exerc*. Sep 1996;28(9):1097-1105.
54. Haddock BL, Hopp HP, Mason JJ, Blix G, Blair SN. Cardiorespiratory fitness and cardiovascular disease risk factors in postmenopausal women. *Med Sci Sports Exerc*. Jun 1998;30(6):893-898.
55. Hagberg JM, McCole SD, Ferrell RE, et al. Physical activity, hormone replacement therapy and plasma lipoprotein-lipid levels in postmenopausal women. *Int J Sports Med*. Jan 2003;24(1):22-29.
56. Cauley JA, LaPorte RE, Kuller LH, Black-Sandler R. The epidemiology of high density lipoprotein cholesterol levels in post-menopausal women. *J Gerontol*. Jan 1982;37(1):10-15.
57. Cauley JA, La Porte RE, Sandler RB, Orchard TJ, Slemenda CW, Petrini AM. The relationship of physical activity to high density lipoprotein cholesterol in postmenopausal women. *J Chronic Dis*. 1986;39(9):687-697.
58. Cauley JA, Kriska AM, LaPorte RE, Sandler RB, Pambianco G. A two year randomized exercise trial in older women: effects on HDL-cholesterol. *Atherosclerosis*. Aug 1987;66(3):247-258.
59. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol*. Jul 1 2002;22(7):1175-1180.
60. Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. *Ann Med*. 2004;36(5):332-346.
61. Rice B, Janssen I, Hudson R, Ross R. Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men. *Diabetes Care*. May 1999;22(5):684-691.

62. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. *Ann Intern Med.* Jul 18 2000;133(2):92-103.
63. Liao D, Asberry PJ, Shofer JB, et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. *Diabetes Care.* Sep 2002;25(9):1504-1510.
64. Arroll B, Beaglehole R. Does physical activity lower blood pressure: a critical review of the clinical trials. *J Clin Epidemiol.* May 1992;45(5):439-447.
65. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. *Int J Sports Med.* Jan 2000;21(1):21-24.
66. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. *Arch Intern Med.* Jun 10 2002;162(11):1286-1292.
67. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. *Arterioscler Thromb Vasc Biol.* Nov 1 2002;22(11):1869-1876.
68. Colbert LH, Visser M, Simonsick EM, et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. *J Am Geriatr Soc.* Jul 2004;52(7):1098-1104.
69. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. *Am J Epidemiol.* Feb 1 2001;153(3):242-250.
70. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. *Jama.* Dec 16 1998;280(23):2001-2007.
71. Simkin-Silverman L, Wing RR, Hansen DH, et al. Prevention of cardiovascular risk factor elevations in healthy premenopausal women. *Prev Med.* Sep 1995;24(5):509-517.
72. Simkin-Silverman LR, Wing RR, Boraz MA, Meilahn EN, Kuller LH. Maintenance of cardiovascular risk factor changes among middle-aged women in a lifestyle intervention trial. *Womens Health.* Fall 1998;4(3):255-271.
73. Simkin-Silverman LR, Wing RR, Boraz MA, Kuller LH. Lifestyle intervention can prevent weight gain during menopause: results from a 5-year randomized clinical trial. *Ann Behav Med.* Dec 2003;26(3):212-220.

74. Kuller LH S-SL, Wing, RR, Meilahn EN, Ives DG. Women's Healthy Lifestyle Project: A Randomized Clinical Trial - Results at 54 Months. *Circulation*. 2001;103:32-37.
75. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. *Circulation*. Sep 30 2003;108(13):1554-1559.
76. Wilson PW, Paffenbarger RS, Jr., Morris JN, Havlik RJ. Assessment methods for physical activity and physical fitness in population studies: report of a NHLBI workshop. *Am Heart J*. Jun 1986;111(6):1177-1192.
77. Wood D. Established and emerging cardiovascular risk factors. *Am Heart J*. Feb 2001;141(2 Suppl):S49-57.
78. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. *Ann Intern Med*. Nov 1 1995;123(9):673-675.
79. Kannel WB, Cupples LA, Ramaswami R, Stokes J, 3rd, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. *J Clin Epidemiol*. 1991;44(2):183-190.
80. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. *Nutrition*. Sep-Oct 1993;9(5):452-459.
81. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation*. Aug 25 1998;98(8):731-733.
82. Pouliot MC, Despres JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. *Diabetes*. Jul 1992;41(7):826-834.
83. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. *Stroke*. May 2001;32(5):1104-1111.
84. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. *Ann Intern Med*. Jul 3 2001;135(1):1-8.
85. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. *N Engl J Med*. Jun 19 1997;336(25):1769-1775.
86. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. *Ann Intern Med*. Dec 15 1992;117(12):1016-1037.

87. Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. *Maturitas*. Sep 1990;12(3):259-285.
88. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. *Prev Med*. Jan 1991;20(1):47-63.
89. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. *N Engl J Med*. Oct 24 1985;313(17):1038-1043.
90. Jick H, Dinan B, Rothman KJ. Noncontraceptive estrogens and nonfatal myocardial infarction. *Jama*. Apr 3 1978;239(14):1407-1409.
91. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. *Jama*. Dec 1 1978;240(23):2548-2552.
92. Szklo M, Tonascia J, Gordis L, Bloom I. Estrogen use and myocardial infarction risk: a case-control study. *Prev Med*. Sep 1984;13(5):510-516.
93. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in postmenopausal women. *N Engl J Med*. Jun 3 1976;294(23):1256-1259.
94. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS. Noncontraceptive estrogens and myocardial infarction in young women. *Jama*. Jul 25 1980;244(4):339-342.
95. Talbott E, Kuller LH, Detre K, Perper J. Biologic and psychosocial risk factors of sudden death from coronary disease in white women. *Am J Cardiol*. May 26 1977;39(6):858-864.
96. Pfeffer RI, Whipple GH, Kurosaki TT, Chapman JM. Coronary risk and estrogen use in postmenopausal women. *Am J Epidemiol*. Jun 1978;107(6):479-497.
97. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. *Lancet*. Apr 18 1981;1(8225):858-860.
98. Bain C, Willett W, Hennekens CH, Rosner B, Belanger C, Speizer FE. Use of postmenopausal hormones and risk of myocardial infarction. *Circulation*. Jul 1981;64(1):42-46.
99. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. *Br Med J (Clin Res Ed)*. Apr 18 1981;282(6272):1277-1278.

100. Beard CM, Kottke TE, Annegers JF, Ballard DJ. The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982. *Mayo Clin Proc.* Dec 1989;64(12):1471-1480.
101. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. *Arch Intern Med.* Jun 27 1994;154(12):1333-1339.
102. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. *Am J Epidemiol.* Feb 1 1997;145(3):269-277.
103. O'Keefe JH, Jr., Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. *J Am Coll Cardiol.* Jan 1997;29(1):1-5.
104. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. *J Epidemiol Community Health.* Jun 1989;43(2):173-178.
105. Sidney S, Petitti DB, Quesenberry CP, Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. *Ann Intern Med.* Oct 1 1997;127(7):501-508.
106. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. *Ann Intern Med.* Mar 1988;108(3):358-363.
107. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. *Am Heart J.* May 1988;115(5):954-963.
108. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. *Am Heart J.* Jun 1989;117(6):1209-1214.
109. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. *Am J Obstet Gynecol.* Mar 1 1979;133(5):525-536.
110. Lafferty FW, Helmuth DO. Post-menopausal estrogen replacement: the prevention of osteoporosis and systemic effects. *Maturitas.* Jul 1985;7(2):147-159.
111. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. *N Engl J Med.* Oct 24 1985;313(17):1044-1049.

112. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. *Circulation*. Jun 1987;75(6):1102-1109.
113. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. *Obstet Gynecol*. Sep 1987;70(3 Pt 1):289-293.
114. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. *Am J Epidemiol*. Sep 1988;128(3):606-614.
115. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. *Am J Obstet Gynecol*. Aug 1988;159(2):312-317.
116. Croft P, Hannaford P. Risk factors for acute myocardial infarction in women. *Bmj*. Mar 11 1989;298(6674):674.
117. Hernandez Avila M, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. *Epidemiology*. Mar 1990;1(2):128-133.
118. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. *Arch Intern Med*. Dec 1990;150(12):2557-2562.
119. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. *Arch Intern Med*. Jan 1991;151(1):75-78.
120. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. *N Engl J Med*. Sep 12 1991;325(11):756-762.
121. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. *Am J Obstet Gynecol*. Feb 1991;164(2):489-494.
122. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. *Am J Cardiol*. Apr 1 1997;79(7):847-850.
123. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. *Ann Intern Med*. Dec 19 2000;133(12):933-941.

124. Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. *J Am Coll Cardiol*. Jul 2001;38(1):1-7.
125. Heckbert SR, Kaplan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. *Arch Intern Med*. Jul 23 2001;161(14):1709-1713.
126. Burch JC, Byrd BF, Jr., Vaughn WK. The effects of long-term estrogen on hysterectomized women. *Am J Obstet Gynecol*. Mar 15 1974;118(6):778-782.
127. Hunt K, Vessey M. Long-term effects of postmenopausal hormone therapy. *Br J Hosp Med*. Nov 1987;38(5):450-453, 456-460.
128. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. *Obstet Gynecol*. Jul 1979;54(1):74-79.
129. Herrington DM RD, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Walters D. Effects of Estrogen Replacement on the Progression of Coronary Artery Atherosclerosis. *The New England Journal of Medicine*. 2000;343(8):522-529.
130. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. *Jama*. Nov 20 2002;288(19):2432-2440.
131. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofield PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. *Bjog*. Sep 2002;109(9):1056-1062.
132. Gordis L. *Epidemiology*. Philadelphia, PA: W.B. Saunders Company; 2000.
133. Krauss RM. Dense low density lipoproteins and coronary artery disease. *Am J Cardiol*. Feb 23 1995;75(6):53B-57B.
134. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. *Am J Cardiol*. Oct 17 2002;90(8A):22i-29i.
135. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med*. Nov 7 2002;347(19):1483-1492.
136. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. *J Clin Endocrinol Metab*. Jul 1988;67(1):30-35.

137. Carr MC, Kim KH, Zambon A, et al. Changes in LDL density across the menopausal transition. *J Investig Med*. Jul 2000;48(4):245-250.
138. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. *Clin Chem*. Jul 2004;50(7):1189-1200.
139. Campos H, Walsh BW, Judge H, Sacks FM. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. *J Clin Endocrinol Metab*. Dec 1997;82(12):3955-3963.
140. Caspersen CJ. Physical activity epidemiology: concepts, methods, and applications to exercise science. *Exerc Sport Sci Rev*. 1989;17:423-473.
141. Ravussin E, Bogardus C. A brief overview of human energy metabolism and its relationship to essential obesity. *Am J Clin Nutr*. Jan 1992;55(1 Suppl):242S-245S.
142. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. *Public Health Rep*. Mar-Apr 1985;100(2):126-131.
143. Kriska A. Ethnic and cultural issues in assessing physical activity. *Res Q Exerc Sport*. Jun 2000;71(2 Suppl):S47-53.
144. Pereira MA, FitzerGerald SJ, Gregg EW, et al. A collection of Physical Activity Questionnaires for health-related research. *Med Sci Sports Exerc*. Jun 1997;29(6 Suppl):S1-205.
145. Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. *Lancet*. Nov 28 1953;265(6796):1111-1120; concl.
146. Paffenbarger RS, Hale WE. Work activity and coronary heart mortality. *N Engl J Med*. Mar 13 1975;292(11):545-550.
147. Kriska AM, Bennett PH. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. *Diabetes Metab Rev*. Dec 1992;8(4):355-372.
148. Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the Five-City Project. *Am J Epidemiol*. Jan 1985;121(1):91-106.
149. Bassett DR, Jr., Ainsworth BE, Leggett SR, et al. Accuracy of five electronic pedometers for measuring distance walked. *Med Sci Sports Exerc*. Aug 1996;28(8):1071-1077.
150. Bassett DR, Jr. Validity and reliability issues in objective monitoring of physical activity. *Res Q Exerc Sport*. Jun 2000;71(2 Suppl):S30-36.

151. Jacobs DRJ, Ainsworth BE, Hartman T, Leon AS. A simultaneous evaluation of 10 commonly used questionnaires. *Medicine and Science in Sports and Exercise*. 1993;25:81-91.
152. Lemaitre RN, Heckbert SR, Psaty BM, Siscovick DS. Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. *Arch Intern Med*. Nov 27 1995;155(21):2302-2308.
153. O'Connor GT, Hennekens CH, Willett WC, et al. Physical exercise and reduced risk of nonfatal myocardial infarction. *Am J Epidemiol*. Dec 1 1995;142(11):1147-1156.
154. Lissner L, Bengtsson C, Bjorkelund C, Wedel H. Physical activity levels and changes in relation to longevity. A prospective study of Swedish women. *Am J Epidemiol*. Jan 1 1996;143(1):54-62.
155. Manson JE GP, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS. Walking Compared with Vigorous Exercise for the Prevention of Cardiovascular Events in Women. *The New England Journal of Medicine*. 2002;347(10):716-725.
156. Haddock BL H-MH, Manson JJ, Blix G. The Effect of Hormone Replacement Therapy and Exercise on Cardiovascular Disease Risk Factors in Postmenopausal Women. *Sports Medicine*. 2000;29(1):39-49.
157. Sternfeld B, Ainsworth BE, Quesenberry CP. Physical activity patterns in a diverse population of women. *Prev Med*. Mar 1999;28(3):313-323.
158. Lokey EA, Tran ZV. Effects of exercise training on serum lipid and lipoprotein concentrations in women: a meta-analysis. *Int J Sports Med*. Dec 1989;10(6):424-429.
159. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. *N Engl J Med*. Aug 4 2005;353(5):468-475.
160. Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr., Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. *Jama*. Nov 3 1989;262(17):2395-2401.
161. Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. *Jama*. Sep 24 2003;290(12):1600-1607.
162. Simonsick EM, Montgomery PS, Newman AB, Bauer DC, Harris T. Measuring fitness in healthy older adults: the Health ABC Long Distance Corridor Walk. *J Am Geriatr Soc*. Nov 2001;49(11):1544-1548.

163. Newman AB, Haggerty CL, Kritchevsky SB, Nevitt MC, Simonsick EM. Walking performance and cardiovascular response: associations with age and morbidity--the Health, Aging and Body Composition Study. *J Gerontol A Biol Sci Med Sci*. Aug 2003;58(8):715-720.
164. Cooper KH. A means of assessing maximal oxygen intake. Correlation between field and treadmill testing. *Jama*. Jan 15 1968;203(3):201-204.
165. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. *Br Med J (Clin Res Ed)*. May 29 1982;284(6329):1607-1608.
166. Knox AJ, Morrison JF, Muers MF. Reproducibility of walking test results in chronic obstructive airways disease. *Thorax*. May 1988;43(5):388-392.
167. McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. *Br Med J*. Jul 22 1978;2(6132):241-243.
168. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J*. Apr 15 1985;132(8):919-923.
169. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. *Br Med J (Clin Res Ed)*. Mar 8 1986;292(6521):653-655.
170. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: a quick measure of functional status in elderly adults. *Chest*. Feb 2003;123(2):387-398.
171. Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. *Jama*. May 3 2006;295(17):2018-2026.
172. Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk. *J Am Geriatr Soc*. Jan 2006;54(1):127-132.
173. Medicine ACoS. *ACSM's Guidelines for Exercise Testing and Prescription*. 6th ed. Baltimore, MD: Lippincott, Williams & Wilkins; 2000.
174. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. *Diabetes Care*. Apr 1990;13(4):401-411.

175. Schulz LO HI, Smith CJ, Kriska AM, Ravussin E. Energy intake and physical activity in Pima Indians: comparison with energy expenditure measured by doubly-labeled water. *Obes Res.* 1994;2:541-548.
176. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc.* Sep 2000;32(9 Suppl):S498-504.
177. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic spectroscopy. *Clinical Cardiology.* 1999;22:1121-1127.
178. Otvos J. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. *Clinical Chemistry.* 1991;37:377-386.
179. Otvos J. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. *Clin Chem.* 1992;1992:1632-1638.
180. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol.* Mar 15 1990;15(4):827-832.
181. Sutton-Tyrrell K, Mackey RH, Holubkov R, Vaitkevicius PV, Spurgeon HA, Lakatta EG. Measurement variation of aortic pulse wave velocity in the elderly. *Am J Hypertens.* May 2001;14(5 Pt 1):463-468.
182. Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, et al. Correlates of aortic stiffness in elderly individuals: a subgroup of the Cardiovascular Health Study. *Am J Hypertens.* Jan 2002;15(1 Pt 1):16-23.
183. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. *Am J Med.* Sep 6 2004;117 Suppl 5A:72S-78S.
184. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol.* Apr 17 2006;97(8A):89C-94C.
185. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med.* Mar 31 2005;352(13):1293-1304.
186. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet.* Oct 8 2005;366(9493):1267-1278.

- 187.** Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. *Ann Intern Med.* Mar 7 2006;144(5):326-336.
- 188.** Coughlin SS. Recall bias in epidemiologic studies. *J Clin Epidemiol.* 1990;43(1):87-91.
- 189.** Durante R, Ainsworth BE. The recall of physical activity: using a cognitive model of the question-answering process. *Med Sci Sports Exerc.* Oct 1996;28(10):1282-1291.
- 190.** Jacobs DR, Jr., Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation of 10 commonly used physical activity questionnaires. *Med Sci Sports Exerc.* Jan 1993;25(1):81-91.